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The heart and a balloon have more in common than meets 
the eye. Like the heart, a balloon is a exible bag that can 
be inated and emptied. Using this example one can 
readily understand basic heart function and several reasons 
for failure. Consider a balloon that is lled with air for 10 
seconds and then empties its volume for 10 seconds. The 
total time of balloon function or “balloon cycle” (lling and 
ejecting) is 20 seconds. Now let us imagine that the balloon 
cycle time of lling (“balloon lling”) is reduced to 5 
seconds; we have less time available to ll the balloon with 
air and hence the balloon will only be partially inated. 
Thus a “balloon failure” condition appears. The ability to ll 
a balloon with air is also dependent on the properties of 
the material that it is made of. The thicker and more 
inexible the material (“stiffer”1), the harder it will be to 
inate (“balloon stiffness”), and a greater force or “stress”2 
must be applied to achieve the same results. This is 
analogous to a condition where the walls of the heart 
become thicker and/or increase in stiffness (“heart 
stiffness”) and it gets harder for the heart to ll. Again the 
“failure” condition ensues. Importantly these processes 
can occur without changing the balloon lling time. Since 
both types of balloon failure described (balloon lling time 
and balloon stiffness) occur during the lling of the balloon 
we term it “balloon lling dysfunction”. 
The heart is not that different from a balloon, and a 
chronic perturbation of the heart cycle – “cardiac cycle” – is 
clinically classied as a cardiac disease or heart failure (HF) 
condition. Just in Europe over 15 million people are 
diagnosed with HF and this number continues to rapidly 
increase, representing a major cause of hospitalization and 
death. About half of the HF patient population have a heart 
which is unable to proper relax and distend (ll). Classically, 
heart function has been separated into several distinct 
phases. Even though the events of the cardiac cycle are 
mutually related, their modus operandi is distinct. Similar to 
the emptying and lling of the  balloon, the heart needs to 
rst stop “squeezing” (ejecting blood) so that it can start to 
relax – “myocardial relaxation” (inactivation). Only after the 
heart relaxes will it be able to ll and distend. During the 
lling phase alterations to the macro- (e.g. wall thickness, 
chamber geometry) or micro-properties (e.g. sarcomere 
stiffness and collagen deposition) of the tissue will change 
the heart’s diastolic stiffness, stress and “elasticity”3. It 
takes a healthy heart ~0.1 seconds to completely relax 
(isovolumetric relaxation); and another ~0.4 seconds to ll 
and distend to a total of 120 ml of blood (lling phase) 
before “isometric contraction” takes place. Together these 
processes of relaxation and lling are known as the 
diastolic phase of heart function. Hence, perturbations or 
disruption to these processes lead to “DIASTOLIC 
DYSFUNCTION”.
In this thesis, I have studied the mechanisms that affect 
myocardial relaxation and contribute to 
DIASTOLIC DYSFUNCTION of the heart. 
These include changes of “SARCOMERE LENGTH”, 
“Ca2+“ and “MYOCARDIAL ENERGETICS”.
A heart completely lled with blood is able to generate 
more pressure during contraction than a half full heart. This 
is because more of the heart muscle is engaged to contract 
and eject blood. This provides the basic frame work for 
what is known as the “FRANK-STARLING LAW”. This Law 
relates the extent of heart lling (known as 
“length-dependency”) with the amount of pressure 
generated during contraction. From these ndings comes 
the universal principle that the amount of blood ejected 
from the heart must equal the amount of blood acquired 
during lling. The force for heart contraction is generated 
by the unitary building blocks of the heart muscle, which 
are known as “sarcomeres”. Sarcomeres increase in length 
during lling which increases contractility of the heart cells. 
The term “SARCOMERE LENGTH-DEPENDENT 
ACTIVATION” describes the FRANK-STARLING LAW at the 
single cell level. Disruption of sarcomere lengthening 
function can result in improper lling of the heart 
(DIASTOLIC DYSFUNCTION) which affects the hearts 
ability to generate force and limits the amount of blood 
pumped to the body. If it takes the healthy heart ~0.5 
second to entirely ll to a total of 120 ml blood during the 
diastolic phase, it will take another ~0.3 seconds to 
contract and eject – “systolic phase” – 70 ml of that blood 
to maintain a steady ow to the body. The heart never 
completely empties as residual volume is present at all 
times. In HF patients the FRANK-STARLING RESERVE is 
limited, which is detrimental to maintaining a steady blood 
perfusion to the body (cardiac output). Exploring deeper 
into the sarcomeres reveals the myolament proteins. 
These come in two types: thin- (actin-containing) and thick- 
(myosin-containing). Molecular interactions between the 
actin and myosin proteins (“cross-bridges”) generate the 
contraction of the sarcomere. Cross-bridges activation is 
regulated by Ca2+ and the MYOCARDIAL ENERGY 
RESERVE that regenerates ATP from ADP.
As it will be seen, it is the interplay of SARCOMERE 
LENGTH, Ca2+ and MYOCARDIAL ENERGETICS that 
regulate the diastolic function of the heart. 
When any, or several, of these mechanisms fail 
DIASTOLIC DYSFUNCTION follows.
1Stiffness - The rigidity of an object to which it resists deformation in 
response to an applied force. The SI unit is N/m.
2Stress or Pressure - The force exerted on a material normalized to 
the area over which the force is acting. The SI unit of stress is the 
pascal (Pa). 1 Pa = 1 N/m2. Force applied perpendicular to the 
material surface – compressional or extension stress. Force exerted 
parallel to the surface - shear stress.
3Elasticity - The property of a material to deform in response to an 
applied force and returns to its original state when the force is 
removed.
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9part I • foreword
One that initiates a PhD research project, for which I include my teenage self and many 
of my friends, wrongly assumes that the current knowledge in all fields of Science is 
only a few decades old and that all fundamental knowledge about Science is well 
known to man. This leads to the unfortunate situation of forgetting the persons that 
paved the ways in Science, and additionally may discourage a newcomer to initiate 
a research project. However, and importantly, one should learn from history that our 
current understanding of Nature is by no means only decades old, has not stopped, 
and that it is the convergence of intellectual knowledge gathered over hundreds 
and hundreds years of research. I find the words of William Thomson at the end of 
the 19th century the best way to illustrate the above. In 1900 the British physicist and 
engineer William Thomson better known as Lord Kelvin, when addressing the British 
Association for the Advancement of Science, remarked that in physics there were no 
more fundamental discoveries to be made.
There is nothing new to be discovered in physics now. All that remains is more and 
more precise measurement.
Kelvin made important contributions to the analysis of electricity and 
the formulation of the 1st and 2nd laws of thermodynamics and is best known for 
determining the precise value of the lowest temperature existing in the universe 
(absolute zero). This value approximates -273ºC; Units of Kelvin, a measure of 
temperature, named in his honor. Lord Kelvin’s quote always comes to mind, 
because I believe that nowadays we share the same erroneous belief as those that 
lived hundreds of years ago. Lord Kelvin’s remark may have been triggered by 
the discoveries of several fundamental Laws of Nature by Nicolaus Copernicus, 
Galileu Galilei, Isaac Newton, Michael Faraday, James Clerk Maxwell to name a few. 
However, what history teaches us over and over again is that his remark could not 
be more wrong. For instance, just 5 years after Kelvin spoke those words, a young 
German graduate physicist living in Bern, Switzerland, at the age of 26, published 
4 papers, which are considered some of the most important contributions to Physics 
and Science of all time. His name was Albert Einstein. The year of 1905 became 
known as “Annus mirabilis” from the Latin “miraculous year” of Einstein, and 
Special/General relativity would change the Newtonian view of the universe forever. 
I do not intend to end and conclude with that we should all be Albert Einstein, but 
instead that we should be open to the idea that there is still more exciting and 
fundamental knowledge to be discovered, that complexity should not discourage us, 
and that there is a lot to be gained from pursuing ones dreams.
I hope you will enjoy reading the fundamental studies I performed during my PhD, 
for which I also desire to understand Nature’s Laws, secrets and the remarkable 
complexity attached to it. I hope the generalizations of my findings provoke 
the exchange of constructive ideas among researchers everywhere.
1
introDuCtion witH tHesis outline
“It’s not that I’m smart, it’s just that I stay with problems longer.”
Albert Einstein
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Heart failure anD DiastoliC DysfunCtion
In Europe over 15 million people are diagnosed with heart failure (HF) and this 
number continues to rapidly increase, representing a major cause of hospitalization 
and death.1 HF is a clinical syndrome defined as the inability of the heart to sufficiently 
supply blood to organs and tissues.2 About half of the HF patient population presents 
with contractile dysfunction and ventricular dilation (HF with reduced ejection 
fraction). The other half of the HF patient population has a heart which is unable to 
properly relax and distend.3 These patients show near normal contractile function and 
often hypertrophy of the heart, and are characterized by abnormal diastolic function 
(HF with preserved ejection fraction, HFpEF).3
Diastolic dysfunction does not solely affect non-familial cardiac disorders as it is 
a common defect in patients with cardiomyopathies. Hypertrophic cardiomyopathy 
(HCM) is the most common inherited form of cardiomyopathy, frequently caused 
by gene mutations encoding sarcomere proteins and characterized by asymmetric 
hypertrophy.4 HCM-causing mutations that affect genes encoding the thick- and 
thin-filament proteins account for ~98% of all HCM mutations reported thus far in 
humans.5 Importantly, both animal6,7 and clinical8-10 studies have shown that carriers 
of HCM-causing mutations demonstrate signs of diastolic dysfunction, even before 
a hypertrophic phenotype is observed.
In this thesis, I have studied cellular mechanisms (calcium, sarcomere length, 
ADP and protein phosphorylation) that, in a complex interplay, regulate relaxation of 
the heart muscle. Perturbations in these cellular mechanisms may underlie diastolic 
dysfunction of the failing heart.
CarDiaC CyCle
The cardiac cycle is characterized by the periods of systole and diastole, which are 
central to the propelling of blood throughout the four cavities of the heart. Systole 
is the ability of the heart to contract and eject the blood to the lungs and systemic 
circulation, while diastole refers to the period of cardiac relaxation and filling. 
Cardiac muscle relaxation is the active process that follows contraction, during 
which the heart decreases its pressure inside the ventricle, fills with blood and 
prepares for the next cycle of contraction. In the healthy heart the relaxation phase 
encompasses part of the ejection phase, pressure fall and the initial part of rapid 
filling.11 Even if the contraction of the heart is normal, shortening of the relaxation 
phase will limit proper filling of the ventricle and thereby reduce cardiac output, which 
can result in HF. 
Determinants of DiastoliC funCtion
Myocardial relaxation is intimately related to the ability of the heart muscle 
to i) decrease intracellular Ca2+ levels, ii) reduce myofilament Ca2+-sensitivity 
(i.e. thin-filament deactivation), iii) efficiently modulate ATP hydrolysis and iv) detach 
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cross-bridges (ATP-dependent and mechanical-dependent), which reduces sarcomere 
stiffness. Moreover, myocardial relaxation is modulated by v) β-adrenergic receptor 
activation. A detailed description of each is given below (Figure 1).
I. Modulation of myocardial relaxation via intracellular Ca2+-decline
Striated muscle contraction and relaxation is dependent on the modulation of 
intracellular Ca2+. It takes ~1 mM extracellular Ca2+ to increase free cytosolic Ca2+ from 
0.1 μM during diastole to ~1.6 μM in systole to induce myofilament contraction.12 Ca2+ 
is highly buffered in cells, which can be attributed to the Ca2+ bound to the thin-filament 
cardiac troponin C (TnC) and the intracellular Ca2+ store (sarcoplasmic reticulum, SR), 
regulated by the SR-Ca2+-ATPase (SERCA).12 In contrast to skeletal muscle, that almost 
entirely depends on Ca2+ released from the SR to initiate contraction, cardiac muscle 
depends on both Ca2+ entering the cell via the sarcolemma and Ca2+ released from 
the SR (termed Ca2+-induced Ca2+-release) during an action potential.12-15 In order 
for relaxation to occur, Ca2+ must be removed from the cytoplasm through four Ca2+-
transports: 1) uptake of Ca2+ into the SR by SERCA; 2) Ca2+ removal via the Na+/Ca2+- 
exchanger; 3) mitochondrial Ca2+-uptake; and 4) Ca2+ removal by the sarcolemmal 
Ca2+-ATPase pump.16 
Impaired Ca2+-reuptake/removal by one or several of these regulators will increase 
diastolic [Ca2+], resulting in a state of permanent cross-bridge activation and limited 
myocardial relaxation.17 
II. Modulation of myocardial relaxation via myofilament Ca2+-desensitization 
(thin-filament deactivation)
Myofilament activation and contractility depend on the interaction between the thin 
actin and thick myosin filament. This interaction is initiated upon electrical activation 
of cardiomyocytes and the resulting increase in cytosolic [Ca2+]. It has been suggested 
that the myofilaments oscillate between three biochemical equilibrium transitions, 
reflecting different interactions between actin and myosin termed the blocked 
(B-state), closed (C-state) and open (M-state) states of thin-filament regulation.18,19 
In the B-state Ca2+ is not bound to cTnC and tropomyosin sterically blocks the myosin-
binding sites on actin. The B-state equilibrium is associated with a weakly bound state 
of cross-bridges. In the C-state, Ca2+ binds to cTnC, which changes conformation of 
the troponin complex and results in a ~25º movement of tropomyosin on the thin 
filament, thereby exposing most of the myosin-binding sites on actin.19,20 However 
in the C-state the myofilament is not yet activated as non-tension-generating cross-
bridges are still weakly-bound to actin. The C-state is characterized by intermediate 
thin-filament activation. The third and final state, the M-state, involves the strong-
binding of tension-generating cross-bridges that induces an additional ~10º 
movement of tropomyosin on the actin filament, resulting in myofilament contraction 
and force development.19,20 Muscle relaxation depends on the equilibrium between 
the 3 states of thin-filament activation. 
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Disease-mediated changes in myofilament properties may shift the equilibrium to 
a more activated state (C- or M-state), and thereby increase accessibility of myosin-
binding sites on actin, which would increase myofilament force development and limit 
cardiac relaxation. Defective myofilament proteins as a result of HCM gene mutations 
may directly impair regulation of muscle contraction. Evidence from genetic mouse 
models and in vitro experiments indicates that HCM sarcomere mutations sensitize 
myofilaments to Ca2+.4,21-23 The sensitizing effects of HCM mutations will increase 
the Ca2+-buffering capacity21 and affect diastolic function. In Chapter 3 we performed 
a comprehensive study on a large set of human HCM samples to identify whether 
high Ca2+-sensitivity is a hallmark of human HCM at low and high sarcomere length. 
In Chapter 6 we investigated if mutant proteins alter the accessibility of myosin-
binding sites on actin. 
III. Modulation of myocardial relaxation via efficient ATP hydrolysis of Ca2+-
handling proteins
Ubiquitous to the majority of energetic processes in living cells is the enzyme-
catalyzed breakdown of phosphoryl groups as a molecular energetic source. A highly 
relevant reaction is the hydrolysis of ATP into ADP and inorganic phosphate (Pi). 
Because Ca2+-reuptake by the SR is an ATPase driven reaction, a decline in the rate of 
ATP breakdown will limit Ca2+-decline in the cytosol. This may result from decreased 
availability of ATP and/or elevation of ADP/Pi, which will reduce the free energy 
released from ATP hydrolysis (∆GATP). This thereby depresses the activity of SERCA 
and other sarcolemmal pumps, and delays cytosolic Ca2+ -decline, contributing to 
Ca2+-overload.24 Again, this will lead to a permanent state of cross-bridge activation 
during the diastolic phase due to high diastolic Ca2+. In Chapter 5 we measured Ca2+-
transients of intact rat cardiomyocytes following elevation of ADP to assess alterations 
of Ca2+-handling properties.
IV. Modulation of myocardial relaxation (ATP-dependent and mechanical-
dependent)
ATP-induced detachment of myosin from actin
At the myofilaments, ATP is the energy-producing reaction whereby ATP hydrolysis 
(chemical) powers the interaction and sliding of myosin on actin, in order to generate 
force and motion (i.e. mechanical work). Even though the energy released from ATP 
hydrolysis is the driving force for myosin-actin interaction and cross-bridge cycling, 
cross-bridge detachment is independent of the hydrolysis of ATP. Indeed, myosin 
detachment from actin occurs upon ATP binding to myosin (after ADP has diffused 
from the nucleotide-binding site of myosin). As little as 0.1 mM ATP is sufficient for 
cross-bridge detachment and sarcomere relaxation.25 The relatively high myocardial 
in vivo ATP levels in the healthy heart (8-11 mM) and various cardiac pathologic 
conditions (7-10 mM)26-28 thus favour efficient myofilament relaxation. 
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However, supra-physiological [ADP] (≥250 µM) has been shown to reduce 
myofilament shortening velocity and generate rigor tension in cardiac muscle from 
animals by reducing the rate of cross-bridge detachment.29,30 In vivo myocardial 
ADP levels ranging from 10-50 μM in healthy and of 40-140 μM in diseased hearts26-
28 have been reported in animal models. Elevated ADP levels may thus represent 
a cause of diastolic dysfunction. To test this hypothesis, in Chapter 5 we performed 
a comprehensive molecular, cellular and whole organ study to dissect the physiological 
levels of ADP and Ca2+ necessary to impair myofilament function.
Mechanical-induced detachment of myosin from acting
Actomyosin cross-bridge detachment is not solely dependent on ATP-binding. 
There is theoretical31,32 evidence that supports a mechanical detachment of cross-
bridges, where up to 80% of attached cross-bridges mechanically detach from actin 
upon stretch. Indeed, rapid shortening and re-lengthening procedures in muscle 
showed that myosin can be mechanically detached from actin.33,34 Such mechanical 
cross-bridge detachment would be favored by high filling of the ventricles during 
diastole.  One may hypothesize that conditions which decrease the detachment 
rates of myosin, impose rigor stiffness and limit muscle lengthening. In Chapter 5 
these concepts were directly tested by applying a protocol of a rapid shortening 
and relengthening procedure to evaluate how sarcomere stiffness is affected by 
physiological levels of ADP and Ca2+. In Chapter 6 we used the concepts which were 
established in Chapter 5 in human cardiomyopathy samples to evaluate if cross-
bridge rigor stiffness is altered in sarcomere-mutation positive HCM.
V. Modulation of myocardial relaxation via β-adrenergic receptor activation
Regulation of intracellular Ca2+-levels is directly associated with sympathetic activation 
of the β-adrenergic receptor pathway as occurs during increased cardiac stress 
(i.e. exercise). Upon stimulation of the β-adrenergic receptors by catecholamines, 
cyclic AMP (cAMP) levels are elevated35,36, resulting in activation of the catalytic 
subunit of protein kinase A (PKA)37-43. PKA mediates positive inotropic, lusitropic 
and chronotropic responses via phosphorylation of a multitude of factors including 
Ca2+-handling proteins44-46 and the myofilament proteins cardiac troponin I (cTnI)43,47, 
cardiac myosin-binding protein C (cMyBP-C)48-50 and titin.51 β-adrenergic receptor 
activation accelerates Ca2+-reuptake to the SR  via reductions in myofilament Ca2+-
sensitivity40,41,52-54 and increased SERCA activity, which in concert positively modulate 
myocardial relaxation. Along these lines, the Ca2+-sensitizing effects of the HCM-
associated troponin T (I79N, F110I) mutations, and the Ca2+-sensitizing drug EMD 
57033, increase the Ca2+-binding affinity (“sticky myofilaments”).55,56 This delays Ca2+-
reuptake during diastole and increases end-diastolic Ca2+ and makes diseased hearts 
more susceptible to lethal arrhythmias.55,56 In Chapter 3, we studied the myofilament 
function of human HCM samples before and after treatment with exogenous PKA to 
reveal if myofilament defects are caused by the mutant protein or by a secondary 
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disease-related reduction in PKA-mediated protein phosphorylation. Moreover, in 
Chapter 6 we investigated if PKA-phosphorylation deficits alter accessibility of myosin-
binding sites on actin, which are predicted to modulate myofilament Ca2+-sensitivity.
frank-starling relationsHiP – a regulator of 
DiastoliC funCtion
The ability of the heart to adjust the force of its contraction in response to the dynamic 
changes in ventricular filling forms the basis of the Frank-Starling Law. Ventricular filling 
regulates the relation between length and tension, thereby controlling ventricular 
contraction and ejection.57,58 An increase in muscle fiber length as a result of increased 
filling during diastole, enhances the maximal force generating capacity and sensitivity 
of myofilaments to Ca2+, leading to increased force development during ventricular 
contraction.57,58 In other words there is a direct relation between sarcomere length 
and myofilament sensitivity to Ca2+ ions, such that more force is generated at a given 
concentration of Ca2+ when sarcomere length is increased. The term ‘myofilament 
length-dependent activation’ describes the length-dependent properties of 
the myofilaments.57 Clinical observations have shown that HFpEF59-61 and end-stage 
HF62,63 patients have limited capacity to recruit the Frank-Starling reserve. Impaired 
length-dependent activation is also observed in membrane-permeabilized end-stage 
human cardiomyocytes.64 
It has long been appreciated that β-adrenergic receptor activation induces a potent 
inotropic response of the heart. At the cellular level, length-dependent activation was 
shown to be positively regulated by isoproterenol, a β-adrenergic receptor agonist65-
67. Notably, in HF patients β-adrenergic receptors and PKA are down-regulated, 
while protein kinase C (PKC) is over-expressed68. Length-dependent activation 
can be modulated by protein phosphorylation. Hence, reduced PKA-mediated 
phosphorylation and increased PKC-mediated phosphorylation may underlie 
the blunted length-dependent activation which is observed in HF.  
A limited Frank-Starling reserve has been observed in HCM patients.69 This 
is supported by recent studies in human9,10 and mice7 with HCM that clearly show 
defects of cardiac relaxation that precede the occurrence of left ventricle hypertrophy. 
The diminished capacity to relax, decreases diastolic filling and limits the effects 
exerted by length increases, i.e. the Frank-Starling reserve is not used. Indeed, 
a restricted Frank-Starling reserve has been observed in HCM mutation carriers 
and transgenic mice models with severe left ventricle hypertrophy.10,70-72 Data on 
length-dependent activation in transgenic mouse models harboring HCM mutations 
have been conflicting and reported either reduced or preserved length-dependent 
activation.52,73-75 Findings in mouse models are sometimes difficult to extrapolate to 
human due to differences in myosin-heavy chain (MyHC) background: the α-MyHC 
isoform is predominant in mouse ventricles, whereas β-MyHC is the predominant 
form in the human adult ventricle. A recent study by Ford and colleagues75 in mice 
expressing the troponin T R92L mutation in the physiological (mouse-like) α-MyHC 
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background demonstrated preserved length-dependent Ca2+-activation. Interestingly, 
length-dependent activation was impaired in mice harboring the R92L mutation in 
a human-like β-MyHC background.75 These studies emphasize the importance of 
myofilament studies in cardiac samples from human HCM patients. Therefore, in 
Chapter 3 we conducted a large study in human HCM samples to assess if impaired 
length-dependent activation is a common feature of human HCM, and if this is related 
to reduced PKA-mediated phosphorylation of myofilament proteins. Moreover, in 
Chapter 4 we investigated if high PKC target-site phosphorylation (Thr143) of cTnI 
regulates length-dependent activation.
figure 1. Schematic drawing of the determinants contributing to myocardial relaxation.
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aim of tHis tHesis
As discussed above, myocardial relaxation is regulated through interacting mechanisms 
such as the rate of intracellular Ca2+ decay, myofilament Ca2+-desensitization, ATP 
hydrolysis, the rate of cross-bridge cycling, ATP-dependent and mechanical cross-
bridge detachment and post-translation modulation (Figure 1). The aim of this thesis 
was to dissect the cellular alterations related to myocardial relaxation that may 
contribute to impaired diastolic function in heart failure. 
tHesis outline
Part 1. Regulation of length-dependent activation, the cellular basis of  
the Starling Law of the Heart
In Chapter 2 an historic perspective of muscle function is provided. Herein a century 
of scientific research is “revived” from the heart’s fundamental protein constituents 
(contractile proteins), to their assembly in the muscle (the sarcomeres) culminating 
in an overview of the synergistic events that underlie the Frank-Starling mechanism. 
As the Frank-Starling Law is a vital mechanism for the healthy heart, it is of utmost 
importance to understand its mechanical basis to develop and optimize therapeutic 
strategies to rescue the failing human heart. It is my personal belief that much can be 
gained by understanding the Frank-Starling relation at the cellular and whole organ 
level, so that we can tackle the pathophysiologic mechanisms underlying heart failure.
In Chapter 3 we conducted a comprehensive study on a large set of human 
HCM samples to identify whether length-dependent activation provides a unifying 
explanation for impaired diastolic function in HCM caused by thick-and thin-filament 
protein mutations. Measurements in membrane-permeabilized single cardiomyocytes 
isolated from sarcomere mutation-positive HCM, sarcomere mutation-negative HCM 
and non-failing donors were performed. To provide direct proof that mutant protein is 
responsible for the observed effects, troponin exchange experiments with exogenous 
recombinant wild-type troponin were performed in a unique HCM sample carrying 
a homozygous troponin T mutation. Finally, myofilament protein phosphorylation 
was determined using a combination of Pro-Q Diamond/Sypro Ruby staining and 
phospho-specific antibody targeting. Myofilament Ca2+-sensitivity, phosphorylation 
background and length-dependent activation mechanisms were studied to 
understand if determinants of diastolic function are affected by gene mutations in 
sarcomeric proteins.
In Chapter 4 the effects of cTnI threonine 143 (Thr143) phosphorylation by PKC 
on length-dependent activation were studied. Troponin exchange experiments were 
performed in membrane-permeabilized human cardiomyocytes. Human recombinant 
wild-type troponin and troponin containing pseudo-(de)phosphorylated cTnI at 
Thr143 were exchanged in non-failing donor and failing cardiomyocytes. Because 
increased PKC-mediated phosphorylation of Thr143 has been reported in HF models, 
we investigated if phosphorylation of Thr143 modifies myofilament length-dependent 
activation in human cardiomyocytes.
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Part 2. Myocardial ADP accumulation and contribution of cross-bridge 
formations to diastolic dysfunction
In Chapter 5 we analyzed the effects of myocardial ADP accumulation as a contributor 
to diastolic dysfunction. In this study two main determinants of myocardial relaxation 
were tested, including processes that affect the rigidity of the myocardial wall and 
the rate of myocardial relaxation. Measurements in membrane-permeabilized single 
cardiomyocytes isolated from human failing hearts were performed in the presence 
of ADP (in the absence of Ca2+), in the presence of Ca2+ (in the absence of ADP) and 
in the presence of Ca2+ in concert with ADP. Also, the contribution of cross-bridges 
(actin-myosin interaction) relative to titin was studied with conditions mimicking 
the in vivo situation. We investigated if and how cytosolic ADP accumulation, in 
concert with diastolic [Ca2+], may underlie impaired diastolic performance.
In Chapter 6 we studied if ADP-stimulated force development (without Ca2+) can 
be used to reveal changes in actin-myosin blockade (i.e. accessibility of myosin-
binding sites on actin) in human cardiomyopathy cardiomyocytes. Cardiac samples 
from HCM patients, harboring thick- and thin-filament mutations, and idiopathic 
dilated cardiomyopathy, were compared with sarcomere mutation-negative HCM and 
non-failing donors. Also, experiments were performed in the presence of Ca2+ and 
force development and stiffness was analyzed. We investigated if the equilibrium of 
the thin filament activation states is disrupted in human cardiomyopathies, and may 
contribute to impaired diastolic function. 
Part 3. Summary, Conclusions & Curriculum Vitae
Chapter 7, Summary, Conclusions & Future Perspectives
Chapter 8, Curriculum Vitae of the PhD candidate
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“It had long since come to my attention that people of accomplishment  
rarely sat back and let things happen to them.  
They went out and happened to things.”
Leonardo da Vinci
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HistoriCal musCle PersPeCtive
No other organ has inspired so many writers, poets and songwriters as the heart. It is 
the symbol of love and passion and was once believed to be the place where the soul 
resides. Even looking at it with cold, unromantic eyes of science, one can appreciate 
the beauty of this remarkable organ and the circulation attached to it. (with permission 
Diederik Kuster)
tHe Heart
The heart and its vessels, comprises one unique – cardiovascular - system that is 
responsible for the motion of blood throughout the body.1 William Harvey’s 1628 
publication “Exercitatio anatomica de motu cordis et sanguinis in animalibus” 
(On the motion of the heart and blood in animals) showed for the first time: 1) “that 
the blood moved in a ceaseless stream, as it were in a circle” and 2) “that the heart 
is the great propelling power”.1 Although the anatomy of the heart was well known 
to physicians at the time of Harvey, namely the existence of four cavities divided by 
an “impermeable” septum and valves that prevented backflow of material, it was 
however generally accepted that the heart was “a generator of vital spirits, and of 
heat” and that the propelling of blood was an “act of inspiration, and its flow to any 
part of the body determined by special excitation” (Figure 1).1 
figure 1. A schematic overview of the cardiovascular system over time. A. Veins (blue) and 
arteries (white) are separate. Veins transport blood, in opposition to arteries that transport air. B. 
Arteries (red) transport blood from right side of the heart, after it passes through invisible pores in 
the septum. C. Establishment of the pulmonary circulation that transports blood through the lungs 
to the left side of the heart, and the liver was the source of veins and the propelling power of blood. 
D. Harvey’s view of the cardiovascular system. (Figure adapted from Aird WC, 20112 with permission 
John Wiley and Sons).
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As we look back to ancient times it is thus obvious to understand why the heart 
has captured the imagination of so many people. The heart is the only organ whose 
function we can assess at the body’s surface. Can you imagine the admiration our 
ancestors felt when feeling their heart beat after a threatening or a positive emotional 
situation? It was only natural to them that this “generator of vital spirits, and of heat” 
was emanating some powerful spirit or emotion, which they could feel instantly in 
their chests via the acceleration of its beat. 
The anatomy of the heart, as it was known before William Harvey in 1600, remains 
almost unaltered today. Four chambers are observed: two superior atria, right and 
left atrium; and two inferior ventricles, the right and left ventricle. A transverse 
inter-dividing septum separates the right from the left side. Veins connect the right 
and left atria, the venae cavae and pulmonary veins, respectively; in opposition to 
arteries that connect to the right and left ventricles, the pulmonary artery and the 
aorta, respectively. Semilunar valves both at the pulmonary artery and aorta prevent 
backward motion of blood into the right and left ventricle, respectively. In addition, 
atrioventricular or cuspid valves (tricuspid, the right valve; bicuspid or mitral, the left 
valve) prevent backflow of blood from the ventricles into the atrium during contraction.
Cardiac cycle
The cardiac cycle is characterized by the periods of systole and diastole.  In brief, 
systole comprises isovolumetric contraction and ejection, while diastole refers 
to the period of isovolumetric relaxation and filling. The cardiac cycle periods are 
central to the propelling of blood through the four cavities of the heart. Notably, 
the concepts of systole and diastole did not always have the same meaning. 
As Brutsaert and Sys3 describe: 
This is not surprising, as the meaning of most scientific words may be subject to 
modification as long as the experiments, observations, theories, and concepts 
to which they refer have not been clearly elucidated. Due to the confusion about  
the meaning and delineation of systole and diastole, Edgren, as early as 18894, 
insisted that both these terms ought to be banished altogether from medical literature 
and ought to be replaced simply by contraction and relaxation, respectively. (Brutsaert 
and Sys3 with permission Physiological Reviews)
William Harvey was the first to correctly define diastolic (relaxation) and systolic 
(contraction) phases of the heart, as it was previously believed that diastole reflected 
the contraction period (´the dilatation of arteries at each pulse´).1
Whence the motion which is generally regarded as the diastole of the heart, is in truth 
its systole. And in like manner the intrinsic motion of the heart is not the diastole but 
the systole. (William Harvey1. Publisher and author could not be located) 
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It took 300 years before Carl J. Wiggers5,6 consolidated the meanings of systole 
and diastole that survive with minor modifications up to day; the clinical division 
of systole and diastole is based upon the closure and opening of the mitral and 
aortic valves.3 
“The working capacity of a pump is measured by its output”
In the human body the heart is the main responsible for the supply of blood perfusion 
with vital nutrients and gases to organs and tissues. It is thus only natural that 
the study of the heart parallels that of a pump, which moves fluids by mechanical 
action. The pump function of the heart is used to assess cardiac function in humans. 
As stated by Patterson and Starling, “the working capacity of a pump is measured 
by its output.”7 In the heart, cardiac output (CO) is the interdependence of blood 
volume ejected by the ventricles per contraction/heart beat - stroke volume (SV) - and 
the heart beat frequency - heart rate (HR) - occurring in one minute [CO = SV x HR]. 
Harvey’s description of the motion of blood greatly advanced the thinking of 
nineteenth-century physiologists8-11 and remains remarkably accurate to day. This was 
summarized by Patterson and Starling7 one hundred years ago (1914),
At the beginning of ventricular systole the ventricular muscle passes rapidly from 
a condition of relaxation to one of contraction. The auriculo-ventricular valves 
close at the very commencement of the ventricular contraction. The contraction of  
the muscle, or rather the rise of contractile stress, then proceeds for a time isometrically 
[this phase is not entirely isometric, but is isovolumic (volume remains unaltered), 
as individual fibers undergo changes in length (shortening and/or lengthening)12,13], 
while the pressure in the ventricle is rising to the pressure in the aorta. When  
the pressure rises to this point the aortic valves open and the muscle fibres are able 
to shorten. The pressure, however, continues to rise for a time and then falls […].  
The contraction then ceases and relaxation begins with coincident rapid fall of 
pressure in the ventricle below that in the aorta, which causes a closure of the aortic 
valves. From this time forward the relaxation of the ventricular muscle [ensues] [...] in 
order that the ventricular muscle may lengthen, the ventricles have to be distended by  
the inflow of fluid, though the pressure necessary to distend them is almost negligible. 
But whereas in the case of the skeletal muscle (under ordinary experimental conditions) 
the tension exerted by the extending force is the only factor of importance, in  
the heart the rate of application of the extending force, i.e., the rate of inflow of 
the blood, is still more important than the tension exerted by it on the walls of  
the ventricle. The ventricles cannot dilate unless fluid enters them, so that they may 
be, so to speak, ‘after-loaded’ at every stage of their relaxation. If blood therefore 
does not enter the heart, the ventricles do not dilate at all during diastole and may 
become smaller and smaller with each systole until they are empty. (Patterson and 
Starling7 with permission John Wiley and Sons)
Identical processes occur on the right side of the heart, differing mainly from 
the left side by: 1) thinner right ventricular wall, associated with 2) lower pressures, 
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and 3) lower resistance to outflow – afterload - into the 4) pulmonary trunk 
(pulmonary circulation).1,14,15
tHe frank-starling law of tHe Heart
The ability of the heart to adjust the force of its contraction in response to changes in 
ventricular filling (end-diastolic volume, EDV) forms one of the main pillars of muscle 
physiology. Ventricular filling sets the relation between sarcomere length and tension 
development, and determines the degree of muscle shortening, which thereby 
regulates ventricular contraction and ejection.
The observation that cardiac muscle contraction is the interdependent relation 
between tension development, heat production and the extent of muscle shortening, 
as a function of the initial length of a muscle fiber, was first described for skeletal 
muscle by Magnus Blix16 and von Kries17,18. They proposed that the energy of 
a contracting muscle is a function of its length and that its shortening velocity is directly 
proportional to the “afterloaded” condition (e.g. shortening velocity increases as 
afterload decreases). The latter findings were later applied by the German physiologist 
Otto Frank11,19 to the heart, who proposed that the developed pressure was directly 
proportional to the initial diastolic tension. 
Length and tension changes in skeletal muscle correspond to changes in volume 
and pressure [in the heart]. By measuring these values and establishing their 
time relationships, one is able to examine the play of forces in the entire heart.  
(Otto Frank19 with permission Elsevier)
[…] if initial tension (or filling) is continuously increased by means of raising  
the blood-reservoir, the ejected volume increases until the initial tension has become 
equal to the pressure in the arterial system. (Otto Frank19 with permission Elsevier) 
However, Otto Frank’s experiments were inconclusive to whether an increase in 
the force of contraction was related to the initial diastolic tension or length of muscle 
fibers.20 Ernest Starling and colleagues7,20,21 later showed that “it is length rather than 
tension which determines the energy of contraction” and therefore stated: 
There can be no question therefore that it is the volume of the ventricles at  
the beginning of contraction rather than the pressure within their cavities, which 
determines the amount of energy set free during the contraction. (Ernest Starling22 
with permission Nature Publishing Group)
This relation between the length of the heart fibre and its power of contraction I 
have called ‘the law of the heart’ [...] The law of the heart is therefore the same as 
that of skeletal muscle, namely that the mechanical energy set free on passage from 
the resting to the contracted state depends [...] on the length of the muscle fibers 
[...]. The greater the length of the fibre, and therefore the greater amount of surface 
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of its longitudinal contractile elements at the moment when it begins to contract,  
the greater will be the energy in the form of contractile stress set up in its contraction 
(Patterson, Piper and Starling20 with permission John Wiley and Sons)
Accordingly, the “Law of the Heart” or the “Frank-Starling relation”, reflect 
the ability of the heart to adjust the force of its contraction, in response to volume 
changes in venous return. 
Thus the Frank-Starling relation explains beat-by-beat adjustment of cardiac 
output by both sides of the heart (“events on the right side reflect those in 
the left side of the heart, unless failure is present”7,23) and pathological conditions that 
directly affect the Frank-Starling response (e.g. diastolic dysfunction) represent life-
threatening situations. As we will see below, the Frank-Starling relation is inherently 
associated with its fundamental constituents - cardiac muscle cells. Notably, in 1914, 
Ernest Starling already desired to understand the pathological conditions that lead 
to heart failure (HF):
If there is increase inflow followed by optimal ED [end-diastolic] dilatation [...] beyond 
this point, the heart dilates pathologically and performance falls of. (Patterson and 
Starling7 with permission John Wiley and Sons)
Within physiological limits the larger the volume of the heart, the greater are  
the energy of its contraction and the amount of chemical change at each contraction. 
(Ernest Starling22 with permission Nature Publishing Group)
Fatigue of the heart may go on to heart failure. This occurs when the dilatation, 
which is the mechanical result of unchanging inflow and failing outflow and is  
the automatic means of regulating outflow to inflow, proceeds to such an extent 
that the tension of the muscle fibers becomes increasingly inadequate in producing 
rise of intracardiac pressure. (Patterson, Piper and Starling20 with permission  
John Wiley and Sons)
Frank-Starling Law of the heart, and its place in history
Several concepts initially scrutinized this Law, including 1) the originality of Frank 
and Starling’s ideas, namely that for several authors they rediscovered the relation 
of increased contractile power when the muscle size is increased;24,25 and 2) 
the objections to the clinical applicability of the concepts of the Frank-Starling relation 
over the last century.
1. For instance, in 1936, Hans Gremels26 was the first to speak about the “Frank-
Starling Law of Cardiac Work”19, advancing what some previously noted as some sort 
of a “flaw”: 
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The so-called Law of the Heart, which Starling rediscovered ten years later [than 
Frank]26 and that is linked with Starling’s name especially in the English literature (Otto 
Frank19 with permission Elsevier)
In addition, it is still open for debate as to whom the credit for the Frank-
Starling relation should be given.24,25 Abe Guz remarked in the introduction of 
the “Ciba Foundation Symposium 24 - Physiological Basis of Starling’s Law of 
the Heart”27 in 1973:
I have been asked why the title of this symposium was not ‘The Physiological Basis 
of the Frank-Starling Relation of the Heart’. If we were to give credit in full, we would 
have to call it the ‘Hales28-Haller29-Müller30-Ludwig31-Roy32,33-Howell34-Donaldson34-
Frank11-Starling22 relation (Abe Guz27 with permission John Wiley and Sons)
But earlier Chapman and Mitchell35 had argued that:
In any event, Starling’s work represents a convergence of various German and British 
intellectual forces [...] It was his genius that brought these various forces together in 
meaningful synthesis and it was largely his generalizations that provoked, and still 
provoke, highly constructive exchanges on the subject of myocardial control between 
biomedical scientists everywhere. (Chapman and Mitchell35 with permission Prof. Jere 
Mitchell)
It is my personal belief that Ernest Starling stated it as a “Law” and this view 
was expressed by Stephen Hawking (in his book the Grand Design) who stressed 
the importance of Nature’s Law’s to the success of mankind: “Today most scientists 
would say a [L]aw of nature is a rule that is based upon an observed regularity and 
provides predictions that go beyond the immediate situations upon which it is based.”
A Law requires the prediction of phenomena or events that go beyond the mere 
observation and can be measured and validated by others. 
2. The impact of the Frank-Starling Law gained wide acceptance after Starling 
presented his concepts in 191522 and 192036. This historical period is greatly illustrated 
by Chapman and Mitchell35, for which the author will present a short summary with 
authors’ quotes (Chapman and Mitchell35 with permission Prof. Jere Mitchell).
Starling’s concepts rapidly diffused from the 1920s till the 1940s, gaining wide 
appreciation in particular to describe HF. Later on, his work was subjected to intense 
scrutiny, mainly because during exercise it was stated “that with increasing work 
loads cardiac size increased; but the cardiac size was never as much as would be 
expected in view of the associated increase in cardiac output per minute”35 and that 
it could not explain cardiac failure37 as it was “found that injection of human albumin 
[albumin temporarily increases blood volume and pressure] into normal subjects and 
into patients with circulatory failure produced a rise in right atrial pressure but did 
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not affect cardiac output in a consistent manner”35. However, in the 1950s Starling’s 
concepts consolidated as one of the most important mechanisms of the heart, if 
not perhaps the most important. First by the work of John McMichael38 where “he 
published three theoretical curves [...] relating stroke work with filling pressure for 
the normal, the hypodynamic and the hypertrophied heart. The suggestion was 
that all three curves might be seen in a single heart, depending on experimental 
conditions”23 and secondly by the “curves hypothesis” from Sarnoff and Berglund39:
Many investigations of this matter in the presence of a complete circulation have 
been either inadequate or misleading largely because of the following: (1) stroke 
volume or cardiac output and not stroke work has been used as the measure of  
the “energy of contraction”; (2) attempts have been made to correlate right sided 
filling pressure with left ventricular stroke work; (3) attempts have been made to 
correlate filling pressure with ventricular work per minute instead of per stroke, and (4) 
perhaps most important, it has not been generally appreciated that a single Starling 
curve cannot always satisfactorily explain the observed phenomena; for any given 
heart there is a series or family of curves. (Sarnoff and Berglund39 with permission 
Wolters Kluwer Health, Inc) 
This line of thought has been since then further reevaluated and confirmed by 
experimentation with the final conclusion that the “[Frank-]Starling’s law of the heart 
is applicable to man”35.
CarDiaC reserve meCHanisms
The normal heart is able to maintain or increase its output by several mechanisms that 
are mutually related: 1) recruitment of the Frank-Starling reserve; 2) increasing heart 
rate, which enhances the force of contraction via increases in the force-frequency 
relationship or Bowditch effect; 3) increases in the peak force generated during 
a contraction - positive inotropic response or enhanced contractility (e.g. hormones); 
and 4) elevations of afterload and the Anrep effect. Following an afterload elevation 
(e.g. vascular resistance) there is a rapid increase of end-diastolic volume that increases 
contraction (Frank-Starling). This initial rapid response is followed by a progressive 
and time-dependent (1-2 minutes) enhancement of contractility, which is independent 
of length-alterations and allows the ventricle to recover towards its normal volume.40
Cardiac inotropic reserve
Other factors, such as hormones affect the pump function of the heart.36,40,41 In 1891 
Erik Johansson observed in dogs that stimulation of the splanchnic nerves raises 
arterial blood pressure.42 Later, Arno Lehndorff43 investigated a two-part rise of blood 
pressure confirming that the initial rise was due to vasoconstriction of the splanchnic 
area, and the second due to increased heart rate. Four years later, Thomas R. Elliott44 
demonstrated that the second rise was caused by secretion of adrenalin. Then Glen 
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von Anrep40 established the link between accelerated heart rate and the secretion of 
adrenalin described by Thomas R. Elliott44.
In this paper I give an account of some observations with regard to this, made at the 
suggestion of Prof. Starling [...] I have shown that the acceleration [of the heart beat] 
is due to the increased production of adrenalin. (Glen von Anrep40 with permission 
John Wiley and Sons)
These findings were extended by Ernest Starling36 who noted that secretion of 
adrenalin dramatically increases “the energy available at each contraction.”, i.e. 
the modern positive inotropic effect introduced in 1904 by Theodor W. Engelmann45. 
Charles M. Gruber46,47 observed similar findings in skeletal muscle, who showed that 
epinephrine exerts potent positive inotropic effects. 
The Anrep effect or slow force response
In 1912, Glen von Anrep40, working in Ernest Starling’s laboratory, observed that if 
arterial resistance was abruptly elevated, the end-diastolic volume first increased but 
then after several minutes an increased contractility occurred allowing ventricular 
volume to return to baseline40. Anrep showed that this phenomena was especially 
marked after adrenaline administration.40
We may conclude therefore that a mechanical rise of arterial pressure, even a very 
small one, always produces a passive dilatation. If however the blood-pressure be 
maintained steady at its new height, the heart always reacts in such a manner that it 
tends to return more or less to its normal volume, whether the change in pressure has 
been one of diminution or of increase. This reaction of the heart is especially powerful 
after the administration of adrenalin. (Glen von Anrep40 with permission John Wiley 
and Sons)
Two years later Patterson, Piper and Starling20 observed the same phenomena,
This two-fold effect of a rise or fall of arterial pressure was described by Anrep as an 
attempt of the heart to return to its proper volume. (Patterson, Piper and Starling20 
with permission John Wiley and Sons)
but attributed it effect to “improved nourishment of the muscle”, suggesting that 
myocardial metabolism occurs with increased coronary flow when arterial resistance 
is increased. The authors excluded the increased contractility has the resulting 
improvement of the contractile state of muscle. Anrep later discarded his own 
observations in favor of the much simpler explanation proposed by Patterson, Piper 
and Starling.35 However, in 1959, it was found by Rosenblueth and colleagues48 that 
the effect reported by Anrep was independent of coronary blood flow changes, which 
was also confirmed one year later by Sarnoff and colleagues49. Sarnoff and Mitch called 
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this the “Anrep effect”50, and named it the “homeometric autoregulation”49, because 
it did not depend on changes in length to distinguish it from the length changes in 
the Frank-Starling relation, the “heterometric autoregulation”. In brief, the Frank-
Starling mechanism is regarded as a rapid force response because it depends on fiber 
length alterations that act at each beat, thence classically operating on a “beat-by-
basis”; in contrast to the Anrep effect, a slow force response that is dependent on 
the contractile state and develops after a few minutes. In vitro studies commonly use 
the term “slow force response”.51 
Parmely and Chuch52 used isolated papillary muscle to show that stretching 
induces the Frank-Starling effect followed by a slow increase in inotropic state 
if the muscle length remained constant. This slow force response has been 
attributed to slow increases of the Ca2+-transient (in contrast to the Frank-Starling 
effect that is independent on Ca2+-alterations) due to stretch-induced release of 
autocrine/paracrine effectors, including angiotensin II, influx of Na+ or/and Ca2+ via 
stretch-activated sarcolemmal channels and augmented Ca2+ sparks as a result of 
stretch-induced production of nitric oxide.51 It is worth considering that the existence 
of such slow force responses may represent a compensatory mechanism that allows 
a given change in cardiac work (output) to be accomplished with smaller changes in 
end-diastolic volume (cardiac size). One can speculate that the second, slow force 
response compensates for the excessive use, or “fatigue”, of the Frank-Starling reserve. 
In other words, because the heart operates on the ascending limb of the Starling 
curve (1.8 μm to 2.3 μm sarcomere length; discussed below), enhanced dilation of 
the heart would impair the maximal force and shortening velocity developed. Thence, 
the heart, by the existence of sophisticated inotropic responses, efficiently regulates 
myocardial performance.
striateD musCle struCtural unit, tHe sarComere
Seventeenth century microscopists Robert Hooke and Antonie van Leeuwenhoek 
paved the way for the characterization and description of skeletal and cardiac 
muscle cells.53,54 Both types of cells have a striated pattern when observed under 
the optical microscope, and thus are collectively known as “striated muscle”. Solely 
controlled by the central nervous system, skeletal muscle cells are regarded as 
a “voluntary” muscle, as opposed to “involuntary” cardiac muscle, which is controlled 
by an intrinsic pacemaker activity under the control of the autonomic nervous system. 
Notably, the heart is able to maintain its contractility even without stimulation of the 
nervous system.
From this [dog heart-lung] preparation we learn that the heart, freed from all its 
nervous connections, has the power of automatically adjusting the force and extent 
of its contractions to the task which is set by the two factors determining its work, viz:  
the inflow into the heart from the veins, and the resistance offered to the outflow by 
the arterial pressure.(Ernest Starling36 with permission BMJ Publishing Group Ltd)
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Striated muscle fibers are composed of small assemblies, called “myofibrils” that 
contain the contractile components (Figure 2, upper image). They contain a succession 
of transverse striations that form the fundamental structural unit - the sarcomere 
(Figure 2, lower image).55,56 Each sarcomere is delineated by a pair of “Z-lines” 
(from the German word “Zwischenscheibe”; meaning “intermediate disc”55). 
Sarcomeres are characterized by alternate zones of light I (isotropic) bands and dark 
A (anisotropic) bands.53,57,58 Each I-band is bisected by a Z-line and consists of thin-
filaments, while the central A-band contains both thin- and thick-filaments.59 The H-band 
(from the German “Heller”; meaning “brighter”) in the middle of the A-band solely 
composed of thick-filament structures.60 Finally, a dark M-line in the middle of 
the H-band (so called from the German “Mittelscheibe”; meaning “central disc”),61 is 
critical for the organization of the thick-filaments in the sarcomere.62
Contractile components of muscle
During each heart beat, cardiomyocytes undergo changes in length and load to allow 
the filling or ejection of blood. The sarcomeres shorten by converting chemical energy 
into mechanical force to perform work. They contain the contractile proteins that 
govern muscle contraction and relaxation, and the structural proteins. Myofilament 
contraction requires the interaction of the thin- (actin-containing) and thick- 
(myosin-containing) filaments.64 Force production or/and muscle shortening are 
the collective sum of all the tension-generating cross-bridges. Regulation of this 
interaction depends on Ca2+ and ATP as well as the regulatory troponin-tropomyosin 
complex bound to the actin thin-filaments.65,66 The cytoskeleton forms the scaffold 
that regulates cell shape, provides mechanical integrity and resistance, and stabilizes 
the sarcomeric proteins. Importantly this framework mediates biomechanical and 
biochemical cell signaling that alters gene expression, post-translational modulation 
and protein synthesis.67,68
The sliding filament hypothesis
The official date of the ‘birth’ of the sliding filament theory of muscular contraction 
is May 22, 1954. On this day the journal Nature published two papers consecutively 
under the general title: ‘Structural Changes in Muscle During Contraction’. The first 
paper by Andrew F. Huxley and Dr. Rolf Niedergerke[69] was entitled: ‘Interference 
microscopy of living muscle fibres’. The second paper by Dr. Hugh Huxley and Dr. Jean 
Hanson[70] was entitled: ‘Changes in the cross-striations of muscle during contraction 
and stretch and their structural interpretation’. (Jack A. Rall71 with permission Springer)
These papers provided the molecular and mechanical foundations for muscle 
contraction. Both used high-resolution microscopy to study the structural arrangement 
of sarcomeres during contraction. They observed that during contraction, 
the A-band length remained constant, while the I-band changed length as it slid 
past the A-band.69,70 These observations signaled the ‘birth’ of the “sliding filament 
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hypothesis”. In 1957 Andrew F. Huxley64 proposed that the two sets of filaments 
interact and overlap forming several individual structures that Hugh E. Huxley termed 
as “cross-bridges”.72
Bridges are observed between primary [thick-filament] and secondary filaments [thin-
filament]. These bridges form part of the primary filaments, and in stretched muscles 
can still be seen projecting into the space from which the secondary filaments have 
been withdrawn […] Cross-bridges between primary and secondary filaments are 
prominent features of all these pictures. (Hugh E. Huxley72 permission not required)
figure 2. Anatomy of cardiac muscle. The (upper image) illustrates a group of myofibrils connected 
to the sarcolemma via the costamere network. The (bottom image) shows an individual sarcomere. 
Note the formation of distinct bands. The components are not drawn to scale. (Figure adapted from 
Sequeira et al, 201363 with permission Elsevier)
40
The resulting force is the collective sum of all “activated” cross-bridges that pull 
actin filaments towards the center of the sarcomere. Thick-filaments are organized 
in hexagonal arrays, and each thick-filament is surrounded by six actin filaments.73-77 
Myosin molecules are packed “tail-to-tail” at the center of the sarcomere in anti-
parallel alignment and optimize contact with the actin monomers (Figure 3A).78,79 
Filament movement is directed towards the center of the sarcomere and is entirely 
determined by the actin filaments on each side of the Z-disc. Relative sliding of 
the two sets of filaments occurs when actins are “pulled” by myosins.79 The cross-
bridges were originally described as “oar-like”80 but when their structure was revealed 
at atomic resolution, the cross-bridges are now known to maintain a fixed angle with 
respect to the thin-filaments and the rotation is due to the converter domain closer to 
the base of the cross-bridge81.
musCle ultrastruCture: elementary ComPosition
Myosin, the major component of thick-filaments
Originally known as “globulin”, myosin was defined in 1895 by Otto von Fürth.83 
It was the first sarcomeric protein to be studied. Major advances in its chemistry 
and localization were performed by Annemarie Weber who showed that 
the birefringent properties of the A-bands were the direct result of the birefringence of 
figure 3. A. Diagram of myosin arrangement in the thick-filament. B. Represents actin molecule 
polarity pointing away from the Z-line. (Figure adapted from Huxley HE, 197082 with permission 
Royal Society).
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“myosin threads”.84,85 In 1939, Engelhardt and Liubimova86 reported that myosin is 
the main enzyme responsible for the hydrolysis of ATP.
Structurally and each myosin has a long “rod-like” silhouette composed 
of one heavy chain and two light chains (Figure 4).87-91 Each heavy chain has 
a light-meromyosin (LMM), the smaller shorter component, and a heavy-meromyosin 
(HMM), the larger component.92,93 These two components can be separated by 
digestion with papain and/or trypsin using gel electrophoresis (Figure 4).94-97 
The LMM forms the structure of the thick-filament, while the HMM acts as 
a “hinge”, allowing S1 to move towards actin.98 This hinge property, propelled by 
figure 4. Schematic representation of myosin (Figure adapted from Huxley HE, 197082 with permission 
Royal Society). Here S1 represents the myosin head, S1 and S2 comprise the cross-bridge, and LMM 
forms the bulk of the thick filament.
the hydrolysis of ATP, governs actin-binding. The HMM is additionally divided into 
two sub-fragment extractions: sub-fragment 1 (S1)87,96,97 and sub-fragment 2 (S2)99. 
S1 accounts for 55-60% of HMM87 and comprises two globular heads containing an 
actin-binding component and catalytic ATPase activity. S2 separates the rigid LMM 
from the very flexible HMM.88
Actin, the major component of thin-filaments
The main constituent of the thin-filament is actin.70,100,101 The actomyosin complex was 
originally budded “myosin B” in 1941 by Banga and Szent-Györgyi102 to distinguish 
it from the myosin (called myosin A) based on their different solubility and viscosity 
properties. Actin was thought to represent a second form of myosin when extracted 
from muscle, but Brunó F. Straub103 later found that it does not contain myosin B, but 
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instead contains an association of proteins called “actin” that combine with myosin 
(actin + myosin). Myosin B was later called actomyosin, representing the polymerized 
form of actin and myosin.103 
Actin exists in two forms. A continuous monomeric strand of globular “inactive” 
actin (G-actin) spontaneously polymerizes to form the filamentous “active” actin 
(F-actin), a double-stranded polymer, forming the backbone of the thin-filament.70,103,104
In the absence of salts it is present in solution as inactive actin, in the presence of salts 
as active actin (Brunó F. Straub104 with permission S. Karger)
In striated muscle, two isoforms are predominantly expressed: α-skeletal actin 
(ACTA1; over 95% present in adult skeletal muscle) and α-cardiac actin (ACTC1; over 
80% present in the adult heart) that share near 99% homology.105 Actin assembles 
into F-actin that serves as a rigid cytoskeleton platform for the binding of troponin-
tropomyosin, the thin-filament. Spanning the I-band, the opposing fast growing 
(barbed) ends of actin filaments are “capped” (blocked) and anchored by a protein 
called “CapZ”106 to the Z-disc, as opposed to the slow growing (pointed) filament 
ends that are capped in the A-band by tropomodulin.107
Actomyosin/cross-bridges and ATP
An essential property of biological systems is their ability to convert chemical 
energy into mechanical energy. It was originally believed, and almost unchallenged, 
that the primary energy-producing reaction of muscle was lactic acid formation via 
the usage of glycogen. In 1927 Fiske and Subbarow108 showed that an “unstable form 
of phosphorus (which we shall for the present designate as ‘labile phosphorus’)”, 
i.e., phosphocreatine (PCr), decreased during contraction and was restored upon 
recovery. Evidence for the latter came in the early 1930s from Einar Lundsgaard in 
a series of papers109-111 whose concepts overthrew the lactic acid theory of contraction. 
He showed that muscles poisoned with iodoacetate resulted in muscle spasm and 
stiffness (rigor) without lactic acid formation. Lundsgaard concluded that PCr was 
likely the direct source of contraction based on the observation that PCr content was 
zero in the poisoned muscles.109 Together these data triggered the interest in the 
study of PCr. Nevertheless, experiments performed in the same decade indicated 
that no enzyme could use PCr as a direct fuel source in muscle.112 In 1934112 and 
1935113, Lohmann demonstrated that “creatine kinase” (CK) could breakdown PCr, 
resulting in the conversion of ADP to ATP: 
PCr + ADP → Cr + ATP
The author concluded that ATP breakdown preceded PCr breakdown in muscle 
contraction, thus providing strong evidence that ATP cleavage is the energy 
producing reaction of muscle.112 Today we know that ATP splitting (chemical) powers 
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the interaction and sliding of myosin on actin, in order to generate force and 
motion - work (mechanical). CK belongs to a group of energy buffering systems that 
maintain in vivo levels of ATP. CK catalyzes the transfer of phosphate from PCr to ADP 
regenerating ATP while preventing accumulation of ADP.114
One of the most accepted theories explaining the sliding process is the cross-
bridge theory, which suggests that the energy released from ATP hydrolysis is 
the driving force for myosin extension towards actin.64,69,70 Here, each bridge 
performs a number of cycles of attachment to and detachment from actin, which is 
accompanied by changes in myosin orientation and its initial conformation, changing 
the affinity of myosin’s for actin. It has been shown that full ATPase activity of the S1 
is greatly stimulated by Mg2+ - MgATPase activity.115-117 When ATP is present, myosin 
and actin do not interact (step 2,  Figure 5).118 Because myosin-S1 can hydrolyze ATP 
into ADP and Pi (step 3’, Figure 5)
119,120 this process121 is strongly enhanced by binding 
to actin (step 4, Figure 5).81 Moreover, formation of weak-binding cross-bridges 
occurs. A change of actomyosin conformations occurs (steps 5 and 6, Figure 5) with 
the release of Pi from the S1 head (step 7, Figure 5) accompanied by strong-binding 
cross-bridges.122-124 Force generation and work accompany muscle shortening. ADP 
is then released (step 8, Figure 5) and a new ATP molecule binds to the actomyosin 
complex to begin a new cross-bridge cycle (step 1, Figure 5). If ATP is lower than 
0.1 mM125,126, cross-bridges become permanently attached75 (step 8, Figure 5) and 
the muscle becomes rigid (“rigor mortis”).118,127 For a detailed summary of 
events see128.
figure 5. Cross-bridge cycle. (Figure adapted from Gordon et al. 2000128 with permission 
Physiological Reviews).
Tropomyosin, a thin-filament associated protein
Tropomyosin (Tm) spans each seven actin monomers. Discovered by Kenneth Bailey 
in 1946129 the author proposed that due to its “analytical and structural similarities [...] 
[tropomyosin] is a species of myosin differing mainly in the length of the polypeptide 
chain” and so “in proposing the present name, we have deemed it desirable to retain 
the word ‘myosin’ and to add a prefix which suggests this specific relationship.” 
(Kenneth Bailey129 with permission Nature Publishing Group)
Today, tropomyosin is far from being a species of myosin. It has two parallel 
α-helical chains, overlapping head-to-tail along the thin-filament. 
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Setsuro Ebashi was the first to recognize the role of tropomyosin in muscle.130,131 
He demonstrated that a new protein with similarities to the tropomyosin described 
by Kenneth Bailey was required for the ability of the actomyosin complex to be 
sensitive to Ca2+.130 This protein (“native” tropomyosin) was the combination of 
tropomyosin with a new globular protein Ebashi later called “troponin”.132 Troponin 
exhibited “cementing” (stabilizing) effects on the interaction between actin and 
tropomyosin,133-135 and regulated the position of tropomyosin on actin, in a Ca2+-
dependent manner.66,136-139
Troponin complex, thin-filament associated component
Troponin (Tn) was initially termed by Ebashi and colleagues133,140 in 1965 as 
a “tropomyosin-like protein” due to its similarities to the tropomyosin reported by 
Bailey141 as follows,
viscosity-ionic strength relationship, the binding capacity to F-actin and  
the sensitivity to trypsin digestion […] the presence of the [troponin] component 
makes actomyosin tend to relax, or dissociate, if the concentration of free calcium 
ions are lowered. (Ebashi S. and Ebashi F.132 with permission Oxford University Press)
Troponin bound Ca2+ and regulated tropomyosin movement on actin.138 
Nevertheless, instead of a single protein exerting multiple roles in muscle contraction, 
a “flavour” of different troponin subunits was discovered with distinctive structures 
and functions.142-150 The troponin complex was separated into 2-4 gel fractions when 
precipitated under particular conditions, such as the presence or absence of Ca2+, 
actin, myosin, actomyosin and tropomyosin.142-150 The identification and clarification 
of each fraction became a challenge with distinct methodologies producing differing 
results, including separation of different fractions on gels, different molecular weights 
and nomenclatures (troponin A, troponin B, inhibitory factor, Ca2+-sensitizing factor, 
TN-I, TN-T, TN-C, fraction I, II, III and IV).151 Table 1 below (from Perry and colleagues)152 
illustrates this dilemma.
Several properties of the troponin subunits included components that: 1) were 
capable of binding Ca2+ (troponin C, troponin A, Ca2+-sensitizing factor, troponin 
fraction III and troponin 4); 2) inhibited actomyosin interactions (troponin I, troponin 
B, inhibitory factor, troponin fraction II and troponin 2); and 3) interacted with 
tropomyosin (troponin T, 37,000 component, troponin fraction T and troponin 
3). The fourth fraction was suspected to be a contaminant and is omitted 
from Table 1.144,150,153
Based on these data, Hugh E. Huxley in 1972136 proposed the adoption of 
the following scheme:
There is some divergence about nomenclature, and although I hesitate to intrude 
into this field, I think everyone might agree that there are advantages to be gained 
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from a common nomenclature that may outweigh the disadvantages of losing some 
of the symbols to which one has become attached personally. I would therefore like 
to propose that the following scheme be generally adopted: that the Ca-binding 
component of troponin (mol wt ~18,000) be called Tp C; that the inhibitory component 
(mol wt ~23,000) be called Tp I and that the tropomyosin-binding component (mol wt 
~37,000) be called Tp T. [Today these are known as TnC, TnI and TnT].
There is general agreement that only Tp C binds significant amounts of calcium over 
the range of Ca++ concentrations in which regulation occurs (10-7-10-5 M), and that Tp C 
on its own has no effect on the ATPase of actin plus myosin plus tropomyosin. Tp I acts 
as an inhibitor of actomyosin ATPase […] [and the] presence of Tp T is needed for the 
normal functions of the original troponin complex to be fully reconstituted, but there 
are still some residual divergences about the precise role of this component. However, 
there is general agreement that the troponin complex contains one unit of each of  
the three components mentioned, and that in the presence of one mole of tropomyosin, 
such a complex can regulate the activity of about seven actin monomers. (Hugh E. 
Huxley in 1972136 with permission Cold Spring Harbor Laboratory Press)
The thin-filament “functional unit”: (A7TmTn)
The thin-filament consists of individualized functional units each with seven actin 
monomers spanned by one tropomyosin dimer and one troponin complex (A7TmTn). 
It is interesting to note (citations for the next statements can be found here158) 
that cTnI solely inhibits the interaction between myosin and actin in the presence of 
tropomyosin. In the absence of tropomyosin and cTnT, cTnC is insensitive to Ca2+, 
that is, it binds to cTnI and removes its inhibitory function, irrespective of the absence 
of Ca2+. Additionally, cTnI can maximally inhibit ATPase activity, in the absence of 
tropomyosin, if it is in a 1:1 ratio with actin. In the presence of tropomyosin, solely 
a single cTnI subnit per each four actin monomers is necessary to inhibit contraction, 
table 1. Components of troponin (Table adapted from Perry et al.152 with permission Cold Spring 
Harbor Laboratory Press).
Calcium-binding Protein inhibitory Protein 37,000 Component references
Troponin A Troponin B Hartshorne and Mueller, 
1968142
Calcium-sensitizing factor Inhibitory factor 37,000 component Schaub and Perry, 
1969154; Wilkinson et al., 
1971155, 1972150
Troponin 4 Troponin 2 Troponin 3 Greaser and Gergely, 
1971146
Troponin III Troponin II Troponin T Ebashi et al., 1971145
Component III Component II Component I Murray and Kay, 1971156
Troponin C Troponin I Troponin T Potter and Gergely, 
1974157
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which supports for the existence of cooperativity, or cooperation, in muscle. 
The interaction of cTnC to cTnI is increased and strengthened by Ca2+, in the presence 
of cTnT and tropomyosin.
figure 6. An early model of the thin-filament structure. (Figure adapted from Ebashi et al, 1969101 
with permission Cambridge University Press) 
figure 7. Schematic drawing of the thin-filament functional unit. Five actin monomers (gray) spanned 
by one tropomyosin dimer (red) and one troponin complex: cTnC (pink), cTnI (blue) and cTnT (orange). 
Letters “N” and “C” depict N- and C-terminal protein ends, respectively. Dark-blue tropomyosin 
depicts near-neighbor tropomyosin dimer interaction.159,160 Myosin-S1 is depicted in solid green 
(light-green myosin-S1 to better understand its transition states). The orientation of thin-filament 
proteins is: the N-terminal region of cTnT points towards the pointed end (M-band), while the core 
domain of the troponin complex is oriented to the barbed end (Z-disk).161 Interacting sites and 
structural regions of actin-tropomyosin-troponin proteins are matched in accordance with available 
literature162. Cardiac TnI residues 1-34 are arbitrarily positioned. Our figure follows the proposed 
mechanism for Ca2+-regulation of contraction proposed by Murakami et al.163 (Figure adapted from 
Sequeira et al, 2013162 with permission Wolters Kluwer Health, Inc)
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The third filament: titin
The existence of another filament was initially observed by Hugh E. Huxley and Jean 
Hanson70 in 1954, when through actin-myosin extractions the authors showed that 
the sarcomere remained intact. The authors70 proposed that an elastic component 
called the “S-filament” provided continuity between an actin filament and 
the opposite actin filament in a sarcomere, and attached to myosin. 
The backbone of the muscle fibril is made up of actin filaments which extend from 
the Z-line up to one side of the H-zone, where they are attached to an elastic 
component (not the series elastic component) which for convenience we will call  
the S-filaments. The S-filaments provide continuity between the set of actin filaments 
associated with one Z-line and that associated with the next. (Hugh E. Huxley and 
Jean Hanson70 with permission Nature Publishing Group)
Nonetheless, it was difficult at the time to confirm the existence of such an elastic 
and integrative component. Years later the existence of a giant elastic protein called 
“connectin” was reported consistent with the earlier proposed S-filaments.164 Today 
it is better known as “titin”165 based on its large proportions (molecular weight 
ranging from 3MD-3.8MDa166,167). Titin is the third-most abundant filament protein 
by weight.168 Partially responsible for the generation of resting tension, titin is also 
the mechano sensor of the sarcomere.169
The N-terminal region of titin
This part of titin resides in the Z-disc and interacts with actin170 and possibly with 
α-actinin171,172 via 45 amino acid repeat regions (Z-repeats) that provide a mechanism 
of Z-disc assembly resulting from alternative splicing.173 The I-band region of titin is 
the extensible region and consists of three elastic components that act as a spring 
element (Figure 8): 1) tandem immunoglobulin (Ig)-like domains with proximal 
figure 8. Schematic overview of titin depicted in half-sarcomere. Note the extension of the elastic 
components of titin when the sarcomere is stretched (Figure adapted from Linke W, 2010169 
permission not required)
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(near Z-disc) and distal (near I-A regions) segments; 2) the PEVK sequence-region 
rich in proline (P), glutamic acid (E), valine (V) and lysine (K); and 3) the N2B and 
N2BA elements (both isoforms contain N2B segments, but only the N2BA has 
the N2A element).167 
C-terminal region of titin
The C-terminal A-band region of titin is inextensible. It interacts with thick-filament 
and associated proteins, including myosin and cardiac myosin-binding protein C 
(cMyBP-C).174-176 In the M-band, titins from opposing half-sarcomeres intersect and 
interconnect with M-band proteins, thereby forming a continuous filament from 
the M-band towards the Z-disc.177,178 Titin may be arranged in the thick-filament as 
a dimer179 and presumably a bundle of “six titin molecules connect each end of 
the thick-filament to the Z-disk” (Ahmed Houmeida and colleagues180 with 
permission Elsevier). 
Titin is present in both skeletal and cardiac muclse, but differs in its size.181 Cardiac 
isoforms are smaller, ranging from 3MDa (N2B) up to over 3.2MDa (N2BA),182 opposite 
to the even larger skeletal isoforms (N2A) that can reach as much as 3.8MDa.167,169
Titin and its “elastic” tension of muscle
Under resting conditions, striated muscle resists muscle lengthening by producing 
passive tension in response to stretch. In the heart, titin accounts for approximately 
80% of total passive tension between physiological operating sarcomere lengths - 1.8 
to 2.2 μm. When over-stretched (>2.2 μm), where the contribution of collagen is greater, 
the titin stretch-based passive tension remains high, indicative of the central role of 
titin to respond to stretch.183,184 Passive (resting) tension results from the extensible 
I-band spring segment that elongates as sarcomere length increases. The tandem 
Ig-like segments are the first to extend, followed by the PEVK segment and lastly, 
the elongation of the N2B segment.177,178 The flexibility and stretch-based passive 
tension of the titin spring elements can be regulated by two major mechanisms: a fast 
“acute” modulation by post-translational modifications via protein phosphorylation 
and a “chronic” isoform shift due to alternative splicing of the I-band encoding region 
of the titin (TTN) gene, giving rise to different isoforms.
MyBP-C, thick-filament associated component
The thick-filament that titin is not solely bound to myosin, but also to another 
protein in the C-zone of the A-band.174,185,186 Called “C-protein”187,188 or “cMyBPC”189, 
this protein appears to hold a central role in cross-bridge binding190,191 and 
cycling kinetics191,192.
cMyBP-C mainly consists of immunoglobulin-like C2 domains (eight domains) and 
three/four fibronectin type-III domains. In addition, cMyBP-C has a proline-alanine 
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rich region between domains C0 and C1 and a M-domain between domains C1 and 
C2 (Figure 9). Both linker domains have important functional roles - vide infra.
MyBP-C was first identified in 1973 by Offer et al.187 from skeletal muscle. While 
MyBP-C’s interaction with myosin187 and actin195-197 were reported soon after its 
discovery, the exact role of MyBP-C in muscle contraction remained poorly understood. 
Discovering the individual interaction partners of the N’ and C’ domains was key to 
understanding the function of MyBP-C in regulating contraction.
C-terminal region of MyBP-C
The C-terminal domains are important for the binding of MyBP-C to thick-filaments198 
that occur via interaction with the LMM region of myosin-heavy chain (MHC)199,200. 
Although the C10 domain was identified as the myosin LMM binding domain, 
domains C7-C9 are also needed for proper incorporation into the thick-filament.198 
This might be mediated by the interaction of the C’ domains of cMyBP-C with titin, 
which involved domains C8-C10.175
figure 9: Schematic domain structure of cMyBP-C. Cardiac MyBP-C consists of eight Ig-like and three 
fibronectin domains labeled C0 (N-terminus) through C10 (C-terminus). Two additional domains are 
present in the N-terminal part of the protein, the Proline-Alanine rich region (PA) and the M-domain 
(M). Four phosphorylation sites, Ser275, Ser284, Ser304 and Ser311, have been described in 
the M-domain. A recent study193 revealed a novel phosphorylation site on serine 133 in the PA region 
(Figure from Sequeira et al, 2013194 with permission Springer).
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N-terminal region of MyBP-C
While the C-terminus of cMyBP-C is important for its location and anchoring to the thick-
filaments, the N-terminus is the region through which cMyBP-C exerts its regulatory 
role on contraction. The best understood aspect of cMyBP-C’s function is its effect on 
cross-bridge cycling kinetics (Figure 10). This effect is mediated by the interaction of 
the cMyBP-C N-terminus with the MHC “neck” region.201 This S2 region is the hinge 
region of MHC and connects the LMM to the myosin head (S1 domain). By binding to 
this region, cMyBP-C can slow cross-bridge cycling kinetics (Figure 10). The cMyBP-C/
S2 interaction is phosphorylation-dependent and the phosphorylation sites in the 
M-linker domain are important for modulating this interaction.202 When the cMyBP-C 
M-domain sites are not phosphorylated, cMyBP-C binds to S2. Upon phosphorylation 
of cMyBP-C, this interaction is lost.202 Therefore, the cMyBP-C M-domain, together 
with the adjacent C1 and C2 domains, are thought to be the sites of interaction with 
myosin cross-bridges.201,203 More controversial has been cMyBP-C’s interaction with 
actin. Although cMyBP-C was reported to interact with actin in vitro soon after its 
discovery196,197, the in situ visualization of cMyBP-C‘s direct interaction with actin in 
intact muscle was lacking. In recent years, accumulating evidence provided by in situ 
3D reconstruction approaches (X-ray neutron scattering204, negative EM staining205,206 
and electron tomography207) demonstrated that cMyBP-C interacts with actin. 
The N-terminus of MyBP-C projects towards the thin-filament making direct contact 
with actin. Phosphorylation of sites in the M-domain weaken its interaction with actin 208. 
figure 10. Schematic structure of cMyBP-C. cMyBP-C consists of eight Ig and three fibronectin 
domains labeled C0 (N-terminal) to C10 (C-terminal), with two additional linker domains the PA 
(Proline-Alanine; light blue stripes) region between C0 and C1, and the M-domain (M; yellow and 
orange sripes), between C1 and C2. The C5-C10 domains extend along the thick-filament, while 
the C0-C4 extend to the thin-filament. A7TmTn depict a functional unit composed of 7 actin 
monomers, 1 tropomyosin (Tm) dimer and 1 troponin (Tn) complex.
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In addition, recent evidence suggests that the N-terminal extension of cMyBP-C binds 
the low Ca2+-state (blocked state, B-state; further discussed) position of tropomyosin 
on actin, indicating that cMyBP-C can interfere with tropomyosin-actin interactions 
and regulate thin-filament transitions 205. The functional implications of the putative 
actin/cMyBP-C interaction are not yet fully understood. Another sarcomeric protein 
that was recently identified to interact with cMyBP-C’s N-terminus (more specifically 
the C0 domain) is the regulatory light chain.209 Again, the functional consequences of 
this interaction are not yet understood.
Central role for Ca2+ in musCle ContraCtion
It is well established that cardiac muscle contraction, which was defined as “excitation-
contraction coupling” by Alexander Sandow in 1952210, is initiated by electrical 
activation of cardiomyocytes, resulting in muscle contraction. 
When a stimulus is applied to muscle, the response is indicated first by excitation 
which is set up in the membrane of each reacting fiber, and then by contraction which 
is a function of the substance within the membrane […] We shall designate the entire 
sequence of reactions–excitation, inward acting link, and activation of contraction by 
the term excitation-contraction (E-C) coupling. (Alexander Sandow210 with permission 
Yale J Biol Med)
Central to the excitation-contraction coupling is the increase in intracellular 
[Ca2+] resulting after electrical activation of the membrane. The first indications for 
the importance of Ca2+ in the activation of cardiac muscle were demonstrated in 
the 1880s by Sydney Ringer211,212, who observed that the ventricle of frog hearts beat 
faster when he used a solution prepared from tap water supplied by the New River 
Water Company in England, but not when distilled water was used. The difference 
was due to Ca2+ in the tap water. Ringer could maintain cardiac contractions if CaCl2 
and KCl were added during saline perfusion (0.75% NaCl) at concentrations of about 
0.5 and 1.3 mM, respectively. 
I find that calcium, in the form of lime water, or bicarbonate of lime or chloride of 
calcium, even in minute doses produces the changes in the ventricular beat described 
in my former paper. (Sydney Ringer212 with permission John Wiley and Sons)
The great next step for Ca2+ research was reported by Locke and Rosenheim 
in 1907213 using Ringer’s solution (0.75% NaCl, 0.5 mM CaCl2, 1.3 mM KCl) who 
showed that,
If both calcium and potassium (ions) are omitted from the Ringer’s solution, metabolic 
action in the heart still continues, although actual contractions are minimal or absent. 
[…] Calcium is necessary for the conversion of the heart’s chemical energy into  
the mechanical energy of its beat, while potassium is more necessary for the merely 
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chemical processes of cardiac activity. (Locke and Rosenheim213 with permission John 
Wiley and Sons)
Similar observations were made in 1913 by George R. Mines, who reported that 
a Ca2+-free solution generates normal action potentials, but no mechanical response.214 
Further progress was made in 1940 by Heilbrunn215 who showed that damaged muscle 
fibers could generate contractions in solutions containing high [CaCl2] (>20 mM), 
and in 1942 Bailey216 observed that mM concentrations of Ca2+ activated the ATPase 
activity of myosin. The following is an excerpt from Kenneth Bailey’s paper216, which 
summarizes the available evidence known at the time to support the Ca2+-hypothesis:
The facts which seem to have some relevance when we attempt a correlation of our 
present data with the actual process of contraction can be summarized as follows: (1) 
Myosin and ATP-ase are identical or so closely associated that we can regard them 
as a single entity. (2) Myosin is the contractile element disposed in the form of folded 
chains lying roughly parallel to the axis of the fibre. (3) The reaction which is capable of 
supplying free energy for contraction and which is most closely associated in time with 
the act of contraction is the breakdown by ATP-ase of ATP to ADP and phosphate. 
(4) Of the divalent ions present in muscle, ATP-ase is specifically activated by  
the Ca ion. (5) Ca is necessary for muscular contraction. Its importance in maintaining 
the response of isolated muscle to stimulation has been known from the earliest 
systematic studies in muscle physiology. We may recall the classical experiments 
of Ringer and of Locke, and especially those of Mines [1913] who discovered that  
the excitatory process could proceed in the absence of Ca, although the muscle 
was unable to contract. This recalls the earlier experiments of Locke and Rosenheim 
[1907], who concluded that ‘The State of the active surface in the absence of Ca 
is such that […] an increase of surface energy cannot take place’. (6) The electrical 
change accompanying excitation is connected with the diffusion of ions in the region 
of the excited area. Contraction is also accompanied by ionic changes, and although 
little is known of the divalent ions and much of the evidence is conflicting, there 
appears to be an increase of diffusible Ca [Weise, 1934]. The exchange of univalent 
ions during contraction, e.g. the loss of K in exchange for Na [Fenn and Cobb, 1936], 
is well established and would be expected to affect the distribution of divalent ions. 
(7) The Ca ion cannot be replaced by Mg, either for the maintenance of contraction or 
as activator to the ATP-ase system. The presence of Mg in muscle has been generally 
associated with other phosphorylating enzymes for which it is a specific activator. 
(Kenneth Bailey216 permission not required)
The essential role of Ca2+ in muscle contraction and relaxation was still although 
obscure in the 1960s as noted by Ebashi and Endo217:
It is ironic that recognition of the essential role of Ca ion in contraction has resulted 
mainly from the investigation into the mechanism of relaxation. (Ebashi and Endo217 
with permission Elsevier)
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In the 1950s it was well established that ATP was required for contraction in concert 
with Ca2+. However, muscle physiologists did not understand how muscle relaxation 
proceeded. Marsh218,219 proposed that a  “relaxing factor” of small molecular size 
existed, responsible for the relaxation of muscle. It was believed myokinase was 
responsible for the “relaxing/Marsh factor”.220,221 In 1954 and 1955, Bozler222 and 
Watanabe223 reported that in the presence of ATP, a synthetic compound called 
“EDTA” mimicked the action of this “relaxing factor”. As summarized below by 
Bozler222, EDTA by Ca2+-chelation was responsible for muscle relaxation.
Szent Györgyi (1-3) discovered that ATP produces a strong contraction in muscle 
fibers which have been preserved in glycerol. Later Bozler (4-7) found that such fibers, 
which originally are in rigor, can be transformed into a state closely resembling normal 
relaxation by physiological concentrations of ATP. The fibers then are very extensible 
and plastic, and give a strong contraction on addition of small amounts of CaCl2. This 
state can be produced and maintained only in the presence of Mg and only in rather 
fresh fibers. Following up work by Marsh (8) on the syneresis of muscle homogenates, 
Bendall (9) has shown that the ability of briefly extracted fibers to relax is due to 
the presence of a non-dialyzable factor contained in muscle extract, which will be 
called relaxation factor (“Marsh factor”). […] In the present paper the clarification 
of the mechanism of action of these factors will be attempted, particularly that of  
the relaxation factor. It was found that EDTA closely imitates all the effects of this 
factor. The results indicate that relaxation is caused by the inactivation of bound Ca. 
Previous evidence that the relaxed state is due to the formation of an enzymatically 
inactive ATP-protein complex was confirmed. (Emil Bozler222 permission not required)
Weber recognized in 1959224 that actomyosin preparations only hydrolyzed ATP 
if,  μM of Ca2+ was present. Final confirmation for the role of Ca2+ in muscle activation 
came from Ebashi in a series of papers in the 1960s130,131,225-228 demonstrating 
that indeed μM [Ca2+] was required for the superprecipitation of the actomyosin 
complex and that the “relaxing factor” was in fact a vesicular factor capable of 
removing and storing Ca2+, derived from an organelle with an extensive tubular 
network - the sarcoplasmic reticulum (SR). 
Together with our findings with the vesicular relaxing factor, we would picture the 
following sequence of events. In the resting state, most of the Ca in muscle is 
concentrated in the endoplasmic reticulum, [,..] the vesicular relaxing factor. Excitation 
of the muscle membrane will be conducted into the interior of the cell causing the 
endoplasmic reticulum to release Ca-the trigger for contraction. When the excitation 
is completed, Ca will be again captured by the endoplasmic reticulum and relaxation 
will follow. (Setsuro Ebashi228 with permission Physical Society Japan)
Ford and Podolsky229 suggested that Ca2+ release from the SR could be induced 
by external Ca2+, which was confirmed by Endo et al.230. Despite the strong evidence 
for the role of Ca2+ in contraction-relaxation at the time, several weaknesses were 
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presented by Weber and Winicur231, who observed that some preparations of 
synthetic actomyosin (a mixture of myosin and actin separately prepared) were less 
sensitive to Ca2+. 
Some actomyosin preparations superprecipitate very little or not at all and hydrolyse 
adenosine triphosphate at one quarter or one-half of the maximal rate obtained 
on addition of CaCl2 to give a concentration of 0.1 mM (Weber and Winicur
231 with 
permission American Society for Biochemistry and Molecular Biology)
As shown previously, Ebashi reported that this was due to a third muscle 
component, tropomyosin.130
Roles of Ca2+ and ATP in muscle contraction
Cardiac muscle contraction is initiated upon electrical activation of cardiomyocytes 
and the resulting increase in intracellular [Ca2+] and regeneration of ATP. In the 1970s 
the idea was raised that cross-bridge cycling occurs in two stages. First, the absence 
of Ca2+, tropomyosin physically blocks the myosin-bindings sites on actin (the steric 
blocking model) and second, the concept that with raised intracellular [Ca2+] myosin 
binds and induce force development.232,233 McKillop and Geeves65 in 1993 advanced 
the later ideas and proposed a three-state model of the thin-filament, in which 
myosin-binding to actin in the presence of Ca2+ does not occur in a single step, but in 
two steps that reflect changes in the affinity of myosin for actin. 
We propose a three-state model of the thin filament. A ‘blocked state’ which is unable 
to bind S1 [myosin], a ‘closed state’ which can only bind S1 relatively weakly and 
an ‘open state’ in which the S1 can both bind and undergo an isomerization to a 
more strongly bound rigor-like conformation. (McKillop and Geeves65 with permission 
Elsevier)
In concert, Ca2+ and ATP characterize three distinctive states of a muscle fiber: i) 
relaxed, ii) activated and iii) rigor. In addition, a three-state model of thin-filament 
regulation comprises three distinct biochemical states of muscle: “blocked-
state”,  “closed-state” and “open-state”. Electron microscopy reconstructions66 of 
thin-filament proteins confirmed the solution studies from McKillop and Geeves65, and 
proposed new generic terms to “avoid nomenclature with unintended connotations”66: 
the blocked-state corresponds to the “blocked (B-state)”; the closed-state to “Ca2+-
induced (C-state)”, and the open-state to “myosin-induced (M-state)” (Figure 11).66
Relaxed state, B-state
I. In the relaxed state where Ca2+ levels are low and ATP is present, the muscle does not 
develop active force and muscle stiffness is low. Corresponding to the physiological 
relaxation (diastole), it determines the amount of passive resting tension. At 
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the molecular level, the decline of Ca2+ levels is associated with uncoupling of Ca2+ 
from TnC, and relaxation proceeds.64,69,234 In the B-state, tropomyosin sterically blocks 
myosin-binding sites on the outer domain of actin, thereby promoting inhibition of 
myosin S1 binding to actin (Figure 11A). We know that specific regions of TnI bind to 
the outer domain of actin and thereby “drag” tropomyosin with it, pulling it away from 
the inner groove of actin, blocking actomyosin interactions in the outer region.163,235
Activated state
II. In an activated state, where Ca2+ levels are high and ATP is hydrolysed, 
the muscle generates active force, shortens and becomes very stiff. It corresponds to 
the physiological contraction phase - systole. As cytosolic free Ca2+ increases, it 
binds to regulatory sites on TnC, resulting in the structural arrangement of the TnC 
subunit.236 Because TnC is structurally attached to TnI237,238, it moves TnI away from 
actin, shifting tropomyosin back towards the inner domain of actin. The uncovering 
of the outer domain is propagated from one actin to, at least, fourteen neighboring 
actins (two functional units), leading to cooperative activation of the thin-filament.239-241 
Activation takes place in two distinct biochemical steps:
C-state
II.1. A movement of ~25º of tropomyosin around actin, corresponding to 
the C-state, exposes most of the myosin-binding sites (Figure 11B).135,139 Nonetheless, 
the myofilament is not yet activated because non-tension-generating cross-bridges 
bind weakly to actin (weakly-bound cross-bridges, myosin-ADP-Pi). Notably, not only 
does tropomyosin change its orientation, but slight movements of actin subdomains 
have also been reported.242,243 McKillop and Geeves65 reported that this specific 
transition represents the state of weak binding of the S1 (acto-S1-ATP or acto-S1-ADP-
Pi) to actin.
244,245 Weak-binding cross-bridges are defined by low affinity to actin, very 
fast myosin attachment to and detachment from actin (faster attachment/detachment 
kinetics), and inability to activate thin-filament regulatory units (A7TmTn).
M-state
II.2). The third and last state, the M-state, involves the release of Pi from the cross-bridge 
and strong-binding cross-bridge formation (myosin-ADP) that induces an extra ~10º 
movement of tropomyosin on the actin filament, resulting in myofilament contraction 
and force development (Figure 11C).66,139 The shape complementary of tropomyosin 
to actin (Gestalt binding246) might prevent tropomyosin from extensively rolling away 
from actin.247 Strong-binding cross-bridges are defined by higher affinity to actin, 
myosin binds very strongly to actin and detaches very slowly (slower attachment/
detachment kinetics), and the ability to activate thin-filament regulatory units. 
Overall, the troponin complex inhibits a kinetic transition by trapping the position 
of tropomyosin.123 An increase in the free acto-S1-ADP concentration, enhanced 
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by cooperative thin-filament activation,244,248,249 in a Ca2+-dependent manner, is 
the trigger for S1-strong-binding and consequent cycling and contraction.65,241 A new 
cycle of relaxation ensues, if the Ca2+ levels decline and ATP is readily accessible. 
Rigor state
III. In particular cases the rigor state can be induced (<0.1 mM ATP)125, and although 
it is as stiff as the activated state,250 the muscle does not shorten.118,127
musCle meCHaniCs: lengtH-DePenDent CHanges
Changes in length and load allow the heart to change its ventricular filling and 
regulate ventricular contraction and ejection. Ventricular filling fixes the initial 
sarcomere length-tension and optimizes the i) amount of force development, ii) 
the rate of force development and iii) the velocity of shortening against afterloads, 
i.e. cardiomyocyte workput, ultimately regulating ventricular contraction and 
ejection.261 The Frank-Starling relation thus allows the heart to work on a beat-to-beat 
basis, capable of adjusting the output of both its sides to any alteration affecting 
venous return, or preload. The sarcomere length-tension relationship in skeletal and 
cardiac muscle differs, though active tension shows similar dependence on length. 
The changes in skeletal muscle are discussed below and enable the understanding of 
the Frank-Starling relation.
Skeletal muscle length-dependency
Blix16 and von Kries17,18 proposed that the energy of a contracting muscle is a function 
of its length and that muscle shortening depends on its load. Evans and Hill262 in 
the 1910s showed that developed tension grew by increasing fiber length. In addition, 
a parallel increase of heat production was observed. 
The experiments of which the results are described here were undertaken at  
the suggestion of Professor Starling, with the view to testing the theory put forward 
by Blix that the variable factor among the mechanical conditions which determines  
the mechanical performance and the heat production of muscle is the initial length of 
the muscle and to find what relation, if any, exists between the length of the muscle 
and the tension and heat which it produces on isometric contraction. (Evans and Hill262 
with permission John Wiley and Sons)
The complete length-tension relation for isolated skeletal muscle fibers was 
for the first time provided by Ramsey and Street263 in 1940 (previous experiments 
rarely exceeded 30% resting length changes), who demonstrated the biphasic shape 
alteration of tension development upon length. Almost three decades were needed 
to combine the results obtained from Ramsey and Street263 to the growing advances 
obtained from the analysis of the ultrastructure of skeletal muscle fibers - sliding 
filament theory. In an historic paper published in 1966, Gordon, Andrew F. Huxley 
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figure 11. Schematic drawing of the thin-filament functional unit. Seven actin monomers (gray) 
spanned by one tropomyosin dimer (red) and one troponin complex: cardiac troponin C (pink), 
cardiac troponin I (blue) and cardiac troponin T (orange). “N” and “C” indicate  the N- and C-terminal 
ends of proteins. This representative diagram is based on the structure of actin subdomains,251,252 
the position of tropomyosin on F-actin66,135,139 and the core domain of human troponin.237,253 
The tropomyosin overlap region (head-to-tail) depicts interaction with near-neighbor tropomyosin 
dimer (dark-blue).159,160 The orientation of thin-filament proteins is as follows: the N-terminal region of 
cardiac troponin T points towards the pointed end (M-band), while the core domain of the troponin 
complex is oriented to the barbed end (Z-disk).161 Interacting sites and structural location of actin-
tropomyosin-troponin proteins were matched the best as possible in accordance with the available 
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and Julian264 confirmed the biphasic shape of tension upon length alterations and 
suggested that such changes directly resulted from the overlap of individual cross-
bridges. They demonstrated that active tension in skeletal frog muscles consisted of 
a maximal tension plateau region between sarcomere lengths of 2.0 and 2.25 μm; 
a region wherein myofilament overlap of thick- and thin-filaments was optimal and 
constant (Figure 12). Stretching the muscle above 2.25 μm progressively reduced 
active tension (known as the descending limb of the active tension-length curve) 
and reached a zero level at 3.65 μm sarcomere length, where myofilament overlap 
ceased.264 Upon shortening the muscle below 2.0 μm (known as the ascending limb of 
the active tension-length curve) active tension decreased, which was proposed to be 
the result of thin-filaments colliding at the center of the sarcomere (double overlap) in 
addition to collision of the thick-filaments at the Z-disc. However, a poor correlation 
between the ascending limb and the number of active cross-bridges was subsequently 
suggested, so that as the muscle is shortened below slack length the number of cross-
bridges remains constant while tension drops.265-268 These observations provided 
the first indications that factors other than the degree of myofilament overlap of 
thin- and thick-filaments existed, and accounted for deactivation upon shortening. 
In agreement, Taylor and Rüdel269,270 demonstrated that the addition of low caffeine 
concentrations (which causes the release of Ca2+ from the SR) to the bathing solution 
increased the developed tension at short sarcomere lengths. A similar study was 
performed by Close271 in frog skeletal muscles, showing that inducing twitch- or 
tetanic-activation generated different length-tension curves. Close proposed that 
length-independent changes in activation could also play a role to increase tension.271 
It may be concluded from this that the principal variations in the length dependence of 
the twitch are the result of differences in some extrinsic process involved in activation 
and not differences in the intrinsic strength of the contractile material. (Close R.I.271 
with permission John Wiley and Sons)
frank-starling relation
In 1895, using the frog heart, Otto Frank11 measured isovolumic pressures developed 
at varying lengths. Extending the findings of Blix and von Kries, Frank11,19 observed 
literature.160,237,254-260 A. B-state (blocked); when ATP is present and cytoplasmic [Ca2+] is low and is 
not bound to cTnC, tropomyosin is sterically blocking the myosin-binding sites on actin. B. C-state 
(Ca2+-induced); cytoplasmic [Ca2+] rises such that Ca2+ binds to cTnC, inducing conformational changes 
of the troponin complex, resulting in a ~25º movement of tropomyosin on the thin-filament, thereby 
exposing most of the myosin-binding sites on actin. Note the movement of tropomyosin away from 
subdomains 1 and 2 of actin. In the C-state the myofilament is not yet activated as non-tension-
generating cross-bridges bind weakly to actin. C. M-state (Myosin-induced); the strong-binding of 
tension-generating cross-bridges induces a ~10º movement of tropomyosin on actin, resulting in 
myofilament activation and contraction. Note the transition of tropomyosin into subdomains 3 and 
4 of actin (Figure adapted from Sequeira et al, 2013162 with permission Wolters Kluwer Health, Inc).
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that the developed pressure was directly proportional to the initial (diastolic) tension. 
Nonetheless, Frank’s experiments to determine whether an increase in the force of 
contraction was either related to the initial tension or length of the muscle fibers were 
inconclusive.20 Starling and colleagues7,20,22 measured cardiac shortening as a function 
of cardiac output and its intrinsic relation to initial EDV, and demonstrated that 
the initial fiber length, rather than tension, is the main determinant for contraction.
The performance of skeletal muscle length-tension relationships were investigated 
with cardiac muscle by Abbott and Mommaerts274 and later reexamined in more detail 
by the groups of Sonnenblick275-277 and Grimm278,279. Both groups demonstrated that 
active tension exhibited a similar dependence on length to skeletal muscle, namely 
figure 12. A comparison of length-tension relations for skeletal and cardiac muscle. Skeletal muscle. 
As proposed by Gordon et al.264 using the frog heart, a maximal plateau region over the range of 
2.0 and 2.25 μm sarcomere length is expected due to optimal and constant myofilament overlap. 
When the muscle is stretched above 2.25 μm (descending limb) active tension declines to almost 
zero at a sarcomere length of 3.65 μm. At shorter sarcomere lengths (below 2.0 μm) (ascending limb) 
the thin-filaments collide in the middle of the sarcomere, and thick-filaments collide at the Z-disc 
and tension ceases. Cardiac muscle. The myofilament overlap theory that was the basis for skeletal 
muscle length-tension relations cannot account for the cardiac length-tension relationship. Apart 
from the smaller sarcomere lengths at which the mammalian heart operates (estimated physiological 
levels range from 1.8 to 2.2 μm), cardiac muscle was demonstrated to present length-dependent 
changes in activation. Please note that skeletal muscle almost fully activates at 75% Lmax (length at 
which force is maximal), which contrasts with cardiac muscle where at the same % of Lmax, active 
tension is zero. Lengthening cardiac muscle an extra 15% in length (~90% Lmax) raises the developed 
tension from 0 up to 70%, hence active tension in cardiac muscle is length-dependent. Diagrams 
adapted from Gordon and Julian264, Sonnenblick and Skelton272, and Allen and colleagues273.
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both change with sarcomere length. However the shape of cardiac length-tension 
curves is distinctly different. Skeletal muscle is almost fully activate at 75% of its 
optimal length (Lmax; muscle length at which tension is maximal) compared with cardiac 
muscle where active tension is zero at the same % of Lmax (Figure 12).
272,273 Stretching 
cardiac muscle an extra 15% (~90% Lmax) increases developed tension from 0% up to 
70% (Figure 12).272,273 Based on this observation, it was suggested that active tension 
in cardiac muscle is length-dependent.
Several other inconsistencies between skeletal and cardiac muscle were reported, 
such that maximal tension in the heart muscle only presents a peak at maximal 
lengthening in contrast to the plateau in skeletal muscle, and that the decline in 
active tension (both ascending and descending limb) is much steeper for cardiac. 
A simple approach based on myofilament overlap could not account for the observed 
differences between skeletal and cardiac muscle.272,276
With the growing evidence from skeletal muscle for the role of Ca2+ in 
the “manipulation” of length-tension curves, it was apparent that factors other than 
the degree of myofilament overlap could explain the striking differences in length-
tension curves and the enigmatic length-dependence of heart muscle.
Please note that later findings in the 1980s from Edman and colleagues280 showed 
that the length-tension curve in skeletal muscle exhibits a much smoother shape than 
proposed by Gordon, Andrew F. Huxley and Julian264. Specifically, the length-tension 
relation does not have a pronounce plateau region at 2.0- 2.2 μm sarcomere length, 
while the descending limb was also non-linear. Instead there was a slight sigmoid 
shape280, where the extrapolated zero tension level was reached at 3.49 μm rather 
than 3.65 μm sarcomere length.
Length-dependent activation: Ca2+ as a modulator
It was previously demonstrated in membrane-permeabilized skeletal muscle that the 
shape of the length-tension curve could be varied by adding μM Ca2+.281-283 To this 
extent, Fabiato and Fabiato284 initially suggested that shortening the cardiac muscle 
partially inhibits the Ca2+-triggered Ca2+-release from the SR by monitoring free Ca2+ 
with the Ca2+-sensitive photoprotein “aequorin”. The authors however later dismissed 
their claims and provided proof that the contractile machinery itself is Ca2+-sensitive 
to alterations in muscle length at sarcomere lengths greater than 2.35 μm (descending 
limb).285 Later evidence demonstrated that indeed increasing sarcomere length (over 
the entire sarcomere length range) increases myofilament sensitivity to Ca2+, thus 
“cementing” the myofilament length-dependent activation hypothesis.286,287
Current ConCePtions of tHe meCHanisms unDerlying 
lengtH-DePenDent aCtivation
Over a century of research on the Frank-Starling effect has elucidated our 
understanding of the fundamental mechanical basis of muscle contraction. The Frank-
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Starling relation dictates that an increase in fiber length enhances the maximal force 
generating capacity and Ca2+-sensitivity of myofilaments, leading to increased force 
development.261,288
Although a unifying concept that explains how myofilaments “sense” length 
alterations is still to be proven, stretch-induced effects rather than changes in filament 
spacing, dominate the literature. Also, changes in Ca2+-activation upon muscle 
lengthening have to be accounted for. Overall, myofilament length-dependent 
activation is the composite of several synergistic mechanisms. Length-dependent 
activation is associated with: 1) increased Ca2+-affinity of cTnC; 2) alterations in 
interfilament lattice spacing; 3) titin-induced stretch and formation of strong-binding 
cross-bridges; 4) cTn complex changes; and 5) cooperative mechanisms.
1. cTnC-dependent alterations
1.1. Ca2+-affinity to cTnC
Two hypotheses were proposed to explain length-dependent activation of 
the contractile apparatus by Ca2+. The first is the length-dependent regulation of 
Ca2+ release by the SR suggested by Fabiato and Fabiato284, but this has not been 
confirmed by others. The second hypothesis, that length-dependent modulation 
of Ca2+-affinity by cTnC is emerging as a solid candidate.289-293 Allen and Kurihara289 
microinjected aequorin in isolated papillary and trabeculae muscles, and observed 
a rise in intracellular [Ca2+] following a quick step release during contraction, which 
they attributed to dissociation of Ca2+ from the contractile proteins. Housmans et 
al.290 observed similar phenomena. This view was further supported in membrane-
permeabilized muscle preparations by Allen and Kentish291 who concluded that Ca2+ 
was released by the contractile apparatus. Additional evidence by Hofmann and 
Fuchs292,293 showed that length-dependent changes affect the Ca2+-affinity of cTnC 
where a decrease in sarcomere length reduced the Ca2+-binding affinity of cTnC.
1.2. cTnC is not a length-sensing molecule
It remains to be seen how cTnC “senses” sarcomere length alterations. Initially 
cTnC was considered to act as a “length sensor” itself. Babu et al.294 reported that 
length-dependence of Ca2+-sensitivity was substantially diminished when cTnC was 
exchanged by slow skeletal troponin C (ssTnC) in membrane-permeabilized cardiac 
muscle. They294 attributed the isoform difference of cTnC as the basis for cardiac 
length-dependent activation compared to skeletal muscle. However this proposal 
was dismissed because other groups showed that length-dependent activation is 
independent of cTnC isoform differences.295-297 
2. Interfilament lattice spacing vs. myocyte lengthening
It has been suggested that the increased Ca2+-sensitivity upon myocyte lengthening 
results from lattice spacing reduction, which increases the proximity of myosin towards 
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actin. Alterations in interfilament lattice spacing, such as increases in the lattice 
spacing as a result of shortening, leads to sarcomere thickening and intracellular 
volume redistribution.298-300 In turn, the developed active tension decreases via 
decreased approximation of myosin and actin filaments, and thus less strong binding 
cross-bridges are formed.301,302 Although myocyte lengthening and subsequent lattice 
reduction are intimately linked, accumulating evidence suggests that lattice reduction 
itself does not play per se a major role in length-dependent cardiac muscle activation.
In 1977, Godt and Maughan303 were able to vary the maximum tension of Ca2+-
activated fibers using high-molecular-weight polymers, such as dextran. Because of 
its inability to diffuse into the lattice spacing, dextran could compress the sarcomere 
and decrease the interfilament distance.303 Next, it was found that variations in fiber 
width  (as a function of lattice spacing) could be regulated by varying concentrations 
of dextran.304 The groups of Moss305 and Stienen306 indicated that lattice spacing, 
rather than length, was responsible for the changes in Ca2+-sensitivity in membrane-
permeabilized skeletal muscles. These results were confirmed in skeletal307-309 and 
cardiac308,310 muscle preparations which demonstrated that osmotic compression (as a 
function of muscle width) enhances Ca2+-sensitivity. These findings were in agreement 
with the proposition of Hofmann and Fuchs292,311 who demonstrated that Ca2+-binding 
to cTnC directly regulates cross-bridges interactions (rather than sarcomere length). 
Fuchs and Wang312 observed that both Ca2+-sensitivity and Ca2+-affinity to cTnC were 
directly correlated with the lattice spacing but not with sarcomere length in cardiac 
muscle. This hypothesis, however, remains largely disputed and evidence from the last 
decade suggests another view. In the previous studies, alterations in lattice spacing as 
a function of dextran addition were not directly measured, but were indirectly based on 
alterations in muscle width. To visualize the interfilament lattice spacing as a function 
of dextran application, the group of de Tombe313-315 used synchrotron X-ray diffraction 
in membrane-permeabilized and intact cardiac tissue. The authors observed that Ca2+-
sensitivity was not in a linear relation with interfilament spacing as a result of osmotic 
compression. Rather, compression of the lattice spacing with 4% dextran to match 
the decreased lattice spacing as observed when the sarcomere length is increased to 
the optimal length (≈2.2 μm) did not affect myofilament Ca2+-sensitivity.314,315 These 
studies are a major obstacle against the suggestion that interfilament lattice spacing 
is the major mechanism in the regulation of length-dependent activation.
3. Titin
Evidence from the last decade revealed that the giant elastic protein, titin, may be 
involved in the modulation of active tension and serve as a length-dependent sensor. 
Titin could exert such length-dependent behaviour by two possible mechanisms:
Titin-induced reduction of lattice spacing
A titin-based passive tension potentiation of cross-bridge formation could reduce 
the filament lattice spacing upon stretch.316-318 Along these lines, a correlation between 
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enhanced length-dependent activation and higher levels of passive tension has been 
reported.316,317,319 A recent study reporting a reduced myofilament force development 
and impaired length-dependent activation320 in a rat with a homozygous autosomal 
mutation expressing a giant titin isoform (N2BA-G, ~3.9 MDa)321 appears to support 
this idea. 
Stretch potentiates titin-induced strong-binding cross-bridge recruitment
Another view, however, suggests that titin-induced stretch effects a reduction in 
lattice spacing. Titin is obliquely to the sarcomere axis and since it is attached to 
both myosin and cMyBP-C,174-176 it may impose a passive strain on the thick-filament 
proteins, thereby reducing lattice spacing and changing the geometry of the cross-
bridges.318,322 Recruitment of strong-binding cross-bridges via a titin-induced stretch 
is vital to length-dependent and stretch-activation mechanisms. It has been reported 
in frog skeletal muscle that sarcomere lengthening increases myosin periodicity323, 
such that the transition of the population of rested (order; on the axis plane of 
the thick-filament) cross-bridges to weak binding cross-bridges increases (disorder, 
Figure 13).324,325 A similar finding was recently observed in cardiac muscle where 
the orientation of myosin heads becomes more perpendicular to the thick-filament 
axis when sarcomere length is increased.326 Altogether these studies suggest that 
stretch-induced activation by titin-induced radial strain of the thick-filament is likely 
to increase the number of cross-bridges at the thick-filament, which would allow more 
myosins to attach to actin, in strong-binding states (Figure 13).
4. Cardiac troponin and thin-filament transitions: regulator of length-
dependent activation
4.1. Stabilization of the B-state formation: length-dependent sensitive step
There is evidence to suggest that length-dependent activation is regulated via an 
“on-off” switch of the thin-filament.328 The relevance of the transition from the B-state 
to the C-state for proper length-dependent activation has been shown by Smith 
and Fuchs328 who were the first to provide evidence for a length-sensitive step in 
the transitions of thin-filament activation. A reduction in ionic strength (<0.05 M), 
known to shift the B-state equilibrium towards a stable C-state (where the disordered 
population of cross-bridges is increased329,330; i.e. it mimics the effects of stretch), 
coincided with impaired length-dependent activation.328 Terui and colleagues331 
recently demonstrated that length-dependent activation is associated with titin-
induced strain on the thick-filament, which is highly dependent on the troponin 
complex. The authors observed that reconstitution of cardiac thin-filaments with fast 
sTn reduced length-dependent activation to a level similar to that of skeletal muscle. 
In turn, reconstitution with cTn restored length-dependent activation and decreased 
Ca2+-sensitivity. The authors associated the latter findings as an increased transition 
of the B-state towards the C-state.331
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figure 13. Schematic drawing of half-sarcomere at varying sarcomere lengths. Lattice spacing 
dimensions at each varying length were taken from Konhilas et al.327. As the muscle is stretched 
from a relatively short sarcomere length (A) to higher sarcomere lengths (B and C), lattice spacing 
becomes smaller with increased transition of order cross-bridges (A; projection of cross-bridges in 
X-ray diffraction studies) into disorder (active) states (B and C). The I-band region of titin is the 
extensible region and consists of three elastic components that act as a spring element: 1) tandem 
immunoglobulin (Ig)-like domain regions, with proximal (near Z-disc) and distal (near I-A regions) 
segments; 2) the PEVK sequence-region rich in proline (P), glutamic acid (E), valine (V) and lysine (K); 
and 3) the N2B and N2BA elements (both isoforms contain N2B segments, but only the N2BA isoform 
contains an additional N2A element).167 Titin-induced stretch imposes a passive strain on the thick-
filament proteins, reduces lattice spacing and changes the arrangement of cross-bridges. Distinct 
myosin colours are depicted to better illustrate the transition of ordered to disordered projections. 
α-actinin and desmin illustrate the Z-disc border. According to detailed calculations from Gordon and 
colleagues128 ~1 cross-bridge binds each A7TmTn. Note: cardiac myosin-binding protein C (cMyBP-C) 
was omitted to simplify the drawing and the width and sarcomere length dimensions are not to scale.
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Recent findings from stretch-activation studies in insect flight muscle support 
the view that troponin-tropomyosin thin-filament transitions are central to 
the length-dependent response. Flight muscles require stretch-activation mechanisms 
in addition to Ca2+ to activate the muscle.332,333 Because transition of the B-state 
requires Ca2+ to move tropomyosin to the C-state, insect flight muscles are switched 
“on” due to Ca2+-induced binding to TnC; however, Ca2+ alone is not sufficient 
to uncover the myosin-binding sites - stretch is required. Since muscle stretching 
appears to increase myosin periodicity with orientation of myosin heads on the thick-
filament323,326, one can speculate that insect flight muscle requires the formation of 
strong-binding cross-bridges presumably by stretch in order to move tropomyosin 
and uncover myosin-binding sites. In support, Perz-Edwards and colleagues334 
recently demonstrated that stretch-activation of insect flight muscle requires 
the steric blocking-unblocking model (thin-filament transitions) for the regulation of 
the actomyosin complex and that stretching the muscle causes tropomyosin movement 
and uncovers myosin-binding sites on actin. The similarities between insect flight 
and vertebrate muscle thus suggest that passive strain imposed to the thick-filament 
increases the “activation” of cross-bridges which presumably via binding to troponin 
(“troponin bridges”334) and/or tropomyosin247 regulate length-dependent activation. 
Because mutations on sarcomeric proteins can potentially impair the equilibrium 
affinity and thin-filament transitions, in Chapter 3 we conducted a large study in 
human HCM samples as to assess whether length-dependent activation is preserved 
in tissue with diverse sarcomeric mutations which cause cardiomyopathy. Indeed, 
we provide evidence that a reduced length-dependent increase in Ca2+-sensitivity is 
a common mechanism underlying cardiac dysfunction in HCM with missense mutations, 
indicative for the important role of thin-filament transitions for myofilament length-
dependent activation.
4.2. Post-translational modulation by protein kinase A (PKA) in length-
dependent activation
The suggestion that PKA-mediated myofilament protein phosphorylation has 
a modulatory role in length-dependent activation comes from studies on ferret papillary 
muscles,335 in which isoprenaline, a stimulator of the β-adrenergic receptor pathway, 
enhanced the length-dependent change in the force-Ca2+ relation. Reconstitution 
of cardiac thin-filaments with ssTnI showed higher myofilament Ca2+-sensitivity, but 
significantly reduced length-dependent activation,315,336 indicating a role for cTnI 
phosphorylation in length-dependent activation. In support, recent data from our 
group337  and others338,339 clearly demonstrates that PKA-induced phosphorylation of 
cTnI-Ser23/Ser24 is essential for length-dependent activation. One can speculate that 
because PKA-induced phosphorylation decreases cTnC-cTnI interactions, this leads 
to greater cTnI-tropomyosin interactions and hence, the B-state is favored; this is 
associated with less myosin-binding sites available on actin. In Chapter 6 we provide 
evidence that indeed the B-state is strengthened upon PKA-induced phosphorylation 
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which is partly the resulting contribution of cTnI but also of cMyBP-C. Finally, a study 
by Cazorla et al.340 using transgenic mice lacking cMyBP-C demonstrated high Ca2+-
sensitivity and reduced length-dependent activation compared to wild-type mice, 
and that this could not be restored by exogenous PKA treatment. This study suggests 
that cMyBP-C is required for proper length-dependent sarcomere activation as well.
5. Cooperativity
5.1. What is cooperativity?
The sigmoidal relationship between [Ca2+] and force and/or ATPase activity is 
one of the earlier demonstrations that the binding of Ca2+ appeared to activate 
muscle contraction in a cooperative fashion. Filo and colleagues in 1965341 were 
the first to correlate tension as a function of the free [Ca2+] using glycerinated 
skeletal and smooth muscle preparations. This observation was confirmed by 
Hellam and Podolsky281 in membrane-permeabilized muscle preparations. The 
authors were the first to describe the relationship between free [Ca2+] (defined 
by its inverse logarithm: pCa, i.e., –log10 of the [Ca
2+]) and force as a sigmoidal 
curve. Six years later, Donaldson and Kerrick342 introduced the widely known 
term “pCa50”. When studying the effects of Mg
2+ on muscle Ca2+-contraction in 
membrane-permeabilized fibers, the authors observed no difference in maximal 
tension generated whether Mg2+ was present or not. However, to their surprise, if 
a submaximal tension comparison was made (at 50% of the maximum tension), 
Mg2+ was shown to reduce force generation. pCa50 is a widely used parameter to 
characterize the “Ca2+-sensitivity” of a muscle system. In addition, Donaldson and 
Kerrick342 also assumed the existence of a cooperative system:
The tension in the curves [...] rises from 10 to 90% of maximum in less than 2 pCa [...] 
units which is indicative of interacting sites. Because of the evidence for interacting 
sites these data were analyzed using the Hill equation (Hill, 1913343) which accounts 
for cooperative forces in the binding of a ligand to a macromolecule (Hill, 1913343; 
Loftfield and Eigner, 1969344). (Donaldson and Kerrick342 permission not required)
The coefficient of Hill (or nH) is thus an indication of the relative number of 
interacting sites and represents a measure of the cooperativity of Ca2+ activation 
of the contractile machinery. A hypothetical system with a nH value of 1 describes 
a one-to-one relation, where 1 mole of Ca2+ activates 1 functional unit (A7TmTn). The nH 
for cardiac muscle contraction exceeds 1, both in humans345,346 and in animals315,347,348, 
indicative of a highly cooperative system (Figure 14).
5.2. Cooperativity of length-dependent activation
The thin-filament functional unit comprises seven actin monomers spanned by 
one tropomyosin dimer and one cTn complex (A7TmTn).
136 Ca2+-binding to cTnC 
promotes cTnI detachment from actin and potentiates tropomyosin movement 
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to expose myosin-binding sites on the surface of F-actin. This tropomyosin 
movement allows Ca2+-cooperative activation of the thin-filament with additional 
recruitment of strong-binding myosin and actin monomers. Structural data suggest 
that individual strongly-bound cross-bridges bind to the regulatory unit (A7TmTn 
spanning ~38.5 nm) and regulate tropomyosin movement up to ~3 units (covering 
~115 nm) along the thin-filament, in the presence of Ca2+.139 This was also validated 
in biochemical studies.241,349 Mounting evidence defines the role of tropomyosin in 
thin-filament Ca2+-activation as three biochemical transitions. Tropomyosin increases 
“communication” between neighboring regulatory units, a property that is governed 
by the head-to-tail interaction (i.e., overlap region).239-241,350,351 Removal of this overlap 
reduces cooperative-binding of myosin.350-352 
Two recent studies support the idea that Ca2+-cooperative effects are independent 
of myosin-binding and are strongly associated with the thin-filaments.353,354 Sun et 
al.353 reconstituted cardiac thin-filaments with fluorescent-labelled TnC and analyzed 
changes in the orientation of the structure of troponin. They observed that blebbistatin 
(which prevents strong-binding formation) had no effect on the Hill coefficient.353 
Farman et al.354 reached similar conclusions, because in their experiments blebbistatin 
decreased Ca2+-sensitivity and force, but did not affect the Hill coefficient. Importantly, 
the authors reconstituted rat cardiac thin-filaments with a cTnC mutant incapable of 
binding Ca2+ and observed that both Ca2+-sensitivity and nH were decreased.354 In 
addition, they observed that the effects of the cTnC mutant were greater at short 
(2.0 μm) than at longer (2.2 μm) sarcomere lengths. The authors attributed this result to 
figure 14. Cooperativity in cardiac muscle. In this plot of Ca2+ versus relative force the solid line 
depicts a unique cooperative relation between [Ca2+] and force. The dashed line depicts a hypothetical 
system where cooperative activation is non-existent (x-axis here is non-logarithmic).
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the ability of tropomyosin to recruit more regulatory units (A7TmTn) upon stretching; 
tropomyosin stiffness increases at longer sarcomere length and affects up to three to 
four A7TmTn units, whereas at shorter sarcomere length tropomyosin is less stiff and 
would only affect one or two A7TmTn units. 
Taken together, these data imply that cooperative activation via thin-filaments 
is partly responsible for the length-dependent behaviour. This is consistent with 
the observation of impaired Ca2+-cooperative activation in muscle carrying 
cardiomyopathy-causing mutations in genes encoding cTnT.259,355 Because 
tropomyosin overlap regions are required for proper formation of a ternary 
complex with the N-terminal tail of cTnT356 (which in turn is essential to maintain 
the thin-filament in the B-state357,358), this suggests that troponin mutations disrupt 
the structure of the troponin-tropomyosin complex359. Also, impaired tropomyosin-
tropomyosin interactions could decrease near-neighbour interactions and decrease 
length-dependent activation. 
DisCussion
Over a century of research on the Frank-Starling Law has greatly advanced our 
knowledge of the fundamental basis of muscle. It mandates that, at the single 
cardiomyocyte level, there is a direct relation between sarcomere length and 
myofilament sensitivity to Ca2+ ions, such that more force is generated at a given 
concentration of Ca2+ as sarcomere length is increased. Although a unifying idea 
to explain how the myofilament “senses” length alterations remains in dispute, 
evidence supports the stretch-induced effects are central to length-dependent 
force changes. Also, changes in Ca2+-activation upon muscle lengthening must 
be considered. This review has provided substantial evidence that myofilament 
length-dependent activation is a composite of several synergistically mechanokinetic 
processes. Length-dependent activation is the sum of increased Ca2+-affinity of cTnC, 
alterations in interfilament lattice spacing, titin-induced stretch, and the formation 
of strong-binding cross-bridges, cTn complex changes, and Ca2+-cooperative 
mechanisms.
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abstraCt
rationale: High myofilament Ca2+-sensitivity has been proposed as trigger of disease 
pathogenesis in familial hypertrophic cardiomyopathy (HCM) based on in vitro and 
transgenic mice studies. However, myofilament Ca2+-sensitivity depends on protein 
phosphorylation and muscle length and at present data in human are scarce.
objective: To investigate if high myofilament Ca2+-sensitivity and perturbed length-
dependent activation is characteristic for human HCM with mutations in thick and thin 
filament proteins.
methods and results: Cardiac samples from HCM patients harboring mutations in 
genes encoding thick (MYH7, MYBPC3) and thin (TNNT2, TNNI3, TPM1) filament 
proteins were compared with sarcomere mutation-negative HCM (HCMsmn) and non-
failing donors. Cardiomyocyte force measurements showed higher myofilament Ca2+-
sensitivity in all HCM samples and low phosphorylation of protein kinase A (PKA)-targets 
compared to donors. After exogenous PKA treatment, myofilament Ca2+-sensitivity 
was either similar (MYBPC3mut, TPM1mut, HCMsmn), higher (MYH7mut, TNNT2mut) or even 
significantly lower (TNNI3mut) compared to donors. Length-dependent activation 
was significantly smaller in all HCM than in donor samples. PKA treatment increased 
phosphorylation of PKA-targets in HCM myocardium and normalized length-
dependent activation to donor values in HCMsmn and HCM with truncating MYBPC3 
mutations, but not in HCM with missense mutations. Replacement of mutant by 
wild-type troponin in TNNT2mut and TNNI3mut corrected length-dependent activation 
to donor values.
Conclusion: High myofilament Ca2+-sensitivity is a common characteristic of human 
HCM and partly reflects hypophosphorylation of PKA-targets compared to donors. 
Length-dependent sarcomere activation is perturbed by missense mutations, possibly 
via post-translational modifications other than PKA-hypophosphorylation or altered 
protein-protein interactions, and represents a common pathomechanism in HCM.
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non-stanDarD abbreviations anD aCronyms
HCM   Hypertrophic cardiomyopathy
MYH7 or β-MyHC β-myosin heavy chain
MYBPC3 or cMyBP-C Cardiac myosin-binding protein-C
TNNI3 or cTnI  Cardiac troponin I
TNNT2 or cTnT  Cardiac troponin T
TNNC1 or cTnC  Cardiac troponin C
TPM1 or α-Tm  α–tropomyosin
PKA   Protein kinase A
LV   Left ventricular
HCMmut   Sarcomere mutation-positive HCM
HCMsmn   Sarcomere mutation-negative HCM
SEM   Standard error of the mean
Fmax   Maximal developed force
∆Fmax    Difference in Fmax between sarcomere lengths of 1.8 
   and 2.2 μm
EC50   Ca
2+-sensitivity ([Ca2+] at which half of Fmax is reached)
∆EC50   PKA-mediated or length-dependent change in myofilament  
   Ca2+-sensitivity
ssTnI   Slow skeletal troponin I
Ser   Serine
PTMs   Post-translational modifications
B-state   Blocked state
C-state   Ca2+-induced state
M-state   Myosin-induced state
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introDuCtion
Myofilament contraction is initiated by interaction between the thin actin and thick 
myosin filaments. This actin-myosin interaction (i.e. thin filament-myosin cross-bridge 
binding), and the magnitude of myofilament force generation is tightly regulated 
by muscle length, Ca2+-binding and protein phosphorylation.1 Defective proteins 
as a result of mutations in genes encoding sarcomeric proteins may directly impair 
regulation of muscle contraction and manifest themselves as phenotypic aberrations 
of the heart. Hypertrophic cardiomyopathy (HCM) reflects the pathological phenotype 
associated with sarcomeric gene mutations.2, 3 Affecting 1:500 individuals worldwide, 
HCM is the most common cause of sudden death in young people.2 Genotyping 
studies have identified a disease-causing mutation in ~70% of all HCM patients.4 
Mutations in thick filament-encoding genes, MYH7 (β-myosin heavy chain, β-MyHC) 
and MYBPC3 (cardiac myosin-binding protein-C, cMyBP-C) account for approximately 
80% of all identified sarcomere mutations, while ~18% of the mutations are found 
in thin filament-encoding genes, TNNI3 (cardiac troponin I, cTnI),TNNT2 (cardiac 
troponin T, cTnT), TNNC1 (cardiac troponin C, cTnC), TPM1 (α–tropomyosin, α-Tm) 
and ACTC1 (α-cardiac actin).5 The remaining 2% is attributed to incidental mutations 
in the thick filament genes, MYL3 and MYL2, encoding the regulatory and essential 
myosin light chain, and the sarcomere-associated gene TTN, which encodes 
titin.5 Based on the numerous sarcomeric gene mutations HCM is referred to as 
“disease of the sarcomere”.
Both animal6, 7 and clinical8-10 studies have shown that carriers of HCM-causing 
mutations demonstrate early signs of cardiac dysfunction, even before a hypertrophic 
phenotype is observed. Additionally, sudden cardiac death occurs in young 
individuals in the absence of clinically detectable cardiac hypertrophy.11 This suggests 
that the initial defects in cardiac performance are triggered by mutant sarcomeric 
proteins rather than remodeling of the heart. Sarcomere mutations may directly 
impair myofilament function and contractile performance of the heart,3 or indirectly 
via changes in intracellular Ca2+-handling.12 As the myofilaments represent a major 
intracellular buffer of Ca2+, any perturbation in myofilament Ca2+-sensitivity may 
provide a substrate for cardiac arrhythmias. Only recently, the group of Knollmann13 
showed that TNNT2 mutations alter intracellular Ca2+-handling via myofilament Ca2+-
sensitization in transgenic mice models, which was associated with altered action 
potential regulation and occurrence of arrhythmias. This implies that myofilament 
Ca2+-sensitivity is central in HCM pathology. 
Whether or not myofilament sensitization to Ca2+ is of relevance in human HCM is 
a matter of ongoing research.14-16 Our recent studies in manifest HCM with MYBPC3 
mutations showed higher myofilament Ca2+-sensitivity compared to non-failing donor 
myocardium.15, 16 However, high Ca2+-sensitivity coincided with low phosphorylation 
of target proteins of the β-adrenergic signaling pathway, cTnI and cMyBP-C, and 
was normalized to donor values by exogenous protein kinase A (PKA) treatment.15 
This suggests that the high myofilament Ca2+-sensitivity observed in human HCM 
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with MYBPC3 mutations is due to secondary disease-related post-translational 
modifications rather than the mutation itself. In addition to post-translational protein 
modifications, muscle length represents an important determinant of myofilament 
Ca2+-sensitivity. Recently, we observed impairment of length-dependent sarcomere 
activation evident from a blunted length-dependent increase in myofilament 
Ca2+-sensitivity in HCM with MYBPC3 mutations.15 Under normal conditions 
intracellular Ca2+ buffering will increase with increased myofilament Ca2+-sensitivity 
upon myofilament lengthening.17, 18 Perturbations in length-dependent myofilament 
activation will alter Ca2+ buffering by the sarcomeres and may provide a basis for 
altered Ca2+-handling in HCM.
In the present study, we investigated if perturbed length-dependent activation 
rather than high myofilament Ca2+-sensitivity is a common pathomechanism in human 
HCM with mutations in thick and thin filament genes. Measurements in sarcomere 
mutation-positive HCM (HCMmut) were compared with sarcomere mutation-negative 
HCM (HCMsmn) and non-failing donors. Our study shows that mutation-related 
changes in myofilament Ca2+-sensitivity are diverse and depend on the affected gene. 
We observed impaired length-dependent sarcomere activation in all HCM samples. 
The blunted length-dependence of sarcomeres was due to low phosphorylation of 
PKA targets compared to donor myocardium in patients with a MYBPC3 truncating 
mutations and HCMsmn, but a direct consequence of HCM missense mutations. 
Using troponin exchange in HCM cardiomyocytes with a homozygous TNNT2 and 
a heterozygous TNNI3 mutation, we provide evidence that less than 50% of poison 
peptide is sufficient to impair length-dependent activation of the sarcomeres. Since 
most patients carry a heterozygous sarcomere mutation that may result in relatively low 
levels of mutant (poison) peptide, impaired length-dependent sarcomere activation 
represents a pathomechanism in HCM.
metHoDs
An expanded version of the Methods section can be found in the online-only 
Data Supplement.  
Myocardial samples
Left ventricular (LV) septum tissue was obtained from HCM patients harboring thick 
and thin filament gene mutations during myectomy surgery to relieve LV outflow 
obstruction. Hypertrophic obstructive cardiomyopathy was evident from the high 
septal thickness (normal value <13 mm) and high LV outflow tract pressure gradient 
(normal value <30 mm Hg). Clinical characteristics and mutation information of HCM 
patients are listed in Table 1. Our study included patients carrying heterozygous 
mutations in MYBPC3 (n=21; MYBPC3mut), MYH7 (n=6; MYH7mut), TNNI3 
(n=2; TNNI3mut) and TPM1 (n=1; TPM1mut). The MYBPC3mut group consisted of patients 
with truncating (n=17) and missense (n=4) mutations. Data for these two MYBPC3mut 
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groups are presented separately. Septum tissue was also obtained from 1 end-stage 
failing HCM patient carrying a homozygous TNNT2 mutation (TNNT2mut). Septum 
myectomy tissue from 7 HCM patients in whom no mutation was found after screening 
of 8 genes (sarcomere mutation-negative HCM; HCMsmn) and cardiac tissue from 12 
non-failing donors served as controls. Donors (age range from 14 to 65 years; mean 
39±5 years; 9/3 male/female, respectively) had no history of cardiac abnormalities, 
normal ECG and normal ventricular function on echocardiography within 24 hours 
of heart transplantation. Samples were obtained after written informed consent and 
the study protocol was approved by the local ethical committees. 
Isometric force measurements
Small cardiac tissue samples were thawed in relaxing solution (5.95 mM Na2ATP, 6.04 
mM MgCl2, 2 mM EGTA, 139.6 mM KCl, 10 mM Imidazole, pH 7.0) and cardiomyocytes 
were mechanically isolated by tissue disruption. Cardiomyocytes were chemically 
permeabilized by incubation for 5 minutes in relaxing solution containing 0.5% 
(v/v) Triton-X100 and glued between a force transducer and a piezoelectric motor.15 
Isometric force measurements were performed at maximal and submaximal [Ca2+] 
(ranging from 1 to 30 μmol/L) and sarcomere lengths of 1.8 and 2.2 μm (Online 
Figures IA and IB). Average sarcomere lengths were determined by means of a spatial 
Fourier transformation as described previously.19 Passive force (Fpas) was determined 
by shortening the myocyte in a relaxing solution (10-9 μmol/L) by 30% of its length. 
Maximal developed force (Fmax) was determined by activating the cardiomyocyte at 
saturating [Ca2+] (30 μmol/L), generating a total force value (Ftotal). Fmax was obtained 
by subtracting Fpas from Ftotal (i.e. Fmax=Ftotal-Fpas). Maximal tension (in kN/m
2) was 
calculated as Fmax normalized to cross-sectional area of the cardiomyocytes. Force-
Ca2+ relations were fit to a modified Hill equation and myofilament Ca2+-sensitivity 
was denoted as EC50 ([Ca
2+] at which half of Fmax was reached). The length-dependent 
increase in myofilament Ca2+-sensitivity upon an increase in sarcomere length is 
based on the difference in EC50 at sarcomere lengths of 1.8 and 2.2 μm (∆EC50). 
Additional force measurements were performed following exogenous PKA treatment 
of cells for 40 minutes at 20ºC in relaxing solution containing the catalytic subunit of 
PKA (100 U/incubation, Sigma).
Exchange of recombinant human wild-type troponin complex in single 
cardiac cells
Preparation of recombinant human wild-type troponin complex
Expression of cDNA encoding human wild-type cardiac troponin subunits (cTnC, 
myc-tag labeled cTnT (cTnT-myc), cTnI), purification and reconstitution were 
performed as described previously.20
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Troponin exchange protocol
Single cardiomyocytes from the TNNT2mut heart and one of the TNNI3mut hearts 
were mechanically isolated by tissue disruption in ice-cold rigor solution (132 mM 
NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM Tris, 5 mM EGTA, 1 mM NaAzide, pH 7.1). 
Cardiomyocytes were chemically permeabilized by incubation for 5 minutes in rigor 
solution containing 0.5% (v/v) Triton-X100. After permeabilization, cells were washed 
twice with rigor solution followed by washing in exchange solution (10 mM imidazole, 
200 mM KCl, 5 mM MgCl2, 2.5 mM EGTA, 1 mM DTT) (pH 6.9). Subsequently, single 
cardiomyocytes were incubated overnight at 4°C in exchange solution containing 
the appropriate concentration of recombinant human troponin complex (0.25, 0.5 
and 1.0 mg/mL) with the addition of 4 mM CaCl2, 4 mM DTT, 5 μl/mL protease 
inhibitor cocktail (PIC, Sigma, P8340) and 10 μl/mL phosphatase inhibitor cocktail 2 
and 3 (PhIC, Sigma, P2850, P5726) (pH 6.9). The next day, cells were washed twice in 
rigor solution followed by washing in relaxing solution. Our previous study showed 
a homogenous distribution of recombinant troponin complex in cardiomyocytes using 
this exchange protocol.21
Determination of troponin exchange percentage
Half of the cardiomyocyte suspension was used for isometric force measurements, 
whereas the other half was used to analyze troponin exchange percentage. This 
half was treated with 2D-clean-up kit (GE Healthcare), homogenized in sample 
buffer (15% glycerol, 62.5 mM Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v) DTT) and 
protein concentration was measured with RCDC Protein Assay kit II (Biorad) as 
described previously.20 
To determine the degree of exchange of endogenous mutant troponin by 
recombinant wild-type cardiac troponin Western blotting was performed. Recombinant 
wild-type cTnT was labeled with a myc-tag, which allowed differentiation between 
endogenous and recombinant cardiac troponin complex. Proteins were separated on 
a 1D SDS-PAGE and blotted onto a nitrocellulose membrane. A specific monoclonal 
antibody was used against cTnT (Clone JLT-12, Sigma) to detect endogenous 
and recombinant cTnT by chemiluminescence (ECL, Amersham Biosciences) as 
described previously.20
Myofilament protein phosphorylation
SYPRO Ruby and ProQ-Diamond staining of gradient gels
Myofilament protein phosphorylation levels in HCM and donor myocardium and in 
PKA-treated samples (100 U/mL relaxing solution) were analyzed on 4-15% pre-cast 
Tris-HCl gels (BioRad) and stained with SYPRO Ruby and ProQ-Diamond phosphostain 
as described previously.22 Phosphorylation of cMyBP-C and cTnI was normalized to 
SYPRO-stained cMyBP-C and cTnI, respectively. Protein phosphorylation values were 
normalized to the values found in untreated donors, which were set to 1.
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table 1. Mutations and clinical characteristics of patients.
mutation type age sex lvot st
MYBPC3mut Truncating mutations
1 c.927-2A>G splice site 37 M 61 19
2 c.927-2A>G splice site 48 M 82 18
3 c.927-2A>G splice site 22 M 71 30
4 c.1458-1G>C splice site 41 F 92 22
5 c.2373duplicationG insertion 32 F 100 30
6 c.2373duplicationG insertion 39 F 60 20
7 c.2373duplicationG insertion 45 F 94 20
8 c.2373duplicationG insertion 62 M 64 23
9 c.2373duplicationG insertion 44 F 100 17
10 c.2373duplicationG insertion 69 M 74 19
11 c.2373duplicationG insertion 57 F 74 24
12 c.2373duplicationG insertion 32 M 88 23
13 c.2373duplicationG insertion 60 M 77 23
14 c.2864.2865delCT deletion 42 M 116 23
15 c.2864.2865delCT deletion 45 M 100 20
16 c.2864.2865delCT deletion 62 F 67 15
17 c.3407.3409del deletion 55 M UK UK
MYBPC3mut Missense mutations
18* p.E258K missense 35 M 4 27
19 p.E258K missense 45 M 72 24
20 p.G531R missense 51 M 110 22
21 p.R597Q missense 47 F 85 20
MYH7mut
1 p.R403Q missense 25 M 85 34
2 p.V606M missense 46 F 79 17
3 p.S782R missense 30 F 128 29
4 p.R787H missense 61 M UK UK
5 p.T1377M missense 58 F 100 20
6 p.T1377M missense 43 M UK UK
TNNT2mut
1 p.K280N missense 26 M UK UK
TNNI3mut
1 p.R145W missense 46 M 100 23
2 p.R145W missense 66 M 100 16
TPM1 mut
1 p.I284V missense 65 M 100 16
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Western blot analysis of cMyBP-C phosphorylation at PKA sites
Phosphorylation of the cMyBP-C PKA sites Ser275 and Ser284 was assessed using 
phosphospecific antibodies in Western blots.15 
Phos-Tag acrylamide gels
Phos-TagTM acrylamide gels were performed to visualize phosphorylated cTnI species 
using alkoxide-bridged dication manganese (Mn2+) complex as phosphate-binding 
tag (Phos-tag) molecule. Mn2+-Phos-Tag molecules specifically bind phosphorylated 
proteins and as a result, their migration speed is highly reduced. Non-phosphorylated 
and phosphorylated cTnI species were separated in 1D PAGE with polyacrylamide-
bound Mn2+-Phos-Tag, transferred to Western blots and probed with anti-cTnI 
monoclonal antibody (8I-7 Spectral Diagnostics).23
Data analysis
Data analysis and statistics were performed using Prism version 4.0 (Graphpad 
Software, Inc., La Jolla, CA) and SPSS version 15.0 (IBM, Armonk, NY). Data are 
presented as mean±SEM of all single cardiomyocytes per patient group (8 groups, 
i.e. the 6 HCM sarcomere mutation positive groups (HCMmut), HCMsmn and non-failing 
donor). To take into account the repeated sample assessments within patient/donor 
groups multilevel analysis was performed. Comparison between all groups was 
performed for Ca2+-sensitivity at 2.2 μm sarcomere length and length-dependent 
activation of cardiomyocytes before and after PKA. Paired-group comparisons were 
performed for Fmax at 1.8 and 2.2 μm sarcomere length before and after PKA.
All data was tested for normality using the Shapiro-Wilk Test. Normality was 
assumed when p>0.05 and the variances were equal. When assumption of normality 
was violated the data set was logarithmic-transformed and normality re-tested.24 
Detailed information on statistical analyses of the data presented in Figures 1-2 and 
table 1. (Continued)
mutation type age sex lvot st
HCMsmn Sarcomere mutation negative
1 46 F 105 24
2 57 M 117 25
3 75 F 137 20
4 72 F 88 24
5 65 F 85 19
6 49 M 61 20
7 46 M 81 19
LVOT, left ventricular outflow tract pressure gradient in mmHg; ST, septal thickness in mm; p, protein amino 
residue; c, codon region; del, deletion; UK, unknown. *Patient was operated due to extreme hypertrophy and 
small LV cavity.
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5 and Table 2 of the manuscript are presented in the Online Tables III to X. To take 
differences in group size into account multilevel analysis was performed (Online 
Tables III to VII and X to XI). Two data sets were expressed as logarithmic-transformed 
groups (Online Tables III and V). To check for paired-group differences on Fmax between 
sarcomere lengths of non-treated (Online Table VIII) or treated cardiomyocytes with 
PKA (Online Table IX), paired-samples t-Test was conducted. p<0.05 was considered 
significant for both tests and 95% confidence intervals (CI) were calculated to 
gain insight into the range of the mean differences between and among groups. 
In case of logarithmic transformed data, a set of 95% CIs was calculated by taking 
the exponential of the natural logarithmic values (Online Tables III and V). The CIs 
reflect ratios stating that the mean difference between two groups can be [x to y] time 
higher or lower than the group of comparison.
results
Myofilament Ca2+-sensitivity in HCM compared to non-failing donors
To assess myofilament Ca2+-sensitivity, force-Ca2+ relations were constructed for all 
cardiac samples at a sarcomere length of 2.2 μm. Ca2+-sensitivity for all HCM samples 
was significantly higher compared to donors, based on their lower EC50 values 
(Figure 1A). As the high Ca2+-sensitivity may be due to low phosphorylation levels 
of PKA-target proteins, measurements were repeated after PKA treatment. The PKA-
induced reduction in Ca2+-sensitivity (∆EC50) was larger in all HCM groups compared 
to donors (with significant changes in MYBPC3mut, MYH7mut and TNNI3mut), except for 
the TNNT2mut which only showed a minor non-significant change (Figure 1B). After 
PKA treatment myofilament Ca2+-sensitivity was close to donor values in MYBPC3mut, 
TPM1mut and HCMsmn, while Ca
2+-sensitivity remained significantly higher compared to 
donor in MYH7mut and TNNT2mut (Figure 1C). Interestingly, after PKA Ca
2+-sensitivity 
was significantly lower in TNNI3mut compared to HCMsmn and donor.
Fmax at a sarcomere length of 2.2 μm was significantly lower in all HCM groups 
compared to donor and was not corrected by PKA treatment (Online Table I). In 
addition, the steepness of the force-Ca2+ relation was significantly lower and not 
corrected by PKA in all HCM groups compared to donors (data not shown).
Length-dependent myofilament force characteristics
Force development was measured at various [Ca2+] and two sarcomere lengths to 
determine length-dependent activation of myofilaments (Figure 2A). Following 
a sarcomere length increase from 1.8 to 2.2 μm at maximal Ca2+-activation, donor 
samples showed a significant increase in Fmax (Table 2), which is in accordance with 
the well-known effects of length on force development.25 A significant length-
dependent increase in Fmax was observed in MYBPC3mut, MYH7mut, TPM1mut and HCMsmn 
heart samples, while no significant increase in Fmax was found for both TNNT2mut and 
TNNI3mut. As illustrated in Table 2 the ∆Fmax (difference in Fmax between sarcomere 
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figure 1. Myofilament Ca2+-sensitivity at a sarcomere length of 2.2 μm. A. Myofilament Ca2+-sensitivity 
(EC50) was significantly higher in all HCM groups compared to donors. b. The PKA-induced reduction 
(∆EC50) in myofilament Ca
2+-sensitivity was larger in HCM groups compared to donors, except in 
the TNNT2mut sample, in which PKA had no significant effect. C. Myofilament Ca
2+-sensitivity was 
similar in MYBPC3mut, TPM1mut, HCMsmn and donor after treatment with PKA, while it was higher 
than donor in MYH7mut and TNNT2mut. PKA-treated TNNI3mut cells showed a lower myofilament Ca
2+-
sensitivity compared to HCMsmn and donor. Open bar graph represents MYBPC3 truncating mutation; 
Closed gray bar graphs represent missense mutations. *p<0.05 versus donor; §p<0.05 versus 
TNNT2mut; 
#p<0.05 versus HCMsmn.
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lengths of 1.8 and 2.2 μm) was much lower in HCM with missense mutations compared 
to the other groups.
To investigate the length-dependent increase in myofilament Ca2+-sensitivity, 
force at submaximal [Ca2+] was normalized to the maximal developed force to obtain 
normalized force-Ca2+ relations at both sarcomere lengths (Figure 2B). For all HCM 
and donor groups, the normalized force-Ca2+ relation shifted to the left as sarcomere 
length increased, indicative for increased Ca2+-sensitivity. However, the increase 
in myofilament Ca2+-sensitivity upon an increase in sarcomere length (∆EC50) was 
significantly lower in all HCMmut and HCMsmn samples compared to donors (Figure 2C). 
Stimulation of the β-adrenergic receptor pathway has been shown to enhance 
the length-dependent shift in the force-Ca2+ relation, suggesting a modulating role for 
PKA-mediated protein phosphorylation in length-dependent sarcomere activation.26, 
27 As previous studies showed lower phosphorylation levels of myofilament PKA-
target proteins in HCM compared to donors,15, 16 the blunted length-dependent 
activation in HCM compared to donors may be explained by a difference in protein 
phosphorylation level. Indeed, analysis of protein phosphorylation showed lower 
phosphorylation levels of both cTnI and cMyBP-C in all HCM groups compared to 
non-failing donors, except in TNNT2mut in which phosphorylation of the PKA-target 
proteins did not differ from donor (Figure 3A).
To test if the blunted length-dependent change in Fmax and myofilament Ca
2+-
sensitivity was corrected by PKA-mediated phosphorylation of cMyBP-C and cTnI, 
force measurements were performed after pre-treatment with exogenous PKA in 
a subset of HCM and donor samples. PKA pre-treated MYBPC3mut, MYH7mut, 
HCMsmn and donor cells showed a significant increase in maximal force following 
a sarcomere length increase, similar as observed in non-treated cardiomyocytes 
(Table 2). PKA did not restore the blunted length-dependent increase in Fmax evident from 
the significantly lower ∆Fmax in HCM with missense mutations compared to donor 
(Table 2). Pre-treatment with exogenous PKA significantly enhanced the length-
dependent shift in myofilament Ca2+-sensitivity in HCM with truncating MYBPC3mut 
and HCMsmn samples to values observed in donors, but did not correct the blunted 
length-dependent change in EC50 in all other HCM mutant groups harboring missense 
mutations (Figure 2D). 
As the MYBPC3mut and MYH7mut groups consisted of different mutations, we 
averaged functional data for each HCM mutation separately. Data are shown in 
the supplemental material (Online Table II).
PKA-mediated protein phosphorylation
To determine if absence of an effect of PKA on sarcomere functional properties is 
due to a defect in PKA-mediated protein phosphorylation in HCM myocardium, 
phosphorylation status of PKA-target proteins was analyzed in HCM and donor 
samples incubated with exogenous PKA. Figure 3B shows HCM samples incubated 
without and with PKA separated by 1D-gel electrophoresis and stained with ProQ-
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figure 2. Myofilament length-dependent activation. A. Tension development as a function of [Ca2+] 
at short (1.8 μm) and long (2.2 μm) sarcomere length for donor (left) and TPM1mut (right) heart 
samples. b. Normalized force-Ca2+ relationships for donor (left) and TPM1mut (right) heart samples. C. 
The length-dependent increase in myofilament Ca2+-sensitivity was lower in all HCMmut compared to 
donors before PKA treatment. D. PKA pre-treatment restored length-dependent activation to donor 
in HCM with truncating MYBPC3mut and HCMsmn, but not in HCMmut with missense mutations. Open 
bar graph represents MYBPC3 truncating mutations; Closed gray bar graphs represent missense 
mutations.*p<0.05 versus donor; #p<0.05 versus HCMsmn.
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Diamond and SYPRO Ruby. PKA increased phosphorylation of both PKA-targets, 
cMyBP-C and cTnI, in HCM samples. Phosphorylation levels (normalized to untreated 
donor samples, which were included on the gel and set to 1; dotted line) are depicted 
in Figure 3C and show that phosphorylation of cMyBP-C after PKA was close to values 
observed in donor samples in all HCM samples. 
Analysis of phosphorylation at specific PKA sites (Ser275 and Ser284) on cMyBP-C 
confirmed increased PKA-mediated phosphorylation in HCM samples (Figure 4). 
In addition to cMyBP-C, phosphorylation of cTnI increased by PKA in all HCM samples 
(Figure 3B), although values did not reach the level found in donor myocardium 
(Figure 3C). PKA treatment of donor samples increased cTnI phosphorylation by ~25%. 
Similar data were obtained when cTnI phosphorylation was analyzed by Phos-Tag 
gel electrophoresis creating a pattern of un-, mono- and bisphosphorylated cTnI 
(Online Figure II). PKA-treated HCM samples showed increased bisphosphorylated 
cTnI levels, but some monophosphorylated cTnI remained. Previous Phos-Tag analysis 
of the donor samples (n=12) revealed a distribution pattern of 7% unphosphorylated, 
table 2. Effects of sarcomere length increase on Fmax before and after PKA.
no Pka pre-treatment Pka pre-treatment
fmax (kN/m
2) fmax (kN/m
2)
Sample 1.8 μm 2.2 μm ∆Fmax N/n 1.8 μm 2.2 μm ∆Fmax N/n
Truncating
MYBPC3mut 19.6±1.5 29.8±2.4
** 10.2±1.2 N=14 
n=47
27.6±1.5 37.0±2.0** 9.4±1.3 N=4
n=19
Missense
MYBPC3mut 13.0±1.3 15.5±1.7
** 2.5±0.8* N=4
n=12
11.4±1.0 13.9±1.5** 2.5±1.0* N=4 
n=12
MYH7mut 15.1±1.6 19.1±1.8
** 3.9±1.0* N=6
n=32
18.8±2.6 22.6±3.1** 3.8±1.1* N=4
n=15
TNNT2mut 21.5±3.2 24.4±6.0 3.0±4.4 N=1
n=6
13.7±2.1 15.2±2.4 1.5±1.3* N=1
n=4
TNNI3mut 9.8±2.5 10.1±2.8 0.3±1.1
* N=2
n=8
8.4±1.4 9.5±1.9 0.83±0.8* N=2
n=10
TPM1mut 10.7±2.1 17.0±3.0
** 6.3±1.5 N=1
n=6
9.1±2.3 9.6±1.7 0.58±0.7*# N=1
 n=4
HCMsmn 18.2±1.4 28.3±2.6
** 10.1±1.7 N=7
n=31
26.8±2.3 38.7±2.7** 12.0±1.4 N=3
n=12
DONOR 26.3±2.2 35.1±3.1** 8.8±2.1 N=9
n=32
26.2±1.4 36.2±1.9** 10.0±1.6 N=3
n=12
p<0.05 was considered significant; *versus donor; N= number of samples; n= number of cardiomyocytes; **1.8 μm 
versus 2.2 μm; #∆Fmax (no PKA pre-treatment) versus ∆Fmax (PKA pre-treatment).
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figure 3. Phosphorylation of PKA-target proteins before and after PKA treatment. A. Protein 
phosphorylation values were corrected by the corresponding SYPRO-stained protein bands and 
normalized to the values found in donors, which were set to 1 (dotted line). Phosphorylation of 
cMyBP-C (left) and cTnI (right) was lower in all HCM samples compared to donors, except for 
the TNNT2mut sample, which showed relatively high phosphorylation. Open bar graph represents 
truncating MYBPC3 mutations; Closed gray bar graphs represent missense mutations. Phosphorylation 
of PKA-target proteins before and after PKA treatment. B. Cardiac samples before (-) and after (+) PKA 
treatment separated by 1D-gel electrophoresis and stained with ProQ-Diamond (phosphorylation) 
and SYPRO Ruby (total protein stain). C. Thin filament mutations were clustered in a single group 
(THINmut). ProQ-stained protein phosphorylation values of PKA-treated samples were corrected by 
the corresponding SYPRO-stained protein bands and normalized to values in non-treated donor 
samples, which were included on the gel and set to 1 (dotted line). PKA increased phosphorylation 
of both target proteins in all HCM groups. Numbers of samples included in the analyses are indicated 
in the bar graphs.
102
figure 4. Site-specific phosphorylation of PKA-target sites of cMyBP-C. A. Western blot analysis of 
cMyBP-C phosphorylation with specific antibodies for PKA sites Ser284 (upper panel) and Ser275 
(lower panel) before (-) and after (+) PKA treatment (phosphorylation values were corrected for 
minor differences in protein loading by Ponceau-stained MLC2, myosin light chain 2). b. Protein 
phosphorylation values were normalized to the values found in untreated donor samples, which were 
included on the blot and set to 1 (dotted line). Thin filament mutations were clustered in a single 
group (THINmut). Numbers of samples included in the analyses are indicated in the bar graphs. All 
samples showed an increased phosphorylation at both sites upon PKA treatment.
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27% monophosphorylated and 66% bisphosphorylated cTnI.15 Upon treatment of 
donor samples (n=2) with PKA cTnI was mostly bisphosphorylated (Online Figure II).
Correction of length-dependent activation in HCM with mutant cTnT and 
mutant cTnI by human recombinant wild-type troponin
To determine if mutant sarcomeric protein is the direct cause of the blunted length-
dependent increase in myofilament Ca2+-sensitivity, we performed troponin exchange 
experiments in cardiomyocytes from the TNNT2mut sample. The homozygous TNNT2mut 
necessarily results in 100% mutant cTnT and as such represents a unique tool to 
assess the level at which mutant protein perturbs sarcomere function. Exchange with 
increasing concentrations of wild-type human troponin complex (0.25, 0.5 and 1 mg/
mL in the exchange solution) resulted in 62±2%, 78±1% and 86±1% troponin exchange 
based on Western blot analyses of endogenous and myc-tag labeled wild-type cTnT 
(Figure 5A; left blot). In exchanged cells without PKA pre-treatment, replacement 
of mutant troponin with unphosphorylated recombinant wild-type troponin did 
not restore the reduced length-dependent activation to donor values (Figure 5B). 
However, replacement of endogenous mutant troponin by unphosphorylated 
recombinant troponin reduces cTnI phosphorylation in the TNNT2mut cells. Therefore, 
measurements were also performed in the troponin exchanged cells after PKA 
treatment to increase cTnI phosphorylation to donor levels. 
In cells in which 62% of mutant troponin was replaced by wild-type troponin 
the length-dependent increase in myofilament Ca2+-sensitivity was still significantly 
lower compared to donor values, indicating that 38% of mutant protein is sufficient 
to impair length-dependent activation. However, the blunted length-dependent 
activation was restored to donor values in TNNT2mut exchanged cells harboring 22% 
and 14% endogenous mutant cTnT (Figure 5C). Similarly, exchange of mutant cTnI in 
one of the HCM samples harboring the R145W missense mutation in TNNI3 by ~90% 
unphosphorylated wild-type troponin complex (Figure 5A; right blot) corrected length-
dependent activation only after PKA treatment (Figures 5D, E). Hence, normalization 
of length-dependent activation to donor values upon exchange with wild-type cTn 
complex is only evident after PKA treatment of troponin-exchanged cells.
DisCussion
Our study shows that high myofilament Ca2+-sensitivity in human HCM myocardium is 
independent of the presence of a sarcomere mutation and at least partly explained by 
protein hypophosphorylation. Sarcomere mutations may modify Ca2+-sensitivity, but 
the direction and magnitude of the change depends on the affected gene. Impaired 
length-dependent activation of sarcomeres represents a common pathomechanism 
underlying HCM, and could not be corrected by PKA treatment in HCM with missense 
mutations in genes encoding thick and thin filament proteins. Moreover, our troponin 
exchange experiments provide direct proof that mutant troponin impairs length-
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figure 5. Replacement of endogenous mutant cardiac troponin by recombinant human wild-type 
troponin complex. A. Quantification of troponin exchange in cardiomyocytes from a TNNT2mut and 
TNNI3mut heart. Immunoblots stained with an antibody against cardiac troponin T (cTnT) that recognizes 
both endogenous cTnT (lower band) and recombinant myc-tag labeled cTnT (cTnT-myc; upper band). 
Left panel: An example is shown of a suspension of cardiomyocytes from a TNNT2mut heart exchanged 
with increasing concentrations of wild-type human recombinant troponin complex. Exchange with 0.25 
mg/mL (lane 1), 0.5 mg/mL (lane 2) and 1 mg/mL (lane 3) troponin complex. TNNT2mut heart without 
added recombinant troponin complex (lane 4). Right panel: A suspension of cardiomyocytes from 
a TNNI3mut heart exchanged with 1 mg/mL wild-type human recombinant troponin complex. Similar 
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dependent activation. Our data indicate that mutant proteins resulting from missense 
mutations could perturb length-dependent sarcomere activation and underlie cardiac 
dysfunction observed at early stages of HCM disease development.
Myofilament Ca2+-sensitivity and phosphorylation background
Our studies in human HCM with mutations in both thick and thin filament proteins 
showed high myofilament Ca2+-sensitivity at a sarcomere length of 2.2 μm (Figure 1A). 
This is in agreement with previous studies in transgenic mouse models and in vitro 
studies with mutant proteins, which indicate that HCM sarcomere mutations sensitize 
myofilaments to calcium.3, 12, 13, 28 However, the higher Ca2+-sensitivity in HCMmut groups 
compared to non-failing donors coincided with lower phosphorylation levels of 
cMyBP-C and cTnI (Figure 3A). The difference in myofilament Ca2+-sensitivity between 
HCMmut and non-failing donor can thus be partly explained by hypophosphorylation 
of sarcomeric proteins rather than the sarcomere gene mutation itself. 
A possible explanation for the low phosphorylation levels may reside in a blunted 
β-adrenergic response in HCM patients. A blunted response to isoproterenol, 
a β-adrenoreceptor agonist, has been reported in transgenic mice harboring 
TPM1 and MYH7 mutations.29, 30 Moreover, reduced β-adrenoreceptor density has 
been reported in HCM patients.31 Treatment of HCM samples with PKA increased 
phosphorylation of the PKA-target proteins (Figures 3 and 4 and Online Figure II) 
and normalized myofilament Ca2+-sensitivity in MYBPC3mut, TPM1mut and HCMsmn 
to values observed in non-failing donor. In contrast, after PKA higher myofilament 
Ca2+-sensitivity was still present in MYH7mut and TNNT2mut, suggesting 
a Ca2+-sensitizing effect by these mutations. Interestingly, PKA-treatment significantly 
lowered Ca2+-sensitivity of the TNNI3mut R145W compared to donor. This observation 
contrasts with transgenic animal models and reconstituted thin-filaments using 
recombinant human mutant cTnI.32-34 It has been suggested that the Ca2+-sensitizing 
action of mutations in the inhibitory region of cTnI (residues 137-148) directly impair 
the intrinsic inhibitory activity of cTnI.32, 33 A possible explanation for the contradicting 
amounts were loaded on the blots (shown by Ponceau-stained actin) to allow cTnT analysis within 
the linear detection range. B. The length-dependent activation was significantly lower compared to 
donor in all TNNT2mut cells harboring varying amounts of mutant cTnT (100% without exchange and 
38%, 22% and 14% in cells exchanged with increasing concentrations of unphosphorylated recombinant 
wild-type troponin). C. Measurements were also performed in exchanged cardiomyocytes, which were 
subsequently treated with PKA to normalize cTnI phosphorylation. Pre-treatment with exogenous 
PKA was not able to recover the blunted length-dependent activation in TNNT2mut cells with 38% 
of mutant cTnT, but did recover the reduced length-dependence of TNNT2mut exchanged with 78% 
and 86% wild-type troponin. D. The length-dependent activation was significantly lower in TNNI3mut 
cells exchanged with ~90% unphosphorylated recombinant wild-type troponin (wt-cTn) compared to 
donor cells. E. Pre-treatment with exogenous PKA restored the blunted length-dependent activation 
in TNNI3mut cells exchanged with wt-cTn complex to donor values. 
*p<0.05 versus donor; §p<0.05 
versus TNNT2mut or TNNI3mut.
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results compared to our TNNI3mut samples may reside in the amount of endogenous 
mutant protein expression. Using adenovirus gene transfection to incorporate 
the cTnI R145W mutant into adult rat cardiomyocytes, Davis et al.35 observed no 
elevation of myofilament Ca2+-sensitivity, which was attributed to poor incorporation 
(~35%) of mutant protein into the sarcomeric structure compared with wild-type 
cTnI. In addition, the phosphorylation background of the sarcomeres may have been 
different among studies.
Overall, our data show that high Ca2+-sensitivity is not a specific characteristic 
of human sarcomere mutation-positive HCM, as a similarly high myofilament 
Ca2+-sensitivity was found in HCMsmn compared to donors, which may be ascribed to 
reduced β-adrenergic signaling as part of cardiomyopathy development. Although 
PKA is the archetypical kinase involved in modulating Ca2+-sensitivity through cTnI 
and cMyBP-C phosphorylation, it is by no means the only kinase that phosphorylates 
myofilament proteins. Both cTnI and cMyBP-C are target for a whole range of kinases.36-
40 cMyBP-C phosphorylation is thought to mainly affect cross-bridge cycling kinetics,41 
although a role in mediating Ca2+-sensitivity of force has been suggested.42 Cardiac 
TnI is considered to be the key regulator of Ca2+-sensitivity, and it is mainly through 
phosphorylation of Ser23 and Ser24 that PKA exerts its Ca2+-desensitizing effect, 
though many other phosphorylation sites have been identified.43 Phosphorylation 
is but one of many possible post-translational modifications (PTMs). Recent reports 
have hinted at possible involvement of other PTMs in the regulation of sarcomere 
function, such as oxidation and S-glutathionylation44 or O-GlcNAcylation.45 It would 
thus be an oversimplification to propose that a reduction in PKA-phosphorylation 
of sarcomere proteins is solely responsible for the myofilament changes in HCM. 
However, the baseline Ca2+-sensitivity seems to be dominated by the relatively low 
phosphorylation levels of PKA myofilament target proteins compared to donors. 
Higher phosphorylation levels mimicked by exogenous PKA treatment, as would be 
induced during increased cardiac stress (e.g. exercise), unveils a higher, similar or 
even lower myofilament Ca2+-sensitivity in HCM dependent on the affected gene. 
Our findings suggest diverse mutation-induced changes in Ca2+-sensitivity, while high 
myofilament Ca2+-sensitivity is partly explained by secondary disease-related changes 
in protein phosphorylation. 
Impairment of length-dependent sarcomere activation in HCM
Our data indicate that mutant sarcomeric proteins in HCM perturb length-dependent 
activation of myofilaments, which may contribute to early cardiac dysfunction 
observed in sarcomere mutation carriers. Studies in transgenic mouse models and 
troponin-exchange techniques with mouse tissue harboring HCM mutations were not 
conclusive as a reduced or normal length-dependent activation was found compared 
to controls.30, 46-49 The recent study of Ford et al.49 may shed some light on these 
previous observations as the authors studied length-dependent differences in mice 
expressing TNNT2 mutations either in a α-MyHC (predominant in murines) or β-MyHC 
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(predominant in healthy adult human hearts) background. It was observed that mice 
expressing the R92L mutation in the physiological α-MyHC background presented 
a normal length-dependent Ca2+-activation, while in the presence of the slow cycling 
β-MyHC isoform, length-dependence was lost.49 Defects in length-dependent 
sarcomere properties were not similar in all HCM samples, as the blunted length-
dependent increase in myofilament Ca2+-sensitivity was corrected to donor values by 
exogenous PKA in truncating MYBPC3mut and HCMsmn, while it remained defective in 
HCM with missense mutations in MYBPC3, MYH7, TNNT2, TNNI3 and TPM1. Moreover, 
the increase in maximal force generating capacity upon an increase in sarcomere 
length was almost entirely absent in HCM with troponin mutations (Table 2). Although 
PKA increased phosphorylation of cTnI and cMyBP-C and reduced myofilament Ca2+-
sensitivity at 2.2 μm in all HCM samples (except in the homozygous TNNT2mut), it did 
not restore length-dependent activation in HCM samples with missense mutations. 
Intriguingly, a negative myofilament length-dependent activation was observed after 
PKA in the TPM1mut sample (Figure 2D), suggesting that length-dependent activation 
is even more impaired during increased cardiac stress.
The blunted length-dependent activation may be partly related to the relatively 
low phosphorylation of PKA-targets and high baseline myofilament Ca2+-sensitivity. 
The suggestion that PKA-mediated myofilament protein phosphorylation has 
a modulatory role in length-dependent activation comes from studies in ferret papillary 
muscles,26 in which isoprenaline, a stimulator of the β-adrenergic receptor pathway, 
enhanced the length-dependent change in the force-Ca2+ relation. Studies in cardiac 
tissue in which cTnI was replaced by skeletal TnI (ssTnI), which lacks the PKA-target 
serines (Ser23/24), showed higher myofilament Ca2+-sensitivity, but a significantly 
reduced length-dependent activation,27, 50 indicating a role for cTnI phosphorylation 
in length-dependent activation. A study by Cazorla et al.47 in transgenic mice 
lacking cMyBP-C demonstrated lower length-dependent activation than wild-type 
mice that could not be restored by exogenous PKA treatment, which suggests that 
cMyBP-C is needed for proper length-dependent sarcomere activation. In our human 
samples with truncating MYBPC3 mutations impaired length-dependent activation 
was corrected to donor values by PKA. Our previous study in HCM with truncating 
mutations in MYBPC3 showed reduced expression of full-length cMyBP-C to ~70% 
compared to donor values (i.e. haploinsufficiency). Overall, our studies in human HCM 
with MYBPC3 truncation mutations indicate that the presence of ~70% of full-length 
cMyBP-C protein in the sarcomere is sufficient to preserve the length-dependent 
properties of the sarcomeres.15 
The perturbations in length-dependent activation in HCM with mutations in thin 
filament genes may be explained by the three-state model of filament transition, in 
which the troponin-tropomyosin complex has a central regulatory role. Myofilament 
contraction and force production is tightly regulated by the troponin-tropomyosin 
complex that regulates the interaction between the actin and myosin filaments. 
It is believed that the myofilaments exist in a dynamic equilibrium between three 
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biochemical transitions (Figure 6) that reflect different interactions between actin and 
myosin, termed the blocked (B-state), closed (C-state) and open (M-state) states of 
thin filament regulation.51, 52 In the B-state Ca2+ is not bound to cTnC and tropomyosin 
sterically blocks myosin-binding sites on F-actin (Figure 6A). In the C-state Ca2+ 
binds to cTnC, which changes conformation of the troponin-tropomyosin complex, 
resulting in non-tension-generating cross-bridges which bind weakly to F-actin 
(i.e. weakly-bound cross-bridges) (Figure 6B).52-54 The M-state, involves strong-
binding of tension-generating cross-bridges which results in myofilament contraction 
and force development (Figure 6C).52-54 Because of the central roles of cTnT and cTnI 
in the transition from the B-state to the C-state55-57, it is likely that mutation-induced 
irregularities in protein interactions may translate into thin filament abnormalities. 
The C-terminal half of cTnI docks the troponin-tropomyosin complex onto 
the outer domain of F-actin at low cytoplasmic [Ca2+]58, stabilizing the formation of 
the B-state. Interestingly, ~86% of cTnI HCM-causing mutations (dashed red circle 
in Figure 6D), including the one present in our study, are found in the C-terminal 
half of cTnI (residues 137-210), a region responsible for actin-binding.28, 59 Indeed, 
disruption of the B-state has been suggested in HCM-causing mutations affecting 
cTnI60, but also cTnT.61, 62 The relevance of the transition from the B- to the C-state 
for proper length-dependent activation has been shown by Smith and Fuchs63 who 
were the first to provide evidence for a length-sensitive step in the transitions of 
thin filament activation. A reduction in ionic strength (<0.05 M), known to shift 
the B-state equilibrium towards a stable C-state,64 coincided with impairment of 
length-dependent activation.63 The blunted length-dependent increase in myofilament 
Ca2+-sensitivity observed in the thin filament mutation groups can thus be 
explained by disruption of the B-state and an increased number of weakly-bound 
cross-bridges in the C-state.
Eleven HCM mutations have been identified in α-tropomyosin.59 To the best of 
our knowledge the present study is the first to analyze the effects of a HCM-causing 
mutation (I284V) in the overlap region of tropomyosin, which has a central role in 
cooperative activation of the thin filament.65, 66 The steepness of the force-Ca2+ 
relation, which is an indicator of the relative number of near-neighbor interacting sites, 
was significantly lower in TPM1mut compared to donors (1.98±0.37 and 3.33±0.11, 
respectively; Figure 2B), indicative for impairment of the cooperative response in 
activating the thin filament. Palm et al.67 demonstrated that tropomyosin overlap 
regions are required for proper formation of a ternary complex with the N-terminal tail 
of cTnT. Since the N-terminal region of cTnT is needed to maintain the thin filament 
in the B-state,56, 57 it is likely that mutations in the overlap region of α-tropomyosin 
structurally impair formation of the B-state and thereby impair length-dependent 
activation of myofilaments.
Previous studies indicated that myosin is not involved in the formation of the first 
two equilibrium states, i.e. B- and C-states.52-54 However, myosin is crucial for formation 
of the M-state (myosin-induced), since strong-binding of tension-generating cross-
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figure 6. Schematic drawing of the thin filament functional unit. Seven actin monomers (gray) 
spanned by one tropomyosin dimmer (red) and one troponin complex: cTnC (pink), cTnI (blue) and 
cTnT (orange). Capitals “N” and “C” depict N- and C-terminal protein ends, respectively. Dark-blue 
tropomyosin depicts near-neighbor tropomyosin dimmer interaction.70, 71 The orientation of thin 
filament proteins is as follows: the N-terminal region of cTnT points towards the pointed end (M-band), 
while the core domain of the troponin complex is oriented to the barbed end (Z-disk).72 Interacting 
sites and structural location of actin-tropomyosin-troponin proteins are matched in accordance with 
available literature.28, 53, 54, 58, 71, 73 Cardiac TnI residues 1-34 are arbitrarily positioned. Our drawing 
follows the proposed mechanism for Ca2+-regulation of contraction proposed by Murakami et al.58 
A. B-state (blocked); when ATP is present and cytoplasmic [Ca2+] is low such that Ca2+ is not bound 
to cTnC, tropomyosin sterically blocks the myosin-binding sites on F-actin. B. C-state (Ca2+-induced); 
cytoplasmic [Ca2+] rises such that Ca2+ binds to cTnC inducing conformational changes of the troponin 
complex, resulting in a ~25º movement of tropomyosin on the thin filament, thereby exposing most 
of the myosin-binding sites on F-actin. Note the movement of tropomyosin away from subdomains 
1 and 2 of F-actin. In the C-state the myofilament is not yet activated as non-tension-generating 
cross-bridges bind weakly to F-actin. C. M-state (myosin-induced); involves the strong-binding of 
tension-generating cross-bridges that induce an additional ~10º movement of tropomyosin on 
F-actin, resulting in myofilament activation and contraction. Note the transition of tropomyosin 
into subdomains 3 and 4 of F-actin. D. Solid arrows depict the location of mutations’ sites on thin 
filament proteins present in our human HCM samples. Cardiac TnT residues 1-65 are shortened to fit 
the enlarged scale.
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bridges are required for thin filament activation and force production.52-54 Since five of 
the six samples used in our study have mutations in the myosin S1 domain, responsible 
for actin-binding68 it is likely that the deleterious effects of MYH7 mutations occur via 
perturbation of the M-state. A recent study by Farman et al.69 highlights the essential 
role of myosin heads’ orientation that precede thin filament activation for proper 
lattice spacing and length-dependent activation. 
Thus altered myosin head orientation as a result of mutations may impair formation 
of the M-state and affect length-dependent activation.
The possible involvement of cMyBP-C in the modulation of thin-filament activity 
has been only recently addressed. Electron microscopy and 3D reconstruction of 
thin-filaments with cMyBP-C suggest that the N-terminal extension of cMyBP-C could 
modulate the movement of tropomyosin on F-actin and interfere with actomyosin 
interactions, possibly involved in the regulation of thin-filament activation.74 
The MYBPC3 missense mutations in our study are located along the N-terminal 
extension of cMyBP-C and may alter the tropomyosin-actin interaction and thereby 
impair length-dependent activation.
Study limitations and clinical implications
Although we were able to study a large collection of human HCM samples with 
different mutations in thick and thin filament proteins, care must be taken to 
extrapolate our findings to all HCM patients. Our HCM population consisted of 
patients with LV outflow tract obstruction, and the patient with the homozygous 
TNNT2 mutation had end-stage heart failure. Our data do highlight that mutation-
induced changes in myofilament Ca2+-sensitivity and length-dependent sarcomere 
activation are diverse and depend on the affected gene, and most likely location and 
type of the mutation in the affected protein. We provide evidence that mutant protein 
may impair sarcomere function at ~38% expression (Figure 5C), which emphasizes 
the importance of studying the mutant protein level at which cardiac performance is 
impaired. Future studies in transgenic mice models and human myectomy samples 
are warranted to extend our findings to a broader set of sarcomere mutations and 
assess the toxic dose of mutant proteins.
Although sarcomere mutation-negative patients are commonly used as control 
group, we cannot completely rule out the presence of rare mutations. However, as 
our cardiomyocyte analyses revealed no functional impairments (PKA normalized 
length-dependent activation in HCMsmn), the likelihood of the presence of a rare 
mutation is low.
Our study revealed perturbed sarcomere length-dependent activation as 
a common mechanism underlying cardiac dysfunction in HCM. Pathological 
hypertrophy presumably reflects the compensatory response of the heart to counteract 
impaired sarcomere defects such as the blunted length-dependent myofilament 
activation. The relatively low force generating capacity of cardiomyocytes and the 
inability to increase force upon an increase in sarcomere length may in part underlie 
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cardiac dysfunction and initiate compensatory hypertrophy. Pak and colleagues75 
showed a blunted end-systolic pressure volume relation in HCM patients, suggesting 
that the hearts were unable to properly recruit preload to augment contractility. 
The latter observation may be explained by cardiac remodeling. However, likewise, 
the mutation-induced blunted length-dependent sarcomere activation may limit 
preload-mediated contractile reserve of the heart in HCM patients. Our study in 
combination with others6-10 supports the hypothesis that defective sarcomere function 
as a result of gene mutations is central to early stages of HCM-disease and precedes 
development of hypertrophy. Moreover, the blunted increase in myofilament Ca2+-
sensitivity upon an increase in length may alter Ca2+-buffering in the cardiomyocytes 
and provide a substrate for arrhythmias.
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Editorial
Building on work by Otto Frank in the late 19th century, Ernest Starling described in the early 20th century the 
ability of the heart to change its force of contraction and there-
fore stroke volume in response to changes in venous return, 
which has been called the Frank–Starling law of the heart in 
honor of these 2 physiologists. The Frank–Starling effect en-
ables the heart to match cardiac output to venous return on 
a beat-to-beat basis.1 A major mechanism responsible for the 
Frank–Starling effect and hence the beat-to-beat autoregula-
tion of cardiac output is the sarcomere length-dependent acti-
vation of force development.2
Article, see p 1491
In this issue of Circulation Research, Sequeira et al3 inves-
tigate both the Ca- and length-dependent regulation of force 
development in cardiomyocytes harvested from patients with 
hypertrophic cardiomyopathy (HCM), a familial disorder com-
monly associated with mutations in genes encoding sarcomeric 
proteins.4 Consistent with previous animal and human studies,5 
myofilament Ca sensitivity was increased in all 38 HCM patient 
samples compared with 12 nonfailing donor hearts. Notable, 
the authors observed that length-dependent activation was im-
paired, which, unlike the Ca sensitivity increase, seemed to be 
a primary effect of the mutant sarcomeric proteins because (1) 
it could not be rescued by increasing protein kinase A (PKA) 
phosphorylation and (2) was normalized when mutant troponin 
(Tn) proteins were replaced with wild-type protein. These new 
results suggest that impaired length-dependent activation and 
hence a defective Frank–Starling effect importantly contribute 
to the pathogenesis of HCM (Figure).
Reduced Maximal Ca-Activated Force and 
Increased Ca Sensitivity Are Central Findings 
in Human HCM
HCM is a familial disorder commonly associated with muta-
tions in genes encoding sarcomeric proteins. Mutation car-
riers develop progressive heart hypertrophy and fibrosis and 
are at a high risk for sudden death because of ventricular 
arrhythmia. More than 1000 mutations in >11 genes have 
been identified, which can lead to this disease. The current 
report,3 together with 2 previous smaller human studies,6,7 
indicates that, regardless of the disease-causing mutation, 
human HCM cardiac muscle exhibits reduced maximal Ca-
activated force and increased Ca sensitivity of muscle activa-
tion. This result raises the possibility that HCM mutations 
trigger a common cascade of molecular events that result in a 
similar phenotype (Figure).
Based largely on in vitro studies and animal models, 
myofilament Ca sensitization had previously been associated 
with HCM.8,9 The study by Sequeira et al3 suggests that 
myofilament Ca sensitization indeed is a universal finding in 
human HCM. However, the authors find that Ca sensitization 
is often not a primary property conferred by the mutant 
protein itself. Rather, the increased Ca sensitivity was 
largely a result of an apparent hypophosphorylation of PKA 
targets in the myofilaments. Although all HCM groups had 
higher myofilament Ca sensitivity at baseline, in tissue from 
mutation carriers in myosin-binding protein C, TnI, and 
tropomyosin and from HCM patients without sarcomeric 
mutations, Ca sensitivity was restored to normal levels by 
treatment with PKA. The 2 exceptions were one patient with 
a mutation in TnT and another patient with a β-myosin heavy 
chain mutation, where the Ca sensitivity increase seemed to 
be a property directly conferred by the mutant protein. As 
with any patient study, differences in drug therapy between 
the HCM and the normal donor group may have contributed 
to reduced PKA phosphorylation. Nevertheless, this result 
suggests that increased Ca sensitivity of human HCM 
muscle is mostly the result of posttranslational modifications 
and potentially helps to maintain systolic function, despite 
the reduction in maximal Ca-activated force caused by 
HCM mutations.7 Regardless of its underlying cause, the Ca 
sensitivity increase is likely of major importance for HCM 
pathophysiology, with experimental evidence indicating 
that, regardless of how myofilaments are Ca sensitized, 
an increase in myofilament Ca sensitivity can contribute 
to diastolic dysfunction,10 focal energy deficits,11 and 
arrhythmogenesis12 (Figure).
Impaired Length-Dependent Activation: A 
Trigger of HCM Pathogenesis?
The authors discovered a new common finding in human 
HCM muscle—impaired length-dependent activation, which, 
in contrast to increased Ca sensitivity, was not rescued by 
PKA treatment for all sarcomeric missense mutations studied. 
Furthermore, replacement of mutant with wild-type Tn cor-
rected the impaired length dependence in the 2 mutations that 
could be studied. Hence, impaired length-dependent activation 
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may be a direct effect of many mutations that cause HCM in 
humans (Figure). What is the significance of this finding for the 
pathogenesis of HCM? Because a functional length-dependent 
activation is responsible for the Frank–Starling effect, it is in-
triguing to speculate that HCM mutations generate an intermit-
tent inability to match cardiac ejection to dynamic changes in 
ventricular filling volume (ie, during the respiratory cycle or 
during exercise). The resulting increase in wall stress as a re-
sult of intermittent impaired ventricular emptying could trig-
ger neuroendocrine activation and a hypertrophic gene program 
analogous to acquired heart disease with increased wall stress 
and an impaired Frank–Starling effect, such as postmyocar-
dial infarction cardiomyopathy. Although not tested directly in 
the report by Sequeira, activation of neuroendocrine signaling 
could be the main culprit for the decrease in PKA phosphoryla-
tion of myofilament target proteins found universally in patients 
with HCM (Figure). In addition, some of missense HCM muta-
tion (ie, in TnT or TnI) may directly interfere with the ability 
of PKA to phosphorylate TnI (Figure, dashed arrow b). PKA 
phosphorylation of TnI not only regulates myofilament Ca sen-
sitivity but also is important for physiological length-dependent 
activation of cardiac muscle.13 Hence, PKA hypophosphoryla-
tion can independently contribute to impaired length-dependent 
activation, as was demonstrated by the authors for 2 groups of 
patients with HCM (ie, truncation mutations of myosin-binding 
protein C and genotype-negative HCM). In those patients, this 
can generate a vicious cycle that could be central to the patho-
genesis in HCM, as shown in the Figure.
In addition to the impaired length-dependent activation, 
which is measured experimentally by the increase in Ca sen-
sitivity (ΔpCa50) induced by increased sarcomere length 
(Sequeira et al,3 Figure 2), all sarcomeric missense mutations 
(but not myosin-binding protein C truncation mutants and 
genotype-negative HCM) also impaired the length-dependent 
increase in maximum force (Sequeira et al,3 Table 2). The lat-
ter is measured at fully activating [Ca] and reflects the intrinsic 
force-generating ability of the muscle. Although there can be 
many reasons for the reduced length dependence of maximum 
force (eg, loss of myofibrils), the net result is an even further 
compromised length–tension relationship and hence impaired 
Frank–Starling effect.
Open Questions
Several questions remain. Given that genetic background might 
affect the functional effect of the mutations and many of the 
individuals studied by Sequeira et al3 were family members, 
the results of the study may not be quite generalizable to the 
general HCM population. By necessity, all human myocardial 
samples came from patients with significant cardiac hypertrophy 
and heart failure. Hence, it is still possible that altered length-
dependent activation is the consequence of pathological remod-
eling of the sarcomeric apparatus in the diseased myocardium. 
Nevertheless, the rescue with wild-type Tn protein replacement 
provides compelling evidence that this is not the case, at least 
for 2 specific mutations. Furthermore, passive viscoelastic prop-
erties of human HCM cardiomyocytes are similar to those of 
cardiomyocytes from healthy donor hearts,7 further supporting 
the hypothesis that altered Ca and length-dependent regulation 
of muscle activation are central to the pathophysiology of human 
HCM (Figure). Not directly investigated in the current study, but 
likely also important for HCM pathophysiology is the inefficient 
ATP utilization (increased tension cost) caused by many HCM 
mutations.14 It remains to be seen which of these myofilament 
properties is the most significant driver of the disease.
Altered myofilament properties affect every myocyte in 
the heart starting at birth, and although some heterogeneity 
is expected, there are significant questions remaining. For ex-
ample, what is the reason for the incomplete penetrance of the 
disease (age dependent, but possibly as low as 41%)?15 What 
is responsible for the focal nature of hypertrophy and fibrosis 
in HCM hearts? This clearly shows that the presence of an 
HCM mutation does not inevitably lead to disease, and even 
in an affected patient some regions of the heart remain normal. 
Such a phenotype may imply a second hit that is necessary 
to initiate the disease and remains to be identified. A poten-
tial culprit is the focal energy deprivation that occurs in HCM 
mouse models during stress,11 which can directly contribute to 
reentry arrhythmias11 but also has the potential to drive hetero-
geneous hypertrophy and remodeling.16 The next frontier will 
be to test whether therapeutic interventions aimed at normal-
izing Ca sensitivity, length-dependent activation, or inefficient 
ATP utilization are beneficial in HCM.
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abstraCt
Frank-Starling’s law reflects the ability of the heart to adjust the force of its contraction 
to changes in ventricular filling, a property based on length-dependent myofilament 
activation (LDA). The threonine at amino acid 143 of cardiac troponin I (cTnI) is 
prerequisite for the length-dependent increase in Ca2+-sensitivity. Thr143 is a known 
target of protein kinase C (PKC) whose activity is increased in cardiac disease. Thr143 
phosphorylation may modulate length-dependent myofilament activation in failing 
hearts. Therefore, we investigated if pseudo-phosphorylation at Thr143 modulates 
length-dependence of force using troponin exchange experiments in human 
cardiomyocytes. In addition, we studied effects of protein kinase A (PKA)-mediated 
cTnI phosphorylation at Ser23/24, which has been reported to modulate LDA. 
Isometric force was measured at various Ca2+-concentrations in membrane-
permeabilized cardiomyocytes exchanged with recombinant wild-type (Wt) troponin 
or troponin mutated at the PKC site Thr143, or Ser23/24 into aspartic acid (D) or 
alanine (A) to mimic phosphorylation and dephosphorylation, respectively. In troponin-
exchanged donor cardiomyocytes experiments were repeated after incubation with 
exogenous PKA.
Pseudo-phosphorylation of Thr143 increased myofilament Ca2+-sensitivity 
compared to Wt without affecting LDA in failing and donor cardiomyocytes. 
Subsequent PKA treatment enhanced the length-dependent shift in Ca2+-sensitivity 
after Wt and 143D exchange. Exchange with Ser23/24 variants demonstrated that 
pseudo-phosphorylation of both Ser23 and Ser24 is needed to enhance the length-
dependent increase in Ca2+-sensitivity. cTnI pseudo-phosphorylation did not alter 
length-dependent changes in maximal force.
Thus phosphorylation at Thr143 enhances myofilament Ca2+-sensitivity without 
affecting LDA, while Ser23/24 bisphosphorylation is needed to enhance the length-
dependent increase in myofilament Ca2+-sensitivity.
Key Words: myofilament function, protein phosphorylation, troponin I
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introDuCtion
Frank-Starling’s law of the heart describes the ability of the heart to adjust the force of 
its contraction (stroke volume) to changes in ventricular filling (end-diastolic volume), 
a property based on length-dependent activation (LDA) of the myofilaments (7, 8). 
An increase in sarcomere length within the working range of the heart enhances 
the maximal force generating capacity and the sensitivity of the myofilaments to 
calcium. Length-dependent myofilament activation thus represents an important 
cellular mechanism to adjust cardiac performance in response to increased preload 
of the heart.
Cardiac troponin I (cTnI) is an important regulator of LDA of the myofilaments. 
This has been elegantly demonstrated via replacement of endogenous cTnI by slow 
skeletal troponin I (ssTnI) in cardiac muscle, which significantly reduced the increase 
in myofilament Ca2+-sensitivity upon an increase in sarcomere length (2, 16, 33). More 
recently, it was demonstrated that the threonine residue 143 (Thr144 in rat and mice, 
Thr143 in human) of the inhibitory region of cTnI is essential for length-dependent 
alterations in myofilament Ca2+-sensitivity. Substitution of the threonine for a proline 
at 143 (cTnIThr143Pro), as present in ssTnI and fast skeletal TnI, largely ablated the length-
dependent increase in myofilament Ca2+-sensitivity in cardiac muscle (33).
Interestingly, Thr143 is a well-known target of protein kinase C (PKC) and its 
phosphorylation has been implicated in heart failure (25, 32, 43) where an increase 
in PKC-mediated cTnI phosphorylation has been found together with a decreased 
phosphorylation of the protein kinase A (PKA) sites (43). PKC-mediated Thr143 
phosphoryation may, either alone or in concert with down-regulated PKA-mediated 
phosphorylation, underlie changes in LDA in the heart. In the present study we 
therefore first investigated the effect of Thr143 phosphorylation on LDA in human 
failing cardiomyocytes. Troponin exchange experiments were used to study the 
functional effects of pseudo-phosphorylated cTnI at Thr143 (mimicked by aspartic 
acid) in comparison to unphosphorylated (mimicked by alanine) and wild-type cTnI. 
The effect of Thr143 phosphorylation may depend on the phosphorylation status 
of Ser23/24, since it has been demonstrated that PKA-mediated cTnI phosphorylation 
enhances the length-dependent increase in myofilament Ca2+-sensitivity (16). 
Therefore, secondary experiments were performed with and without exogenous PKA 
incubation after cTn exchange in non-failing donor cardiomyocytes. Also, as previous 
experiments showed that PKA-bisphosphorylation at Ser23 and Ser24 is required 
to decrease Ca2+-sensitivity (39, 44) we investigated effects of pseudo-mono- and 
pseudo-bisphosphorylation at cTnI-Ser23/24. To study the effect of Ser23/24 
phosphorylation on LDA, experiments were performed in failing cardiomyocytes that 
have a low baseline level of cTnI-Ser23/24 phosphorylation. 
Our data show that pseudo-phosphorylation of Thr143 in human cardiomyocytes 
increases myofilament Ca2+-sensitivity without affecting LDA of the sarcomeres. 
Moreover, in human myocardium Ser23/24 bisphosphorylation is required to increase 
the length-dependent shift in myofilament Ca2+-sensitivity.
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materials anD metHoDs
Human myocardial tissue
Troponin exchange experiments were performed in cardiomyocytes from end-stage 
failing idiopathic dilated cardiomyopathy (IDCM) hearts (2 males/1 female, left 
ventricular ejection fraction 16.7±4.4%, age 54.3±1.9 years) or from non-failing donor 
myocardium, obtained during heart transplantation surgery. The tissue was collected 
in cardioplegic solution and stored in liquid nitrogen. Samples were obtained after 
informed consent and with approval of the Human Research Ethics Committee of 
The University of Sydney (#7326). The investigation conforms with the principles 
outlined in the Declaration of Helsinki (1997). The human cardiac samples used 
were extensively characterized (cardiomyocyte force characteristics and cTnI 
phosphorylation) in a previous study (10).
Exchange of human troponin complex experiments
Expression and purification of recombinant troponin subunits
Recombinant human troponin complex was produced as described in detail previously 
(39). Shortly, six different cardiac troponin I (cTnI) forms were made via site-directed 
mutations of Thr143 and Ser23/Ser24 into aspartic acid (D) to mimic phosphorylation 
or into alanine (A) to mimic dephosphorylation: 143D, 143A, 23D/24D, 23D/24A, 
23A/24D, 23A/24A. cDNA encoding human cardiac isoforms (troponin C (cTnC), 
myc-tag labeled cTnT (cTnT-myc), wild-type cTnI and cTnI mutants) were transformed 
in E. coli Rosetta2 (22) and cultured under carbenicillin/chloramphenicol selection 
in Overnight Express TB medium (EMD Biosciences). Cultures were harvested by 
centrifugation, re-suspended in PBS, and centrifuged at 10000xg. Pellets were stored 
at -80°C until use. 
Troponin subunits were purified using fast protein liquid chromatography 
(AKTA-FPLC System; Amersham Biosciences) as described previously (22). 
Reconstitution of troponin complexes
Fractions containing equal ratios of cTnT, cTnC and cTnI subunits were pooled, 
subsequently purified by AKTA-FPLC chromatography using a Resource Q to remove 
residual uncomplexed troponin subunits and finally dialyzed against 10 mM imidazole, 
200 mM KCl, 5 mM MgCl2, 2.5 mM EGTA, 1 mM DTT, 0.1 mM PMSF (pH 6.9; 2 times, 
1L each) prior to concentrating the complexes to a final concentration of >2 mg/mL 
by centrifugation using Centriprep YM-10 centrifugal filters (Millipore). 
Exchange of human troponin complex
Exchange of recombinant cTn in human cardiomyocytes was done as described 
previously (39). Briefly, single cardiomyocytes were mechanically isolated with a glass 
tissue homogenizer, and permeabilized by Triton X-100 (0.5%; v/v) for 5 minutes. 
They were subsequently incubated overnight at 4ºC in exchange solution containing 
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1 mg/mL of recombinant human cTn complex with the addition of 4 mM CaCl2, 4 mM 
DTT, 5 ml/mL protease inhibitor cocktail (Sigma, P8340) and 10 ml/mL phosphatase 
inhibitor cocktail 2 and 3 (Sigma, P5726 and P0044) (pH 6.9). The next day, 
the cardiomyocytes were washed twice in rigor solution and finally in relaxing solution 
(5.95 mM Na2ATP, 6.04 mM MgCl2, 2 mM EGTA, 139.6 mM KCl, 10 mM imidazole, pH 
7.0). This method results in a homogenous distribution of recombinant cTn complex 
within the exchanged cardiomyocytes (22). 
Determination of the degree of troponin exchange 
The degree of troponin exchange was determined as described previously (39). Briefly, 
to determine the degree of cTn exchange and to assess protein phosphorylation status, 
part of the suspension of cells was treated with 2D-clean-up kit (GE Healthcare) as 
described by the manufacturer protocol after overnight cTn exchange. Subsequently, 
tissue pellets were homogenized in sample buffer containing 15% glycerol, 62.5 mM 
Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v) DTT. Protein concentration measured with 
RCDC Protein Assay Kit II (BioRad) ranged between 2 to 4 mg/mL.
Immunoblotting was used to determine the degree of exchange of endogenous 
cTn by recombinant cTn complex. Therefore, recombinant cTnT was labeled with 
a Myc-tag to allow discrimination between endogenous and recombinant cTn complex. 
In a previous study we demonstrated that Myc-tag labeling does not interfere with 
myofilament function (39). Proteins were separated on a one-dimensional 13% SDS-
polyacrylamide gel and blotted onto a nitrocellulose membrane (Hybond) using the 
protocol supplied by the manufacturer in 1 hour at 75 V. A specific monoclonal antibody 
against cTnT (Clone JLT-12, Sigma; dilution 1:1250) was used to detect endogenous 
and recombinant cTnT by chemiluminescence (ECL, Amersham Biosciences). We 
have previously demonstrated that the affinity of the cTnT antibody was the same for 
cTnT compared to cTnT-Myc and that cTnT loading was within the linear range (39).
Myofilament protein phosphorylation
The phosphorylation levels of sarcomeric proteins was determined before and 
after cTn exchange using ProQ-Diamond stained 1D-gels, as described previously 
(39). The phosphorylation signals were normalized to the intensities of the SYPRO 
Ruby stained myosin light chain 2 bands to correct for small differences in protein 
loading. The PeppermintStick Phosphoprotein marker (Molecular Probes) was used 
to correct for differences in staining between gels (41). The ratio of the intensities 
of ProQ-Diamond and SYPRO Ruby stained ovalbumin band was used to correct for 
inter-gel differences. 
The distribution of endogenous phosphorylated species of cTnI was analyzed 
using Phos-tagTM acrylamide gels (FMS Laboratory; Hiroshima University, Japan) as 
described before (10, 18).
128
Analysis of titin isoform composition
Tissue samples were weighed and pulverized in liquid nitrogen using a mortar and 
a pestle. Tissue powder was solubilized in 8M urea buffer with DTT and 50% glycerol 
solution with protease inhibitors (0.16 mmol/L Leupeptin, 0.04 mmol/L E-64 and 0.2 
mmol/L PMSF). Samples were loaded in triplicate on 1% agarose gels stained with 
SYPRO Ruby to determine titin isoform composition as described previously (27).
Isometric force measurements 
Force measurements in cardiomyocytes exchanged with recombinant cTn were 
performed as described previously (17, 37). Isometric force was measured at 15°C 
and LDA was determined by measuring force at different Ca2+ concentrations, 
first at a sarcomere length of 1.8 µm and subsequently at 2.2 µm. The following 
parameters were determined: passive force at pCa 9.0 (Fpas), maximal force at pCa 4.5 
(Fmax: total force minus Fpas), Ca
2+-sensitivity of force development (pCa50) and steepness 
of the sigmoidal force-pCa relation (nHill). Only a minor decrease in maximal force 
development was observed during force measurements at a sarcomere length of 1.8 
(2.1±2.5%) and 2.2 (7.8±1.9%) μm. Force decline during the entire experiment did 
not differ between cells exchanged with the different troponin complexes. Troponin-
exchanged donor cardiomyocytes were incubated with exogenous PKA for 40 minutes 
at 20ºC in relaxing solution containing the catalytic subunit of PKA (100 U/incubation, 
Sigma) after which isometric force measurements were performed at 15°C.
Data analysis
Data analysis was performed as previously described using the Hill equation to fit 
force-Ca2+ relations: F(Ca2+)/F0=[ Ca
2+]nHill/(Ca50
nHill+ [ Ca2+]nHill)
Where F is steady-state force, F0 the steady-state force at saturating [Ca
2+], nHill 
the steepness of the relationship and Ca50 (or pCa50) represents the midpoint of 
the relation. One-way ANOVA followed by a Bonferroni post-hoc test was used to 
compare the amount of exchange of the different cTn-complexes. Two-way ANOVA 
repeated measures followed by a Bonferroni post-hoc test was used to compare 
groups exchanged with the different cTn complexes (#P<0.05, significant difference 
compared to control (Wt for Table 2-4; 23A/24A for Table 5)). When two-way ANOVA 
revealed a significant effect for sarcomere length (P<0.05), paired t-tests were 
performed to compare cell measurements at two different sarcomere lengths in each 
cTn-exchange group (*P<0.05, 1.8 vs 2.2 μm). Data values represent an average of 
all cells of the different IDCM hearts. No significant differences were found between 
the 3 IDCM hearts after cTn exchange with the same complex for all force parameters 
measured. Values are given as means ± S.E.M. of n myocytes.
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results
Pseudo-phosphorylation of Thr143 increases Ca2+-sensitivity without affecting 
length-dependent activation in IDCM cardiomyocytes  
As the effect of pseudo-phosphorylated Thr143 may be modulated by cTnI 
phosphorylation at Ser23/24, we first analyzed baseline cTnI phosphorylation in 
the idiopathic dilated cardiomyopathy (IDCM) samples used in the exchange 
experiments. Phostag analysis showed a relatively low cTnI phosphorylation in IDCM 
hearts (n=3): 7.5 ± 0.9% bisphosphorylated, 27.2 ± 4.7% monophosphorylated and 
65.3 ± 5.1% unphosphorylated cTnI (Figure 1A).
Troponin exchange was determined using immunoblot detection of the myc-tag 
labeled cTnT. Figure 1B depicts a representative immunoblot loaded with IDCM 
cardiomyocytes incubated overnight with recombinant cTn containing pseudo-
dephosphorylated Thr143 (143A), pseudo-phosphorylated Thr143 (143D) and 
wild-type (Wt) cTnI. Myc-tagged cTnT migrates more slowly through the gel in 
comparison to endogenous cTnT and therefore 2 cTnT bands are found. The percentage 
of cTn exchange was calculated from the ratio of myc-tagged recombinant cTnT and 
the total amount of cTnT. The average exchange percentage of the 3 cTn complexes 
figure 1. Baseline cardiac troponin I phosphorylation and quantification of troponin exchange 
in cardiomyocytes. A: Distribution of cardiac troponin I (cTnI) phosphospecies of the three IDCM 
samples and the donor sample used in the exchange experiments determined via a Phos tag-blot. 
B: Immunoblot stained with an antibody against troponin T (cTnT) that recognizes both endogenous 
cTnT (lower band) and recombinant Myc-tag-labeled cTnT (cTnT-myc). An example is shown of 
a suspension of IDCM cardiomyocytes exchanged with recombinant cTn (143A, 143D or Wt). The bar 
graphs indicate average percentages of cTn exchange in cardiomyocytes after overnight incubation 
in exchange solution containing the different cTnI species (average values from 3 IDCM hearts). No 
significant differences were found in exchange percentage between the three complexes. Error bars 
are visible when larger than symbol size. Abbreviations: 143A, pseudo-dephosphorylated cTnI at 
Thr143; 143D, pseudo-phosphorylated cTnI at Thr143; Wt, wild-type cTnI.
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in IDCM amounted to 68.4 ± 3% and did not significantly differ (p = 0.58) between 
the 3 cTn complexes (Figure 1B), indicating similar incorporation in the myofilaments. 
Previous studies indicated that sarcomeric proteins, other than cTnI, may 
modify length-dependent activation (9, 19). To assess if cTn exchange affected 
phosphorylation of myofilament proteins other than troponin, ProQ-Diamond staining 
was performed before and after cTn exchange. In agreement with our previous study 
(39), no significant differences in protein phosphorylation were induced in the other 
contractile proteins studied  (cardiac myosin-binding protein-C, myosin light chain 2 
and desmin) upon cTn exchange (Table 1). Since endogenous cTnT phosphorylation 
level was low, no significant reduction in cTnT phosphorylation could be detected 
upon exchange with unphosphorylated whole troponin complex via ProQ-diamond 
staining. The level of cTnT phosphorylation did not differ between cells exchanged 
with the different cTn complexes (Table 1).
table 1. Myofilament protein phosphorylation before and after troponin exchange.
cmybPc Desmin mlC2 ctnt
Before exchange 0.39±0.02 0.47±0.13 0.35±0.10 0.20±0.04
143A 0.37±0.02 0.48±0.14 0.36±0.10 0.15±0.01
143D 0.37±0.03 0.46±0.17 0.33±0.09 0.15±0.02
Wt 0.35±0.03 0.45±0.08 0.29±0.03 0.17±0.02
Values are means ± SEM of the ProQ/SYPRO intensity ratio. Shown is myofilament protein phosphorylation 
determined with ProQ-diamond staining before and after exchange in three IDCM samples. Troponin exchange did 
not affect myofilament protein phosphorylation (by one-way ANOVA comparing before exchange to the exchanged 
groups). cMyBP-C, cardiac myosin-binding protein-C; MLC2, myosin light chain 2; cTnT, cardiac troponin T; 
A, alanine substitution; D, aspartic acid substitution; Wt, wild-type.
To determine the effects of Thr143 phosphorylation on myofilament force 
development, force measurements were performed in failing cardiomyocytes 
exchanged with 143D. As controls, 143A was used, where alanine was used to mimick 
dephosphorylation at Thr143, and unphosphorylated Wt cTnI. Ca2+-sensitivity of force 
development was measured at 2.2 µm sarcomere length in the cTn-exchanged IDCM 
cardiomyocytes (1 mg/mL recombinant cTn; 3 IDCM hearts, 11-13 cells in total). 
Myofilament Ca2+-sensitivity was significantly increased in 143D, evident from the 
leftward shift of the force-pCa curve for 143D compared to Wt (Figure 2A), while 
143A did not change Ca2+-sensitivity compared to Wt. The midpoint of the force-pCa 
relation (pCa50) was significantly higher in 143D-exchanged cells compared to both 
controls (Wt and 143A; Figure 2B).
To study the effect of Thr143 phosphorylation on length-dependent myofilament 
activation, force measurements were also performed at 1.8 µm (Figure 2C). The effect 
of sarcomere lengthening on myofilament Ca2+-sensitivity is displayed as the ∆pCa50, 
which is the difference in pCa50 at a sarcomere length of 1.8 µm (Figure 2C) and 
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figure 2. Myofilament Ca2+-sensitivity is increased upon Thr143 pseudo-phosphorylation without 
affecting length-dependent activation in cardiomyocytes from failing human hearts. A: Myofilament 
force development measured at 2.2 μm sarcomere length at various [Ca2+] in permeabilized 
cardiomyocytes from idiopathic dilated cardiomyopathy (IDCM) patients in which endogenous 
troponin complex was partially exchanged (68.4±3%) with recombinant myc-tag-labeled troponin 
complexes (11-13 cardiomyocytes in total from 3 IDCM hearts per group). B: Compared to 
unphosphorylated wild-type cTnI (Wt), Ca2+-sensitivity derived from the midpoint of the force–pCa 
relationship (pCa50) was significantly increased after exchange with pseudo-phosphorylated cTnI at 
Thr143 (143D). Pseudo-dephosphorylation at Thr143 (143A) did not alter Ca2+-sensitivity compared 
to Wt. C: The length-dependent increase in Ca2+-sensitivity was studied by measuring force at 
sarcomere lengths of 1.8 and 2.2 μm (8 cells for each group, 71.0±4.4% exchange). D: Exchange 
with 143D did not significantly alter the length-dependent increase in myofilament Ca2+-sensitivity 
(∆pCa50: 1.8 versus 2.2 μm) compared to 143A and Wt. *P<0.05, 143D versus 143A and Wt in 
post-test Bonferroni analyses of one-way ANOVA.
2.2 μm (Figure 2A). For all cTn complexes, Ca2+-sensitivity significantly increased 
upon cardiomyocyte lengthening. The increase in pCa50 did not differ among groups 
132
(∆pCa50 Wt; 0.04 ± 0.01, 143D; 0.05 ± 0.01, 143A; 0.03 ± 0.01; Figure 2D). Sarcomere 
lengthening from 1.8 to 2.2 μm significantly increased maximal (Fmax) and passive 
(Fpas) force in all 3 cTn-exchanged groups (Table 2), which is in accordance with 
the well-known length-force relationship (1). nHill slightly decreased upon sarcomere 
lengthening, only reaching a significant difference for 143A (Table 2). No significant 
differences in Fmax, Fpas and nHill were found between cells exchanged with the 3 cTn 
complexes at both sarcomere lengths. Exchange in IDCM cardiomyocytes with cTn 
complex containing unphosphorylated cTnI (Wt and 143A) did not affect contractile 
parameters compared to control (no cTn exchange) IDCM cardiomyocytes (2 IDCM 
samples; 5 cells) at short and long sarcomere lengths, respectively: Fmax: 12.2±1.5 and 
16.5±2.3 kN/m2; Fpas: 1.5±0.3 and 2.7±0.5 kN/m
2; pCa50: 5.64±0.02 and 5.68±0.02; 
nHill: 3.2±0.3 and 3.1±0.2.
table 2. Force measurements in failing cardiomyocytes after exchange with recombinant troponin.
wt 143D 143a
Fmax 1.8 μm 14.5±0.8 13.8±1.3 12.7±1.8
(kN.m-2) 2.2 μm 18.0±1.0* 17.2±1.5* 16.8±1.5*
Fpas 1.8 μm 2.2±0.1 2.2±0.3 1.9±0.3
(kN.m-2) 2.2 μm 3.3±0.3* 3.4±0.4* 3.0±0.3*
pCa50 1.8 μm 5.64±0.02 5.72±0.03
# 5.62±0.01
2.2 μm 5.67±0.02* 5.76±0.02*,# 5.65±0.01*
nHill 1.8 μm 2.9±0.1 3.0±0.3 3.1±0.1
2.2 μm 2.7±0.1 2.7±0.2 2.8±0.1*
Myofilament force was measured at 1.8 and 2.2 μm sarcomere length and at different Ca2+-concentrations in 
failing cardiomyocytes (8 myocytes per complex) exchanged with troponin complex mutated at cTnI-Thr143 into 
alanine (143A; dephosphorylation) or aspartic acid (143D; phosphorylation) and wild-type cTn (Wt). Maximum 
force (Fmax) at saturating Ca
2+-concentrations, passive force (Fpas) and Ca
2+-sensitivity derived from the midpoint of 
the force–pCa relationship (pCa50) were significantly increased at 2.2 μm compared to 1.8 μm for all complexes. 
nHill (steepness of the force-pCa curves) was slightly lower at 2.2 μm compared to 1.8 μm in all groups. cTn 
exchange significantly increased Ca2+-sensitivity in 143D compared to Wt and 143A at both sarcomere lengths. No 
significant differences between the 3 cTn complexes for Fmax, Fpas and nHill were found at both sarcomere lengths. 
A two-way ANOVA repeated measures followed by a Bonferroni post-hoc test was used to compare groups exchanged 
with the different cTn complexes (#P<0.05, significant difference compared to Wt). When the two-way ANOVA revealed 
a significant effect for sarcomere length (P<0.05), paired t-tests were performed to compare cell measurements at 
two different sarcomere lengths in each cTn-exchange group (*P<0.05, 1.8 vs 2.2 μm). Values are means ± SEM. 
Overall, these data show that phosphorylation at Thr143 increases myofilament 
Ca2+-sensitivity, but does not alter LDA of the sarcomeres in failing cardiomyocytes.
Pseudo-phosphorylation of Thr143 and Ser23/24 in donor cardiomyocytes
The absence of an effect of Thr143 phosphorylation in failing cells may be due to 
a blunted LDA of failing myocardium, as a reduced length-dependent increase in 
myofilament Ca2+-sensitivity has been reported in failing compared to donor cardiac 
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tissue (30). In our recent study we found a ∆pCa50 of 0.10 ± 0.01 in 6 donor samples 
(31), which is significantly larger than the value found in the IDCM samples used 
in this study without cTn exchange (∆pCa50 = 0.04 ± 0.01). Such a blunted length-
dependent increase in Ca2+-sensitivity in failing cardiomyocytes may be due to 
the low baseline cTnI phosphorylation, but could also be related to changes in 
myofilament proteins other than troponin. Therefore, we studied the effects of Thr143 
pseudo-phosphorylation in combination with PKA-mediated effects on LDA in non-
failing donor cardiomyocytes. Effects of pseudo-phosphorylation at Thr143 (143D) 
and at Ser23/24 (23D/24D) were studied without and with treatment with exogenous 
PKA. The average cTn exchange percentage in donor cardiomyocytes amounted to 
82.6 ± 3.1% and did not differ between the 3 complexes (Wt, 143D and 23D/24D). 
Phosphorylation of other myofilament proteins than cTnI in exchanged donor samples 
corresponded to: cMyBP-C: 0.57±0.04; desmin: 0.47±0.06; MLC2: 0.28±0.01 
and cTnT: 0.24 ± 0.02.
Similar to IDCM, 143D significantly increased Ca2+-sensitivity compared to Wt in 1 
donor sample at both sarcomere lengths, while Ca2+-sensitivity was significantly lower 
compared to Wt in cells exchanged with 23D/24D (Figure 3A-C). No differences were 
found in ∆pCa50 between Wt and 143D, while the length-dependent change in pCa50 
was higher in cells exchanged with 23D/24D (Figure 3D and Table 3). 
The relatively low ∆pCa50 in Wt and 143D compared to donor cardiomyocytes 
without cTn exchange (4 cells; ∆pCa50 = 0.10 ± 0.03) and 23D/24D-exchanged cells 
(Figure 3D) may be explained by removal of phosphorylated endogenous cTnI upon 
exchange with recombinant unphosphorylated cTn complex. It is known that donor 
cardiomyocytes are relatively highly phosphorylated at Ser23/24 (10, 39). Phostag 
analysis showed 52.7% bisphosphorylated, 35.9% monophosphorylated and 11.4% 
unphosphorylated cTnI at baseline in the donor tissue used in this study (Figure 1A).
Treatment of cTn-exchanged donor cardiomyocytes with exogenous PKA reduced 
Ca2+-sensitivity in Wt and 143D (Figure 3E) compared to cTn-exchanged cells without 
PKA treatment (Figure 3C). Moreover, PKA treatment increased ∆pCa50 in Wt and 
143D (Figure 3F versus Figure 3D). ProQ-Diamond staining illustrated that cTnI and 
cMyBP-C phosphorylation was 5.5±0.4 and 1.8±0.1 times higher, respectively, in 
cTn-exchanged donor cells treated with PKA compared to untreated cTn-exchanged 
donor cells (Figure 3G). This is in line with our previous study (31), where selective 
PKA-mediated phosphorylation of cMyBP-C and cTnI was found. After PKA treatment, 
Wt and 143D displayed a similar length-dependent increase in myofilament Ca2+-
sensitivity as 23D/24D-exchanged cells (Figure 3F). No effect of PKA-mediated 
phosphorylation on the length-dependent increase in Ca2+-sensitivity was found in 
donor cardiomyocytes after exchange with 23D/24D compared to 23D/24D without 
PKA treatment (Fig 3D, 3F). This most likely demonstrates that PKA-mediated cTnI 
phosphorylation at Ser23/24 was responsible for the observed enhancement in the 
length-dependent increase in Ca2+-sensitivity in human donor cardiomyocytes after 
exchange with Wt and 143D. However, this does not exclude that phosphorylation 
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figure. 3. Phosphorylation of Ser23 and Ser24 regulates the length-dependent increase in Ca2+-
sensitivity in donor cardiomyocytes. Myofilament force development was measured at a sarcomere 
length of 1.8 (A) and 2.2 μm (B) at various [Ca2+] in donor cardiomyocytes in which endogenous 
troponin complex was partially exchanged (82.6±3.1%) with recombinant myc-tag-labeled troponin 
complexes (4-5 cardiomyocytes per group). C: Compared to unphosphorylated wild-type cTnI (Wt), 
Ca2+-sensitivity derived from the midpoint of the force–pCa relationship (pCa50) was significantly 
increased after exchange with pseudo-phosphorylated cTnI at Thr143 (143D) and significantly 
decreased upon pseudo-bisphosphorylation of Ser23/Ser24 (23D/24D) at 2.2 μm. D: The length-
dependent increase in Ca2+-sensitivity (∆pCa50) did not differ between 143D and Wt. However, 
exchange with 23D/24D significantly increased the length-dependent Ca2+-sensitivity increase 
compared to Wt. E, F: Troponin-exchanged donor cardiomyocytes were incubated with exogenous 
PKA. E: PKA treatment decreased Ca2+-sensitivity in cells exchanged with Wt and 143D compared 
to untreated cardiomyoctes after exchange, but had no effect in 23D/24D cells (Figure 3E versus 
Figure 3C). F: PKA treatment significantly increased the length-dependent increase in Ca2+-sensitivity 
for Wt and 143D compared to untreated cells after exchange (Figure 3D versus Figure 3F). No 
significant differences in ∆pCa50 were found after PKA treatment of cells exchanged with the 3 different 
cTn complexes. *P<0.05, Wt versus 143D and 23D/24D complexes in post-test Bonferroni analyses 
of one-way ANOVA. PKA treated cardiomyocytes were compared to untreated cardiomyocytes after 
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of other PKA-mediated phosphorylation targets like titin and cMyBP-C may affect 
the length-dependent increase in Ca2+-sensitivity, since it is possible that 
phosphorylation of cMyBP-C and titin exerted opposite effects on the length-
dependent change in Ca2+-sensitivity (6, 9).
In line with our experiments in IDCM cardiomyoctes, a sarcomere length increase 
from 1.8 to 2.2 μm in donor cardiomyocytes without (Table 3) or with (Table 4) PKA 
treatment increased Fmax and Fpas for all cTn complexes, without changing nHill. 
Between groups (Wt, 143D and 23D/24D), no significant differences were found for 
Fmax and Fpas (Table 3 and 4). nHill was significantly higher in 143D compared to Wt at 
a sarcomere length of 1.8 μm without PKA treatment (Table 3). Overall, our data from 
failing and non-failing human cardiomyocytes show that cTnI pseudo-phosphorylation 
at the PKC site Thr143 does not modulate length-dependent myofilament activation.
Both Ser23 and Ser24 need to be phosphorylated to increase length-
dependent activation
Our data in donor cardiomyocytes confirm a previous study (16) that indirectly 
demonstrated that phosphorylation of cTnI-Ser23/24 enhances the increase in Ca2+-
sensitivity upon an increase in sarcomere length. However, while monophosphorylation 
of Ser23 or Ser24 has been reported in the human heart (42, 43), no functional 
effect of monophosphorylation has been found (39, 44). Therefore, we investigated 
if monophosphorylation of Ser23 or Ser24 would affect LDA of the myofilaments. 
For these experiments IDCM cardiomyocytes were used, which showed less than 7% 
endogenous bisphosphorylation at Ser23/24 (Figure 1A). Due to the low baseline cTnI 
phosphorylation, the remaining endogenous Ser23/24 bisphosphorylation after cTn 
exchange does not interfere with functional effects of mono-and bisphosphorylated 
cTn complexes. IDCM cardiomyocytes (6-9 cells per cTn complex) were exchanged 
with 4 different pseudo-phosphorylation variants of Ser23/24. The average cTn 
exchange percentage was 76.6 ± 1.9% and did not differ between the complexes. 
In accordance with our previous observations in non-failing donor cardiomyocytes 
(39), only pseudo-bisphosphorylation decreased Ca2+-sensitivity compared to mono- 
exchange with the same complex via a Student’s t-test. G: Myofilament proteins of cardiomyocytes 
after cTn exchanged without (lane 1) and with (lane 2) PKA treatment were separated by 1D-gel 
electrophoresis. Staining differences between gels were corrected with phosphorylated ovalbumin 
of the peppermint marker (PM). Phosphorylation signal on ProQ Diamond-stained gels was divided 
by the SYPRO signal of the same protein to correct for minor differences in loading. Phosphorylation 
levels of cTnI and cMyBP-C increased after PKA treatment. Phosphorylation of Ser23 and Ser24 
regulates the length-dependent increase in Ca2+-sensitivity in donor cardiomyocytes. G: Myofilament 
proteins of cardiomyocytes after cTn exchanged without (lane 1) and with (lane 2) PKA treatment 
were separated by 1D-gel electrophoresis. Staining differences between gels were corrected 
with phosphorylated ovalbumin of the peppermint marker (PM). Phosphorylation signal on ProQ 
Diamond-stained gels was divided by the SYPRO signal of the same protein to correct for minor 
differences in loading. Phosphorylation levels of cTnI and cMyBP-C increased after PKA treatment.
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table 3. Force measurements in donor cardiomyocytes after exchange with recombinant troponin 
without PKA treatment.
without Pka wt 143D 23D/24D
Fmax 1.8 μm 12.4±0.5 13.3±1.4 11.7±1.1
(kN.m-2) 2.2 μm 16.2±0.5* 16.7±1.2* 16.3±0.9*
Fpas 1.8 μm 2.2±0.3 2.5±0.6 2.9±0.3
(kN.m-2) 2.2 μm 3.9±0.6* 4.1±0.8* 4.0±0.3*
pCa50 1.8 μm 5.55±0.05 5.69±0.02
# 5.37±0.01#
2.2 μm 5.57±0.05 5.71±0.02# 5.46±0.01*,#
nHill 1.8 μm 1.9±0.1 2.7±0.4# 2.0±0.1
2.2 μm 1.9±0.1 2.4±0.3 1.7±0.1
One donor sample exchanged with 143D, 23D/24D and Wt troponin complex (4-5 myocytes per complex). Myofilament 
force was measured at sarcomere lengths of 1.8 and 2.2 μm at different Ca2+-concentrations. Ca2+-sensitivity derived 
from the midpoint of the force–pCa relationship (pCa50) increased at 2.2 μm compared to 1.8 μm for all complexes, 
however, the difference was only significant in 23D/24D. Stretching of cardiomyocytes from 1.8 to 2.2 μm increased 
maximal (Fmax) and passive force (Fpas) in all groups. There was no significant effect of sarcomere length on nHill 
(steepness of the force-pCa curves). Compared to Wt, 143D significantly increased Ca2+-sensitivity and 23D/24D 
decreased Ca2+-sensitivity at both sarcomere lengths. No significant differences between the 3 cTn complexes for Fmax 
and Fpas were found. nHill was significantly higher in 143D compared to Wt only at sarcomere length 1.8 µm. A two-way 
ANOVA repeated measures followed by a Bonferroni post-hoc test was used to compare groups exchanged with 
the different cTn complexes (#P<0.05, significant difference compared to Wt). When the two-way ANOVA revealed 
a significant effect for sarcomere length (P<0.05), paired t-tests were performed to compare cell measurements at 
two different sarcomere lengths in each cTn-exchange group (*P<0.05, 1.8 vs 2.2 μm). Values are means ± SEM. 
table 4. Force measurements in donor cardiomyocytes after exchange with recombinant troponin 
and subsequent PKA treatment. 
With PKA Wt 143D 23D/24D
Fmax 1.8 μm 12.8±1.1 11.7±1.1 11.1±1.9
(kN.m-2) 2.2 μm 14.9±1.6* 14.5±1.6 16.2±2.2*
Fpas 1.8 μm 2.0±0.2 2.0±0.2 2.6±0.1
(kN.m-2) 2.2 μm 2.9±0.2* 3.4±0.5* 3.6±0.3*
pCa50 1.8 μm 5.34±0.06 5.47±0.01
# 5.37±0.01
2.2 μm 5.44±0.08* 5.56±0.02* 5.48±0.01*
nHill 1.8 μm 2.1±0.1 2.3±0.2 1.7±0.1
2.2 μm 2.1±0.1 2.4±0.2 1.7±0.2
One donor sample exchanged with 143D, 23D/24D and Wt troponin complex with PKA treatment (4-5 
myocytes per complex). Myofilament force was measured at sarcomere lengths of 1.8 and 2.2 μm at different 
Ca2+-concentrations. Ca2+-sensitivity derived from the midpoint of the force–pCa relationship (pCa50) 
significantly increased at 2.2 μm compared to 1.8 μm for all complexes. Stretching of cardiomyocytes 
from 1.8 to 2.2 μm increased maximal (Fmax) and passive force (Fpas) in all groups, without affecting nHill 
(steepness of the force-pCa curves). Compared to Wt, 143D increased Ca2+-sensitivity, reaching significance 
at sarcomere length 1.8 µm (#). pCa50 of Wt did not significantly differ from 23D/24D after PKA treatment. 
No significant differences between the 3 cTn complexes for Fmax, Fpas and nHill were found. A two-way ANOVA 
repeated measures followed by a Bonferroni post-hoc test was used to compare groups exchanged with the 
different cTn complexes (#P<0.05, significant difference compared to Wt). When the two-way ANOVA revealed 
a significant effect for sarcomere length (P<0.05), paired t-tests were performed to compare cell measurements at 
two different sarcomere lengths in each cTn-exchange group (*P<0.05, 1.8 vs 2.2 μm). Values are means ± SEM.
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and dephosphorylated Ser23/24 in IDCM cardiomyocytes (Figure 4A). Compared to 
pseudo-dephosphorylated Ser23/24 (23A/24A), pseudo-monophosphorylation at 
Ser23 (23D/24A) or Ser24 (23A/24D) did not affect LDA (Figure 4B and Table 5). 
Upon exchange with pseudo-bisphosphorylated Ser23/24 (23D/24D), the length-
dependent increase in Ca2+-sensitivity was significantly increased compared to 
23A/24A (Figure 4B). The enhanced length-dependent increase in Ca2+-sensitivity in 
23D/24D was significantly higher compared to control IDCM cardiomyocytes without 
exchange. The sarcomere length increase from 1.8 to 2.2 μm increased Fmax and Fpas 
for all cTn complexes, without changing nHill (Table 5).     
Length-dependent myofilament activation and titin-based passive stiffness
Titin-based passive stiffness has been shown to exert a profound effect on length-
dependent activation. A high expression of the stiff N2B isoform in cardiac tissue 
has been associated with a higher passive force and larger length-dependent 
increase in myofilament Ca2+-sensitivity compared to tissue with a high expression 
of compliant N2BA isoform (9). Thus, changes in titin isoform composition, as have 
been reported in human heart failure (21, 23), may alter length-dependent activation. 
In our exchange experiments, passive tension did not differ between the different 
experimental groups (Tables 2-5). Moreover, no differences were observed in Fpas  and 
titin isoform composition (Figure 5) between the failing and donor samples used in 
the present study.
DisCussion
This study demonstrates that cTnI pseudo-phosphorylation at the PKC-site Thr143 
increases myofilament Ca2+-sensitivity without affecting the length-dependent 
increase in maximal force or Ca2+-sensitivity in human failing and non-failing donor 
cardiomyocytes. The length-dependent increase in Ca2+-sensitivity is enhanced by 
(pseudo-)phosphorylation of Ser23/24 only upon phosphorylation of both sites. 
Phosphorylation of Thr143 increases Ca2+-sensitivity without affecting 
length-dependent activation
Tachampa et al. (33) showed that substitution of a single amino acid at position 143 of 
cTnI (from Thr to Pro) greatly diminished the length-dependent increase in myofilament 
Ca2+-sensitivity. Since Thr143 is a well-known PKC-mediated phosphorylation site that 
has been implicated in heart failure (25, 32, 43), we investigated if phosphorylation 
of Thr143 may modify LDA of the myofilaments in human cardiomyocytes. We 
show that pseudo-phosphorylation of Thr143 does not affect the length-dependent 
increase in maximal force and Ca2+-sensitivity irrespective of the level of cTnI 
phosphorylation at PKA-sites. 
The finding that Thr143 phosphorylation does not affect LDA is not in conflict with 
the previous finding that a substitution of Thr143 by a proline, as present in ssTnI and 
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figure 4. Phosphorylation of both Ser23 and Ser24 is required to increase length-dependent activation 
in failing cardiomyocytes.  Myofilament force development was measured at sarcomere lengths of 1.8 
and 2.2 μm at various [Ca2+] in failing cardiomyocytes in which endogenous troponin complex was 
partially exchanged (76.6±1.9%) with recombinant myc-tag-labeled troponin complexes (6-9 cells 
per group). A: Compared to pseudo-unphosphorylated Ser23/24 (23A/24A), Ca2+-sensitivity derived 
from the midpoint of the force–pCa relationship (pCa50) decreased upon pseudo-bisphosphorylation 
of Ser23 and Ser24 (23D/24D), while no effect was seen with mono-phosphorylated complexes 
(23A/24D and 23D/24A). B: The length-dependent increase in Ca2+-sensitivity was not changed 
compared to pseudo-unphosphorylated Ser23/24 (23A/24A) upon pseudo-monophosphorylation 
of Ser23 or Ser24 (23D/24A, 23A/24D). Pseudo-bisphosphorylation of Ser23 and Ser24 enhanced 
the length-dependent Ca2+-sensitivity increase compared to 23A/24A. *, P<0.05, 23A/24A versus 
23A/24D, 23D/24A and 23D/24D complexes in post-test Bonferroni analyses of one-way ANOVA. 
fast skeletal TnI, severely blunts LDA in cardiac muscle. A proline is a neutral amino acid 
with very specific properties (reviewed by Williamson (40)). Replacement of a Thr by 
a Pro, alters the amino acid charge differently compared to threonine phosphorylation. 
Likewise, mutations in the inhibitory region of cTnI, which are associated with 
inherited forms of cardiomyopathies, may disrupt LDA. We recently reported blunted 
LDA in myocardium from patients with hypertrophic cardiomyopathy harboring 
a mutation (R145W) in cTnI (31). Overall, these results indicate that mutation-induced 
changes in amino acids in the inhibitory region of cTnI and phosphorylation-mediated 
changes of Thr143 exert different effects on sarcomere function. While the threonine 
at position 143 is key for LDA in cardiac muscle, phosphorylation at this site does 
not modulate LDA.
Pseudo-phosphorylation of Thr143 using aspartic acid at amino acid 143 increased 
Ca2+-sensitivity both in IDCM and donor cardiomyocytes. In contrast, exchange in 
mouse fibers with pseudo-phosphorylated Thr143 mimicked by a glutamate did 
not change (5) or non-significantly decreased Ca2+-sensitivity (32) compared to Wt 
exchange. Our data are in line with a study of Wang et al. where incorporation of 
phosphate instead of pseudo-phosphorylation was used (38). By using genetically 
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figure 5. Titin isoform composition in the IDCM and donor tissue. Titin isoform composition was 
analyzed in the IDCM and donor samples. A SYPRO-stained gel shows the compliant N2BA and 
stiff N2B titin isoform. On average, titin composition in the IDCM samples did not differ from 
the donor sample.
table 5. Force measurements in failing cardiomyocytes after exchange with recombinant troponin 
mutated at Ser23 and Ser24.
23a/24a 23a/24D 23D/24a 23D/24D
Fmax 1.8 μm 12.4±0.6 11.9±0.5 13.2±0.5 11.5±0.7
(kN.m-2) 2.2 μm 15.4±0.7* 17.3±1.0* 17.7±0.8* 14.5±0.7*
Fpas 1.8 μm 2.2±0.4 1.7±0.2 1.5±0.3 1.9±0.2
(kN.m-2) 2.2 μm 2.8±0.6* 2.2±0.3* 2.1±0.3* 2.2±0.2*
pCa50 1.8 μm 5.57±0.02 5.60±0.01 5.59±0.02 5.40±0.01
#
2.2 μm 5.59±0.02 5.62±0.02 5.61±0.02 5.49±0.01*,#
nHill 1.8 μm 2.4±0.2 2.1±0.1 2.2±0.1 2.0±0.1
2.2 μm 2.2±0.3 1.9±0.1 2.2±0.1 2.1±0.2
Failing cardiomyocytes exchanged with 23A/24A, 23A/24D, 23D/24A and 23D/24D (6-9 cells per group). Myofilament 
force was measured at sarcomere lengths of 1.8 and 2.2 μm at different Ca2+-concentrations. Ca2+-sensitivity derived from 
the midpoint of the force–pCa relationship (pCa50) increased at 2.2 μm compared to 1.8 μm for all 
complexes, however, the increase was only significant in 23D/24D. Stretching of cardiomyocytes from 
1.8 to 2.2 μm significantly increased maximal (Fmax) and passive force (Fpas) in all groups. There was no 
significant effect of sarcomere length on nHill (steepness of the force-pCa curves). Ca2+-sensitivity was 
significantly lower in 23D/24D compared to 23A/24A at both sarcomere lengths (#, p<0.05). No significant 
differences between the 4 cTn complexes for Fmax, Fpas and nHill were found at both sarcomere lengths. A 
two-way ANOVA repeated measures followed by a Bonferroni post-hoc test was used to compare groups 
exchanged with the different cTn complexes (#P<0.05, significant difference compared to 23A/24A). When 
the two-way ANOVA revealed a significant effect for sarcomere length (P<0.05), paired t-tests were performed to compare 
cell measurements at two different sarcomere lengths in each cTn-exchange group (*P<0.05, 1.8 vs 2.2 μm). Values are 
means ± SEM.
modified mice harboring alanine mutations at the different phosphorylation sites 
of cTnI, they demonstrated that PKC-βII preferentially phosphorylates Thr143 and 
thereby increased Ca2+-sensitivity. This suggests that an aspartic acid pseudo-
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phosphorylation at Thr143 more closely resembles PKC-mediated phosphorylation of 
Thr143 compared to a glutamate pseudo-phosphorylation.
The absence of an effect of Thr143 pseudo-phosphorylation on LDA is in line with 
the preserved LDA at the myofilament level in a mouse model of heart failure induced 
by over-expression of PKCε (20), which has been demonstrated to phosphorylate 
Thr143 (15). Thr143 phosphorylation did not increase the relatively small length-
dependent increase in Ca2+-sensitivity when Ser23/24 are largely unphosphorylated 
in failing cells. One possibility to explain this may be the elevated Ca2+-sensitivity, 
limiting further Ca2+-sensitivity enhancement upon lengthening. However, pseudo-
phosphorylation of Thr143 in combination with phosphorylation of Ser23/24 also did 
not change the enhanced length-dependent increase in Ca2+-sensitivity. In donor 
cardiomyocytes, Wt without PKA showed a pCa50 of 5.57 ± 0.05 and a relatively 
low length-dependent increase in Ca2+-sensitivity (Figure 3C,D), while 143D after 
PKA displayed the same pCa50 (5.56 ± 0.02) with an enhanced  length-dependent 
Ca2+-sensitivity increase (Figure 3E,F). These observations support the conclusion that 
an enhanced length-dependent increase in Ca2+-sensitivity is not directly related to 
a lower myofilament Ca2+-sensitivity induced by phosphorylation of Ser23/24. This 
is in line with our previous study where a low Ca2+-sensitivity at a sarcomere length 
of 2.2 µm was found in a patient with a cTnI mutation (R145W) after treatment 
with exogenous PKA together with a blunted length-dependent increase in 
Ca2+-sensitivity (31). Titin isoform composition did not differ between the samples 
used for exchange experiments and therefore most likely did not contribute to 
the changes observed in length-dependent myofilament activation in our exchange 
experiments. In summary, our data show that PKC-mediated phosphorylation at 
Thr143 sensitizes the myofilament to Ca2+ without affecting length-dependence of 
the sarcomeres independent of the initial value of Ca2+-sensitivity which is set by 
the phosphorylation status of other troponin sites and sarcomeric proteins.
Phosphorylation of both Ser23 and Ser24 increases length-dependent activation
Exchange with wild-type troponin complex did not alter the length-dependent increase 
in Ca2+-sensitivity in IDCM cardiomyocytes compared to (unexchanged) control 
cardiomyocytes, whereas it significantly reduced the length-dependent increase in 
Ca2+-sensitivity in donor cardiomyocytes compared to control cardiomyocytes. An 
important difference in cTn between donor and IDCM cardiomyocytes is that donor 
cardiomyocytes are highly bisphosphorylated at Ser23/24 (>50%), in contrast to 
end-stage IDCM (<10%) (10, 39). LDA has been reported to be regulated by PKA-
mediated phosphorylation of cTnI at these sites, although a reduction (14) and 
enhancement (16) of the length-dependent change in Ca2+-sensitivity has been 
reported upon PKA incubation. In addition, contrasting results have been reported 
when pseudo-phosphorylated cTnI at Ser23/24 was exchanged, showing a blunted 
(28) or enhanced (24) change in length-dependent Ca2+-sensitivity compared to 
Wt exchange. The reason for these differences is unclear, however, one possible 
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explanation for the blunted length-dependent increase in Ca2+-sensitivity that was 
found in previous studies may be that a different protocols was used (14, 28). In the 
present study we first performed all force measurements at a low sarcomere length 
of 1.8 μm and thereafter performed measurements at 2.2 μm. We did not stretch 
cardiomyocytes to a sarcomere length of 2.3 μm to prevent damage to the sarcomeres. 
However, Rao et al. (28) and Kajiwara et al. (14) first measured at a sarcomere length 
of 2.3 μm and thereafter at a shorter sarcomere length of 2.0 μm. 
In this study, we demonstrate using PKA-mediated phosphorylation and 
the exchange of pseudo-phosphorylated Ser23/24, that phosphorylation of Ser23/24 
enhances the length-dependent increase in Ca2+-sensitivity in human cardiomyocytes 
because: 1) Exchange with Wt complex removed endogenous phosphorylation at 
Ser23/24 in donor cardiomyocytes and blunted the length-dependent increase in 
Ca2+-sensitivity compared to baseline measurements in donor cells. 2) PKA treatment 
after Wt exchange restored the length-dependent increase in Ca2+-sensitivity in donor 
cardiomyocytes. 3) Exchange with pseudo-phosphorylated Ser23/24 preserved the 
length-dependent increase in Ca2+-sensitivity in donor cardiomyocytes and enhanced 
the length-dependent increase in Ca2+-sensitivity in IDCM cardiomyocytes to 
levels observed in donor. In support, it has been demonstrated that PKA-mediated 
phosphorylation shifts a shallow length-tension relationship to a steeper length-
tension relationship in rat cardiomyocytes (12). In accordance, exchange with pseudo-
phosphorylated Ser23/24 in rat cardiomyocytes was associated with a steepened 
length-tension relationship providing evidence that phosphorylation of cTnI-Ser23/24 
is essential to enhance length-dependent activation (11). In addition, we demonstrated 
using mono-and bisphosphorylated cTn complexes that phosphorylation at both 
Ser23 and Ser24 is required to enhance the length-dependent increase in myofilament 
Ca2+-sensitivity. 
Implication of cTnI phosphorylation at Thr143 and Ser23/24 and in health 
and disease 
In the present study, we provide evidence that phosphorylation of the PKC site Thr143 
does not affect LDA, while bisphosphorylation of the PKA-sites Ser23/24 enhances 
the length-dependent increase in Ca2+-sensitivity in human cardiomyocytes (Figure 
6). In the healthy heart, sympathetic activation during stress and exercise increases 
heart rate and stroke volume to meet the demands of the body. This is accomplished 
via activation of β1-adrenergic receptors, which leads to activation of PKA. PKA 
phosphorylation of Ca2+ handling proteins and myofilament proteins enhances 
cardiomyocyte contraction and relaxation (for reviews: (3, 35)). The enhanced length-
dependent increase in Ca2+-sensitivity induced upon PKA phosphorylation of cTnI-
Ser23/24 will increase the range of myofilament Ca2+-sensitivities at which the heart 
can operate within a heart cycle (between short and long sarcomere lengths) as is 
illustrated in figure 6 (Wt versus Wt+PKA, 23D/24D, 23D/24D+PKA which resembles 
activation of the heart upon β-adrenergic receptor stimulation). 
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In end-stage heart failure the Frank-Starling relationship has been reported to 
be depressed (13, 29). LDA is believed to be the cellular basis of the Frank-Starling 
mechanism (26, 34).  Schwinger et al. previously reported a reduced length-dependent 
increase in Ca2+-sensitivity in skinned fibers from terminally failing human myocardium 
(30). In our study, replacement of endogenous cTn with pseudo-bisphosphorylated 
cTnI at Ser23/24 enhanced the length-dependent increase in myofilament 
Ca2+-sensitivity in failing cardiomyocytes (Figure 4B). This suggests that the blunted 
length-dependent increase in myofilament Ca2+-sensitivity which has been reported 
previously (30) in end-stage heart failure may be at least partly caused by reduced 
bisphosphorylation at Ser23/24 of cTnI relative to explanted donor tissue, which has 
been reported in several studies (4, 18, 36, 42). 
Apart from reduced PKA-mediated cTnI phosphorylation, increased PKC-mediated 
phosphorylation of Thr143 may modify LDA of cardiac muscle in heart failure since 
this amino acid has been demonstrated to play a key role in the length-dependent 
increase in Ca2+-sensitivity (33). Pseudo-phosphorylation of the PKC site Thr143 did 
not affect LDA properties of human heart muscle, but did increase Ca2+-sensitivity 
as illustrated in Figure 6 (Wt versus 143D, Wt+PKA versus 143D+PKA). Based on 
our results, PKC-mediated phosphorylation of Thr143, which has been implicated 
in cardiac disease (25, 32, 43), does not restore the blunted length-dependent 
Ca2+-sensitivity increase in the failing heart, although it does increase Ca2+-sensitivity. 
The high Ca2+-sensitivity may aid to maintain cardiac output of the failing heart, 
however, it may also contribute to diastolic dysfunction.   
figure 6. Titin isoform composition in the IDCM and donor tissue. Titin isoform composition was 
analyzed in the IDCM and donor samples. A SYPRO-stained gel shows the compliant N2BA and 
stiff N2B titin isoform. On average, titin composition in the IDCM samples did not differ from 
the donor sample.
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“Perhaps they will consider, however, these few generalizations, which I know are true: 
Being right isn’t enough. What you say, however right, must be said in a currently 
acceptable language, must not violate too brutally current taste, and must somehow signal 
your membership in a respectable professional club. If you want to succeed you must play 
all of the game, not just the innings in laboratory or library.”
Paul Gross
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key Points
Diastolic dysfunction in heart failure patients is evident from stiffening of the passive 
properties of the ventricular wall.
Increased actomyosin interactions may significantly limit diastolic capacity, however 
direct evidence is absent.
From experiments at the cellular and whole organ level, in humans and rats, we show 
that actomyosin-related force development contributes significantly to high diastolic 
stiffness in environments where high ADP and increased diastolic [Ca2+] are present, 
such as the failing myocardium.
Our basal study provides a mechanical mechanism which may partly underlie 
diastolic dysfunction.
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abstraCt
Heart failure (HF) with diastolic dysfunction has been attributed to increased 
myocardial stiffness that limits proper filling of the ventricle. Altered cross-bridge 
interaction may significantly contribute to high diastolic stiffness, but this has not 
been shown thus far. Cross-bridge interactions are dependent on cytosolic [Ca2+] and 
the regeneration of ATP from ADP. Depletion of myocardial energy reserve is 
a hallmark of HF leading to ADP accumulation and disturbed Ca2+-handling. Here, 
we investigated if ADP elevation in concert with increased diastolic [Ca2+] promotes 
diastolic cross-bridge formation and force generation and thereby increases diastolic 
stiffness. ADP dose-dependently increased force production in the absence of 
Ca2+ in membrane-permeabilized cardiomyocytes from human hearts. Moreover, 
physiological levels of ADP increased actomyosin force generation in the presence of 
Ca2+ both in human and rat membrane-permeabilized cardiomyocytes. Diastolic stress 
measured at physiological lattice spacing and 37°C in the presence of pathological 
levels of ADP and diastolic [Ca2+] revealed a 76±1% contribution of cross-bridge 
interaction to total diastolic stress in rat membrane-permeabilized cardiomyocytes. 
Inhibition of creatine kinase (CK), which increases cytosolic ADP, in enzyme-isolated 
intact rat cardiomyocytes impaired diastolic re-lengthening associated with diastolic 
Ca2+-overload. In isolated Langendorff-perfused rat hearts, CK-inhibition increased 
ventricular stiffness only in the presence of diastolic [Ca2+]. We propose that elevations 
of intracellular ADP in specific types of cardiac disease, including those where 
myocardial energy reserve is limited, contribute to diastolic dysfunction by recruiting 
cross-bridges even at low Ca2+ and thereby increase myocardial stiffness.
abbreviations 
HF, Heart failure; CK, Creatine kinase; PCr, Phosphocreatine; LVEDP, Left ventricle 
end-diastolic pressure; IDCM, idiopathic dilated cardiomyopathy; Fpas, Passive 
tension; ADP-Ftotal, ADP-stimulated total tension; ADP-Fact, ADP-active tension; Ca
2+-
Ftotal, Ca
2+-stimulated total tension; Ca2+-Fact, Ca
2+-active tension; EC50, ADP- or Ca
2+-
sensitivity (at which half of Fact is reached); ktr, Ca
2+-ADP dependent rate of force 
redevelopment; PV, Pressure-volume; DNFB, 2,4-dinitro-1-fluorobenzene; SERCA, 
Sarcoplasmic reticulum Ca2+-ATPase
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introDuCtion
Heart failure (HF) is a clinical syndrome defined as the inability of the heart to 
sufficiently supply blood to organs and tissues.1 While contractile dysfunction is 
present in about half of the HF patient population almost all patients show impaired 
diastolic function.1,2 Pathophysiological mechanisms which have been related with 
diastolic dysfunction involve alterations of the passive properties of the ventricular 
wall, including high titin-based myofilament passive stiffness and collagen deposition, 
and slow rates of myocardial relaxation due to increased myofilament Ca2+-sensitivity 
and impaired Ca2+-reuptake.3-5 
Depletion of myocardial energy reserve represents a major cause of dysfunction 
of the failing human heart.6 In the healthy heart, creatine kinase (CK) catalyzes 
the transfer of phosphate from phosphocreatine (PCr) to ADP, thereby regenerating 
ATP, while preventing accumulation of cytosolic ADP.7 ATP is essential for cross-
bridge cycling. As little as 0.1 mM ATP is sufficient for cross-bridge detachment and 
sarcomere relaxation.8 The relatively high myocardial in vivo ATP levels in both healthy 
(8-11 mM) and various pathological conditions (7-10 mM)9-11 indicate that reductions 
in ATP levels are unlikely to directly impair relaxation of the heart muscle. Notably, HF 
patients with diastolic dysfunction12,13 and animal models of HF10,11,14,15 show that the 
reduced PCr/ATP ratio (a parameter of myocardial energy reserve measured in vivo) 
is mostly explained by a severe reduction in PCr (up to 50%) rather than changes of 
ATP (≤25%). Reducing PCr or experimental inhibition of CK activity is causally linked 
to the development of HF, as it elevates left ventricle end-diastolic pressure (LVEDP), 
reduces contractile reserve and increases mortality in rats.14-16 Activity of CK isoforms 
is decreased by 50% in animal models of HF.17-19 The consequence of low PCr and/or 
a reduced CK activity is that cytosolic levels of ADP will increase. Indeed, increases 
in [ADP] of >50% have been reported in several animal models of HF.9-11 Selectively 
increasing ADP levels without altering cytosolic ATP levels has been shown to increase 
LVEDP and limit myocardial relaxation in rats.9,16 These studies support the idea that 
limited myocardial energy reserve via elevations of ADP may represent a likely cause 
of diastolic dysfunction. However the exact pathophysiological mechanism has not 
been elucidated.
Intriguingly, ADP can stimulate tension generation, in the absence of Ca2+, in 
membrane-permeabilized rabbit skeletal muscle fibers20 and bovine cardiac muscle21,22. 
These findings indicate that ADP accumulation, as a consequence of disturbed 
myocardial energy reserve, may lead to incomplete relaxation during diastole caused 
by residual actomyosin interactions. However, in HF, the accumulation of ADP occurs 
concomitantly with disturbed Ca2+-handling.23-25 The effects of elevated intracellular 
ADP and high Ca2+ levels on human myofilament function that exist during the diastolic 
phase are currently not known. We hypothesize that in failing hearts enhanced cross-
bridge formation and force generation, as a result of increased levels of ADP and 
diastolic [Ca2+] increase diastolic stiffness. 
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Ethical Approval
Human samples were obtained after written informed consent and with approval of 
St Vincent’s Hospital (#H03/118) and from the Human Research Ethics Committee of 
the University of Sydney (#159401). The investigation conforms with the principles 
outlined in the Declaration of Helsinki (1997). All animal experiments were performed 
with approval of the Animal Care and Use Committee of the VU University Medical 
Center (Amsterdam) and UK Home Office and local ethical review.
Myocardial human samples
Human left ventricular (LV) tissue was obtained during heart transplantion surgey from 
end-stage failing patients with idiopathic dilated cardiomyopathy (IDCM). Tissue was 
immediately frozen and stored in liquid nitrogen.
Isometric force measurements in membrane-permeabilized single human 
cardiomyocytes
Small human cardiac tissue samples (N=3) were thawed in relaxing solution and 
cardiomyocytes were mechanically isolated by tissue disruption as described 
previously.26 Cardiomyocytes were chemically permeabilized by incubation for 5 
minutes in relaxing solution containing 0.5% (v/v) Triton-X100 and glued between 
a force transducer and a piezoelectric motor. Isometric force measurements were 
subsequently performed on single cardiomyocytes at a sarcomere length of 2.2 μm. 
Absolute force values were normalized to cardiomyocyte cross-sectional area and 
expressed as developed tension (in kN/m2). Passive tension (Fpas) was determined by 
allowing the cardiomyocyte to shorten by 30% of its length in relaxing solution. ADP-
stimulated total tension was determined by activating the cardiomyocyte at 10 mM 
ADP (ADP-Ftotal, Figure 1A). Similarly, Ca
2+-stimulated total tension was determined 
by activating the cardiomyocyte at 32 μM Ca2+ (Ca2+-Ftotal; Figure 1A). Active tension 
(Ca2+-Fact or ADP-Fact) was calculated as Fact=Ftotal-Fpas. In addition, the rate of force 
redevelopment (ktr) was determined using a slack-restretch test as follows: after steady 
state force was reached, cardiomyocytes were allowed to shorten to 70% of their 
original length within 1 ms and then re-stretched to the original length after 30 ms. 
A single exponential was fitted to determine the rate constant of force redevelopment: 
ktr was determined at maximal and submaximal [Ca2+] in the presence of ADP to 
assess cross-bridge cycling kinetics.
Experimental solutions
The composition of all solutions was calculated based on a computer program similar 
to that described previously.27 The pH of all solutions was adjusted to 7.1 at 15ºC 
with KOH and ionic strength was adjusted to 180 mM with KCl. The relaxing solution 
contained 2 mM free Mg2+, 1 mM MgATP, 20 mM EGTA, 10 mM BES and 14.5 mM PCr 
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(P7936, Sigma). Several activating solutions were prepared: 1) Ca2+-activating solution 
consisted of 2 mM free Mg2+, 1 mM MgATP, 20 mM EGTA, 10 mM BES and 32 μM 
free Ca2+. Ca2+-activating solutions with lower free [Ca2+] were obtained by mixing of 
the Ca2+-activating and relaxing solutions and assuming an apparent stability constant 
of the Ca2+ -EGTA complex of 106.35; 2) ADP-activating solutions (in the absence of 
free Ca2+) contained 2 mM free Mg2+, 1 mM MgATP, 20 mM EGTA, 10 mM BES and 
MgADP in increasing concentrations from 1 to 10 mM; 3) Ca2+- activating solutions 
in the presence of ADP consisted of 2 mM free Mg2+, 1 mM MgATP, 20 mM EGTA, 
10 mM BES, MgADP concentrations from 0.02 to 6 mM and free Ca2+ from 1 to 32 
μM. PCr was omitted from the activating solutions to preserve the MgADP/MgATP 
ratio. All force measurements were performed at 15ºC. [ATP] was maintained constant 
at 1 mM to avoid rigor cross-bridge formation (reported to occur when [ATP] falls 
below 0.1 mM8) and consecutively increased the [ADP] from 1 to 10 mM. We used 
a maximum [ADP] of 10 mM, since ADP-stimulated tension was maximal at 10 mM 
ADP with 1 mM ATP in bovine cardiac muscle21,22.
Data analysis of isometric force measurements
Ca2+- and/or ADP-force relations were determined by a non-linear fit procedure using 
a modified Hill equation using KaleidaGraph version 3.6 (Synergy Software, Reading, 
PA) as follows accordingly:
P (Ca2+) / P0 = [Ca
2+]nH / (K nH + [Ca2+]nH)
P (ADP) / P0 = [ADP]
nH / (K nH + [ADP]nH)
P (Ca2+-ADP) / P0 = [Ca
2+-ADP]nH / (K nH + [Ca2+-ADP]nH)
where P is steady-state force. P0 denotes the steady isometric force at either saturating 
[Ca2+], high [ADP] or both saturating [Ca2+] and high [ADP], nH describes the steepness 
of the relationship, and K represents the [Ca2+] and/or [ADP] at which force is 
half-maximal (0.5 x P0). Myofilament Ca
2+- and/or ADP-sensitivity is denoted as EC50.
Isolation of intact rat ventricular cardiomyocytes
Intact rat cardiomyocytes were isolated using collagenase digestion of hearts as 
described previously.28 Briefly, adult wild-type male Wistar rats (N=7) weighing ~300 
grams were euthanized with isoflurane and hearts were quickly removed and rinsed 
in cold isolation-Tyrode solution (composition: 130 mM NaCl, 5.4 mM KCl, 3 mM 
NaPyruvate, 25 mM HEPES, 0.5 mM MgCl2, 0.33 mM NaH2PO4, 22 mM glucose) 
containing 0.2 mM EGTA (Tyrode-EGTA) and pH 7.4. The heart was then cannulated 
via the aorta to the Langendorff apparatus and perfused for 2 min with Tyrode-EGTA 
at 37ºC. Thereafter, the heart was perfused with enzyme-Tyrode solution consisting of 
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Tyrode solution, 1.2 mg/ml collagenase (Type II, 265 U/mg; Worthington Biochemical, 
NJ, USA) and 50 μM CaCl2 for a period of 7 min. The right ventricle and atria were 
removed, and the LV was cut into small pieces and triturated with a plastic Pasteur 
pipette for 3 min in stopping buffer solution 1 (SB-1; composition: Tyrode solution, 0.6 
mg/ml collagenase, 100 μM CaCl2 and 10 mg/ml bovine serum albumin (BSA)). The cell 
suspension was filtered through a 300 µm nylon mesh filter into a 50 ml Falcon tube 
and centrifuged for 1 min at 27x g (20-23ºC). The pellet containing cardiomyocytes 
was resuspended in SB solution 2 (SB-2; composition: Tyrode solution, 250 μM CaCl2 
and 10 mg/ml BSA) and incubated for 10 min in a water bath at 37ºC allowing cells 
to settle. The supernatant was discarded and cardiomyocytes were resuspended in 
SB solution 3 (SB-3; containing Tyrode solution, 500 μM CaCl2 and 10 mg/ml BSA), 
incubated for 10 min at 37ºC and subsequently resuspended in experimental Tyrode 
(used for measurements of intact cardiomyocytes), consisting of 1.2 mM CaCl2, 137 
mM NaCl, 5.4 mM KCl, 0.33 mM NaH2PO4, 0.57 mM MgCl2, 5 mM HEPES and 5.6 
mM glucose. Cardiomyocytes were used within the first 6h of isolation.
Isometric force measurements in membrane-permeabilized single rat 
cardiomyocytes
Single cardiomyocytes isolated by collagenase digestion from adult wild-type male 
Wistar rats (N=4) were used. Cardiomyocytes were chemically permeabilized with 0.5% 
(v/v) Triton-X100 as indicated above for human and isometric force measurements 
were performed at sarcomere lengths of 2.2 μm. Experimental temperature and 
solution conditions were similar as previously described for human samples. Ca2+-force 
relations without and with ADP, and the rate of cross-bridge cycling was determined 
as previously described for human samples.
Diastolic stress measurements in membrane-permeabilized rat cardiomyocytes
Single cardiomyocytes isolated by collagenase digestion from adult wild-type male 
Wistar rats (N=5) were used. Cardiomyocytes were chemically permeabilized with 
0.5% (v/v) Triton-X100 as indicated above and isometric force measurements were 
performed in single cardiomyocytes stretched from 1.8 to 2.4 μm sarcomere lengths. 
Experiments were performed at 15ºC to replicate conditions currently employed 
to study diastolic stiffness/stress and at a higher, more physiological temperature 
of 37ºC. Since membrane-permeabilization causes myofilament lattice expansion, 
experiments were also performed with the osmotic agent dextran T500 (4%, w/v) that 
compresses the myofilament lattice to physiological levels.29 Additionally, 30 μM of 
the cross-bridge inhibitor blebbistatin was used to assess the contribution of cross-
bridge formation to passive stress. Force generation was normalized to cardiomyocyte 
cross-sectional area and expressed as diastolic stress (in kN/m2). The composition and 
characterization of all 4 conditions is displayed in Table 1. To mimic conditions currently 
in use to study diastolic stiffness/stress, experiments were performed at 15ºC in 
the 1) absence and 2) presence of blebbistatin. To approach in vivo disease conditions 
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table 1. Solution’s composition of the 4 conditions tested.
Condition
[Ca2+] 
(μm) Dextran 
blebbistatin 
(μm)
PCr 
(mm)
mgatP 
(mm)
mgaDP 
(μm)
Unphysiological
15ºC <0.001 - - 14.5 10 -
15ºC+Blebbistatin <0.001 - 30 14.5 10 -
Physiological
37ºC 0.15 4% - - 10 100
37ºC+Blebbistatin 0.15 4% 30 - 10 100
PCr, Phosphocreatine; pH was adjusted to 7.1 at 15ºC and at 37ºC with KOH and ionic strength was adjusted to 
180 mM with KCl; 2 mM free Mg2+, 10 mM MgATP, 7 mM EGTA and 100 mM BES were present in all solutions; 
Experiments performed at 15ºC were used to mimic conditions currently employed to study diastolic stiffness, 
while experiments at 37ºC better recapitulate the in vivo diseased heart. 
measurements were performed at 37ºC and with Dextran T500 in the 3) absence 
and 4) presence of blebbistatin. Because blebbistatin is photosensitive, experiments 
were performed in the dark. To ensure whether total absolute tension values 
were absent of protocol artefacts due to substantial differences in cross-sectional 
area that could artificially increase or decrease diastolic stress, all cross-sectional 
measurements were done in solutions without dextran. Cross-sectional area did 
not statistically differ between conditions 1 to 4 (342.8±18, 370.1±39, 354±22 and 
350±36 kN/m2/μm, respectively).
Cardiomyocyte shortening and Ca2+-transient of intact rat cardiomyocytes
Unloaded shortening and Ca2+-transients of intact rat cardiomyocytes (n=15 to 20) 
were monitored following field stimulation (1Hz, 4 ms, 7V), and sarcomere shortening 
as well as relaxation kinetics were visualized using a video-based sarcomere length (SL) 
detection system (IonOptix corporation). Wild-type rat cardiomyocytes were incubated 
in Tyrode solution containing 1 µM Fura-2-AM for 15 min and rinsed for a period of 
10 min in Tyrode. Cardiomyocytes were placed into a temperature-controlled (37ºC) 
chamber with platinum electrodes to electrically stimulate cells. Single cardiomyocytes 
were randomly selected (without spontaneous contraction) and continuously perfused 
with Tyrode buffer. After 3-5 min field stimulation sarcomere shortening as well as 
relaxation kinetics and Ca2+-transient were monitored. Cardiomyocytes loaded with 
Fura-2-AM were excited at 340 and 380 nm with emission monitored at 510 nm. 
The F340/F380 ratio was used as a measure of cytosolic [Ca2+]. From the monitored 
Ca2+-transient, Ca2+-release and -reuptake velocity, the time to reach peak systolic 
Ca2+ and the time constant of Ca2+ decline (tau) were determined. 
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Experimental protocol for unloaded rat cardiomyocyte measurements
To test the hypothesis that ADP accumulation impairs myofilament function in 
cardiomyocytes with intact membrane, a protocol was established using a low dose of 
an irreversible inhibitor of CK, iodoacetamide. Specifically, 5 mM fresh iodoacetamide 
(I6125, Sigma) was dissolved in Tyrode buffer and perfused (at 1 ml/min) for 3 min, 
delivering a total dose of 15 μmoles/3 ml. This drug has well-characterized effects 
on the ATP-regeneration system, such that it significantly increases [ADP] without 
altering ATP, PCr, inorganic phosphate and pH levels in isolated perfused hearts.9,16 
ADP is estimated to be lower than 73 μM at this dose range.16
Two protocols were used to test the effects of CK-inhibition (Fig. 5). Cardiomyocytes 
were paced at 1Hz for 3-5 min with continuous perfusion with Tyrode solution (at 1 ml/
min and 36±0.1ºC) to establish a steady state. Thereafter, a number of cells was either 
perfused for 3 min with a total dose of 15 μmoles/3 ml of iodoacetamide (Fig. 5A) or 
continuously perfused with Tyrode solution (Fig. 5C). Following 3 min treatment with 
iodoacetamide, perfusion with Tyrode solution was restored. Perfusion was limited 
to 3 min/ml with 5 mM of iodoacetamide, because the Ca2+-Fura signal deteriorated 
by longer exposure and/or greater concentration of drug. Control experiments to 
check for Ca2+-fluorescence demonstrated that iodoacetamide does not quench Ca2+ 
(data not shown). Measurements were averaged and analyzed in three phases as 
detailed in the legend of Figure 5. The control protocol was the same as the treatment 
protocol except that cells were continuously perfused with Tyrode solution.
Isolated perfused Langendorff hearts: Diastolic pressure-volume relationships
Adult wild-type male Wistar rats were euthanized by stunning and cervical dislocation 
and hearts quickly removed and rinsed in cold Krebs-Henseleit (KH) solution. Diastolic 
pressure-volume relationships were measured in hearts connected to a Langendorff 
apparatus and perfused with Ca2+-free KH solution gassed with 95% O2-5% CO2 
at 37°C and pH 7.4. An inflatable balloon (filled with pre-boiled, degassed Milli-Q 
water) was placed in the left ventricle and the volume adjusted with a syringe pump 
dispensing at 400 μL/min. Balloon volume was inferred from dispensing rate and 
pressure was recorded continuously via a side port connected to a pressure transducer. 
Balloon volume was increased in cycles to elicit a series of pressures from 10-30 
mmHg allowing the balloon to conform to the LV cavity surface; the final cycle to 30 
mmHg was repeated and all diastolic pressure-volume data were obtained from it.30
The experimental procedures were as follows: diastolic pressure-volume 
relationship of Langendorff-perfused rat hearts were recorded after 60 min 
perfusion with Ca2+-free KH with (N=5 hearts) or without (N=6 hearts) 20 μM of 
the cell-permeant Ca2+-chelator BAPTA-AM (Cambridge Bioscience, UK) dissolved 
in DMSO (final concentration <0.1%). Perfusion solution was then switched to 
a Ca2+-free KH containing 20 μM 2,4-dinitro-1-fluorobenzene (DNFB; 42085, Sigma) 
dissolved in ethanol (final concentration <0.1%), for 30 min then PV measurements 
were repeated. DNFB is an irreversible inhibitor of CK which decreases the ATP/
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ADP ratio.31 Because iodoacetamide inhibits enzymes of the glycolytic reaction 
(even though well-oxygenated hearts have normal glycolysis after iodoacetamide-
treatment16), whereas DNFB does not32, we wanted to ensure complete preservation 
of the glycolytic flux following long chemical inhibition of a multicellular system such 
as the whole heart. DNFB has been shown to produce similar effects in isolated 
cardiomyocytes as iodoacetamide.33
Creatine Kinase activity
CK activity levels were assessed using a commercial colorimetric assay kit (ab155901, 
Abcam) that detects kinase activity as low as 1 mU/ml (nmol/min/ml). Activity was 
assessed in freshly isolated cell suspensions from rat cardiomyocytes (N=3) as follows: 
from each single animal, two suspensions of isolated cells were treated (i.e. one 
treated with buffer (control) and another with 5 mM iodoacetamide) for 5 minutes, 
centrifuged for 30 seconds at 27x g (37ºC) and supernatant discarded. The pellet 
containing cardiomyocytes was immediately frozen in liquid nitrogen and freeze-dried 
overnight. Assay was performed as specified by manufacturer supplied information. 
Similarly, CK activity was evaluated in fresh rat cells from 3 animals without and in 
the presence of 20 μM of DNFB.
Statistical analysis
Data analysis and statistics were performed using Prism version 6.0 (Graphpad 
Software, Inc., La Jolla, CA) and SAS/STAT® 9.2 (Statistical Analysis System Software, 
Institute Inc., Cary, NC, USA). 
Data are presented as mean ± SEM of all single cardiomyocytes per patient/animal 
or group. All data was tested for normality using the Shapiro-Wilk Test. Normality was 
assumed when p>0.05 and the variances were equal. Paired- and/or unpaired-sample 
Student’s t-Test was conducted when one variable was tested between 2 groups of 
data. Single classification analysis of variance (ANOVA) was performed when one 
variable was tested in more than 2 groups. When a significant difference was found in 
repeated measures 1-way ANOVA, Bonferroni post hoc testing was used to determine 
the location of significant differences. When more than one variable was tested in 
more than 2 groups a 2-way ANOVA was conducted followed by a Bonferroni post 
hoc test if significant differences were found. A linear mixed model was performed 
to gain insights into the individual trajectories of repeated measurements of each 
data group (e.g. intercepts and slopes) compared with controls. This model takes into 
account the repeated measurements within subjects. Each performed test is specified 
in Tables or Figure legends. The level of significance was set at p<0.05.
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results
ADP stimulates myofilament contraction in the absence of Ca2+
To assess whether ADP alone can induce contraction in human cardiac muscle, 
force produced by single membrane-permeabilized cardiomyocytes from human 
failing hearts was measured at increasing [ADP]. ADP caused force production in 
the absence of Ca2+ with maximal tension (ADP-Fact) achieved with 10 mM ADP and 
tension reaching 80±3% of maximal Ca2+-developed tension (Fig. 1A). Comparable 
to Ca2+, force-ADP relation curves show the common sigmoidal pattern, indicating 
cooperative activation (Fig. 1B). ADP-induced tension at 1 mM ADP amounted to 
14±1% and nearly saturated at 8 mM ADP (94±3%). Half-maximal ADP-Fact (EC50) was 
3.80±0.15 mM ADP (Fig. 1B).
figure 1. ADP causes force production in human left ventricular membrane-permeabilized 
cardiomyocytes. A, Representative tension recordings of a single cardiomyocyte isolated from 
a end-stage failing human heart at 2.2 μm sarcomere length during maximal Ca2+ (32 μM) and 
ADP-activation (10 mM) at 15ºC and 1 mM ATP. B, Normalized force-ADP relationship of human 
cardiomyocytes. 9 to 11 cardiomyocytes from 3 failing human hearts were used.
ADP increases myofilament Ca2+-sensitivity
Myocardial ADP levels in animal models are reported in the range of 10-50 μM 
in health and of 40-140 μM in disease9-11, indicative that in vivo levels of ADP are 
incapable of myocardial activation since in vitro mM levels of ADP are required for 
force generation (Fig. 1B). Cardiomyocytes in vivo are activated by the cytosolic Ca2+ 
transient that varies from ~0.15 μM during diastole to a peak of ~1.6 μM in systole.34 
We therefore investigated if elevation of ADP in concert with physiological levels of 
Ca2+ increases force generation in human membrane-permeabilized cardiomyocytes 
(Fig. 2A). Physiological levels of ADP were chosen in the range of 20 and 100 μM. ADP 
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figure 2. Ca2+-sensitivity and cross-bridge stiffness increases in the presence of ADP in human left 
ventricular membrane-permeabilized cardiomyocytes. A, Ca2+-force relations were constructed 
without and with [ADP] at 15ºC and 1 mM ATP. Light blue panel depicts the free [Ca2+] range in 
in vivo cardiomyocytes (i.e. [~0.15-1.6 μM]). Data was compared using 1-way ANOVA followed by 
Bonferroni post hoc test. All data show significant differences compared with ‘control (no [ADP])’. 
B, Normalization of ktr as a function of Ca2+-activated isometric force. The ktr-force relationship 
shifted to the right and downwards with [ADP] (R2=0.93, R2=0.88, R2=0.76, R2=0.65, R2=0.55 and 
R2=0.81, from 0-6 mM ADP respectively). A linear mixed model assuming force as a continuous 
variable indicates significant differences for the interactions of 2 (p=0.020) and 6 mM (p<0.0001) 
ADP compared with ‘control (no [ADP])’. C, Residual force recording tracings. Top: Residual force 
recordings after a slack-restretch test at high Ca2+ (32 μM) without or with increasing [ADP]. Recording 
of 2 mM ADP is omitted from the graph due to overlap with 6 mM ADP recording. Bottom: Length 
changes of piezoelectric motor by 30% of cardiomyocyte’s original length is depicted. Residual 
force was calculated from the initial force recovery reached after the length change (dashed lines) 
and normalized to each total steady-state force reached before length change. Measurements are 
normalized to each corresponding total force. D, Significant increases in residual force enhancement 
164
shifted the Ca2+-force relation substantially to the left, indicative of increased Ca2+-
sensitization of myofilaments (Fig. 2A). Indeed, as little as 20 μM ADP significantly 
increased Ca2+-Fact generation, evident from the elevated Ca
2+-sensitivity compared 
with the Ca2+-force relation without ADP (EC50=1.69±0.10 and 1.95±0.09 μM Ca
2+, 
respectively). Our data suggests that conditions that promote elevation of myocardial 
ADP result in cross-bridge recruitment even at low Ca2+, supporting delayed 
muscle relaxation.
ADP slows cross-bridge detachment in the presence of Ca2+
The rate of myofilament contraction and relaxation is regulated by the rate of 
attachment and detachment of force producing cross-bridges, i.e. cross-bridge 
cycling. Therefore, the rate of force redevelopment (ktr, a measure of the rate of 
cross-bridge cycling) in the presence of Ca2+ and ADP was examined, and values were 
plotted against the corresponding isometric force (Fig. 2B). When Ca2+-activated 
isometric force rises with increasing [ADP] the ktr relationships shifted substantially 
to the right and downwards with significant differences found for relationships 
with supra-physiological ADP levels present (≥2 mM ADP). This suggests that force 
increases at the expense of slowing cross-bridge cycling (Fig. 2B), likely resulting 
from a population of strongly-bound cross-bridges with slow detachment kinetics. 
This is consistent with significant increases in sarcomere stiffness (i.e. high residual 
force recovery) at [ADP] ≥20 μM, indicative for reduced actomyosin detachment and 
enhanced strain/force per each individual cross-bridge (Figs. 2C and 2D). 
To test whether the latter changes in myofilament Ca2+-sensitivity, cross-bridge 
cycling and residual force recovery (Fig. 2) are species-independent, similar 
experiments were performed in rat membrane-permeabilized cardiomyocytes in 
the presence of 100 μM ADP. Rat membrane-permeabilized cardiomyocytes 
present similar dependence to ADP as humans, such as increased myofilament 
Ca2+-sensitization, slower rates of cross-bridge cycling and high residual 
force recovery (Fig. 3). 
Together these data indicate that in membrane-permeabilized cardiomyocytes 
the combined presence of Ca2+ and physiological ADP levels increases cross-bridge 
stiffness, even at low Ca2+ levels, which could contribute to high sarcomere stiffness 
and reduce LV compliance during the diastolic phase.
at high Ca2+ without or with various [ADP] are observed after a slack-restretch test, indicative for 
increased sarcomere stiffness. Values are normalized to each corresponding total relative force 
reached before the slack-restretch procedure. Data was compared using 1-way ANOVA followed 
by Bonferroni post hoc test. *p<0.05 versus ‘control (no [ADP])’. 9 to 11 cardiomyocytes from 
3 end-stage human failing hearts were used for each ADP concentration.
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figure 3. Ca2+-sensitivity and cross-bridge stiffness increases in the presence of ADP in left ventricular 
rat membrane-permeabilized cardiomyocytes. A, Ca2+-force relations were constructed without and 
with 0.1 mM ADP at sarcomere lengths of 2.2 μm and at 15ºC and 1 mM ATP. Data was compared 
using paired t-Test. Ca2+-sensitivity of force significantly increases in the presence of 0.1 mM ADP 
compared with ‘control (no [ADP])’. B, Normalization of ktr as a function of Ca2+-activated isometric 
force. The ktr-force relationship shifted to the right and downwards with 0.1 mM ADP (R2=0.79 and 
R2=0.95, ‘control (no [ADP])’ and 0.1 mM ADP, respectively). C, Significant increases in residual force 
enhancement at high Ca2+ with 0.1 mM ADP are observed after a slack-restretch test compared 
with ‘control (no [ADP])’, indicative for increased sarcomere stiffness. Values are normalized to each 
corresponding total relative force reached before the slack-restretch procedure. Data was compared 
using paired t-Test. *p<0.05 versus ‘control (no [ADP])’. 12 cardiomyocytes from 4 adult wild-type 
male Wistar rat hearts were used. 
Re-evaluation of the influence of cross-bridges on in vitro diastolic stress 
with in vivo conditions
In the last decade, numerous in vitro studies assessed the diastolic properties of 
human HF myocardium and no evidence was found for the possible contribution 
of cross-bridges to the high diastolic stiffness observed in disease.3,5 Nevertheless, 
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figure 4. Re-evaluation of the influence of cross-bridges on in vitro diastolic stress with in vivo 
conditions. A, Representative force recording example of a left ventricular single rat cardiomyocyte 
moved from a non-activating solution at 37ºC with 14.5 mM PCr and <0.001 μM Ca2+ to an activating 
solution at 37ºC in the presence of diastolic Ca2+ (0.15 μM), dextran (4%), 100 μM ADP and 10 
mM ATP. Upper tracing: solutions used in the protocol are depicted. Middle: Length changes of 
piezoelectric motor is depicted. For measurement of passive force, a slack-restretch procedure of 
30% of cardiomyocyte’s original length is performed. Bottom: Force recording after a slack-restretch 
test is depicted. Diastolic tension value was taken from the 30% slack procedure over a period 
of 10 seconds (period from 30 to 40 seconds). B, Tension-sarcomere length relations are depicted 
from left ventricular rat membrane-permeabilized cardiomyocytes. Rat cardiomyocytes were 
stretched from 1.8 to 2.4 μm and diastolic stress was measured in the following conditions: 37ºC 
(Dextran (4%), diastolic Ca2+ (0.15 μM) and 100 μM ADP) in the absence (dark exponential curve) and 
presence of Blebbistatin (37ºC + Blebbistatin; dashed dark exponential curve); and 15ºC (with 14.5 
mM PCr and <0.001 μM Ca2+) in the absence (gray exponential curve) and presence of Blebbistatin 
(15ºC + Blebbistatin; dashed gray exponential curve). All solutions contained 10 mM ATP. Comparison 
of 37ºC with 37ºC+Blebbistatin shows that the cross-bridge contribution accounts for 76±1% of total 
diastolic stress averaged over all sarcomere lengths. Data was compared using unpaired t-Test within 
independent groups measured at similar temperature for each individual sarcomere length. *p<0.05 
versus ‘in the presence of Blebbistatin’. 12 to 16 cardiomyocytes from 5 adult wild-type male Wistar 
rat hearts were used.
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the majority of the studies thus far have been based on membrane-permeabilized 
myocytes, where the relatively low experimental temperature (15ºC) in concert with 
sarcolemma digestion that causes lattice expansion and removes important differences 
in intracellular milieu (such as increased ADP levels), may largely underestimate 
cross-bridge interactions. To overcome some of these concerns we adjusted 
the protocol previously reported by King et al.28, where diastolic stress was 
measured in rat membrane-permeabilized cardiomyocytes at 37ºC in the presence of 
the osmotic agent dextran to compress myofilament lattice restoring it to physiological 
conditions. By measuring cardiomyocyte diastolic stress, in the presence of diastolic 
[Ca2+] and [ADP] known to occur in disease with and without the cross-bridge inhibitor 
blebbistatin (30 μM), we were able to assess the contribution of cross-bridge formation 
to diastolic myocardial stress/stiffness. Please note that for the initial experiments 
in membrane-permeabilized cardiomyocytes from human (Fig. 2) and rat (Fig. 3) 
the temperature was set at 15ºC. This relatively low temperature was used to avoid 
preparation deterioration and maintain the stability of the muscle preparation during 
several long-lasting series of activation. This was shown not to be problematic for 
the current experiments at 37ºC as a result of lower levels of activation in concert with 
a relatively brief protocol.
Four protocols were performed in which rat membrane-permeabilized 
cardiomyocytes were stretched from 1.8 to 2.4 μm sarcomere length. Conditions 
used are presented in Table 1. A representative recording is presented in Figure 4A 
showing diastolic force generation measured at 37ºC. Note that force is generated 
at 37ºC, which is not seen in the other three conditions. Comparison of 15ºC and 
15ºC+Blebbistatin confirmed the previous observations that cross-bridge contribution 
to diastolic stiffness is nearly absent at non-physiological conditions, with a statistical 
difference found at a sarcomere length of 2.4 μm (Fig. 4B). However, comparison of 
37ºC with 37ºC+Blebbistatin shows that the cross-bridge contribution is significantly 
higher, accounting for 76±1% of total diastolic stress averaged over all sarcomere 
lengths (Fig. 4B). Together these data support that in intracellular environments where 
high ADP and increased diastolic [Ca2+] are present, such as in the failing myocardium, 
the actomyosin contribution to high diastolic stiffness may be substantially higher than 
previously considered and potentially represent a pathophysiological mechanism of 
HF with impaired diastolic function.
CK-inhibited rat cardiomyocytes show impaired relaxation and augmented contractility
To investigate the impact of inactivated CK activity and the consequent increase in 
cytosolic ADP levels, as to replicate the cytosolic environment of HF myocardium, intact 
rat cardiomyocytes were perfused with the irreversible CK antagonist iodoacetamide 
(15 μmoles/3 ml) during pacing at 1Hz and 37ºC. CK activity was inhibited by 
38±7%. Contraction and Ca2+-transient were simultaneously recorded in control and 
iodoacetamide-treated intact rat cardiomyocytes (Fig. 5). No significant alterations 
were observed between controls and iodoacetamide group at baseline (phase I) 
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figure 5. Creatine kinase-inhibited cells show decreased diastolic length but augmented contractility 
in intact left ventricular rat cardiomyocytes. Example of sarcomere length and Ca2+-transient recordings 
of left ventricular single unloaded intact rat cardiomyocytes with iodoacetamide treatment at 1Hz 
pacing. A, Iodoacetamide treatment. Phase (I). Baseline. Measurements just prior to iodoacetamide 
administration (cardiomyocytes paced for 3-5 minutes). Iodoacetamide (start-stop). Perfusion 
(at 1 ml/min) was performed for 3 min with 5 mM iodoacetamide resulting in a total dose of 15 
μmoles/3 ml. Phase (II). Initial perfusion with iodoacetamide. Cardiomyocytes were allowed 1 min 
to adjust to iodoacetamide perfusion and measurements were recorded for 4 min. Phase (III). Post-
iodoacetamide perfusion. Measurements were carried out ranging from 3-10 min  depending on 
cardiomyocytes survival. Phase III was typified by diastolic [Ca2+] increases as well as systolic and 
diastolic sarcomere length alterations. Note: example of cell death in the last 100 seconds of recording. 
B, Alterations of diastolic and systolic sarcomere length from phase I (baseline), throughout phase II 
(initial perfusion with iodoacetamide) to phase III (after iodoacetamide perfusion), in iodoacetamide 
(IA)-treated cells. Relative sarcomere length changes compared with phase I of each corresponding 
group. *versus Phase I. C, Control recording protocol (no treatment) tracing. Similar to (A) except, 
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(Table 2 and Figs. 5A-5G). Control cardiomyocytes remained stable throughout the 
entire protocol for all parameters analyzed, i.e. no significant alterations were observed, 
(compared from phase I to phase III) with the exception for decreases of systolic and 
amplitude Ca2+-signal, likely resulting from deterioration of the fluorescence signal 
over time (Table 2). 
From phase I (baseline) to phase II (initial perfusion with iodoacetamide), diastolic 
and systolic sarcomere length were significantly reduced by 14±2% and 38±6%, 
respectively (Fig. 5B and Table 2), and sarcomere shortening increased by 24±5% 
(Fig. 5E and Table 2). In addition, cardiomyocyte shortening time was significantly 
increased without a significant change in shortening velocity (Table 2). The contractile 
changes were not mediated by changes in Ca2+-transients, since there were no 
statistical alterations in diastolic Ca2+ (Fig. 5F) and the Ca2+ -relaxation time constant 
(tau) (Fig. 5G) from phase I to II.
Between phases II and III (after iodoacetamide perfusion) diastolic and systolic 
sarcomere lengths decreased significantly compared with baseline and phase II 
(Fig. 5B and Table 2). This was accompanied by 35±8% enhancement of sarcomere 
shortening compared with baseline (Fig. 5E). These latter contractile changes are 
associated with disturbed Ca2+-handling, which includes significant increases of 
diastolic Ca2+ (20±6%, Fig. 5F) with prolongation of Ca2+-reuptake by 50±20% (tau) 
(Fig. 5G) compared with baseline (Table 2).
Together these data indicate that inhibiting CK, which elevates cytosolic ADP, 
in intact cardiomyocytes leads to impaired diastolic relaxation (i.e. limited diastolic 
re-lengthening). Initially, these alterations are independent of changes in the Ca2+ 
transient, but prolonged CK-inhibition was associated with diastolic Ca2+-overload 
and slowing of Ca2+ -reuptake.
CK-inactivation decreases ventricular compliance in the presence of diastolic Ca2+ 
Tian et al.9,16 have previously shown that myocardial ADP elevation increases LVEDP 
and impairs myocardial relaxation in isolated rat hearts. However, the authors argued 
against a role of Ca2+ and solely attributed the latter effects to high [ADP] 16. To 
clarify whether ADP is the sole responsible factor for the reported increase in LVEDP, 
instead of iodoacetamide treatment, cardiomyocytes were perfused with buffer solution. Note: during 
both protocols cardiomyocytes were continuously perfused with buffer solution (at 1 ml/min) with 
the exception being the 3 minute period of iodoacetamide perfusion in (A). D, Alterations of diastolic 
and systolic sarcomere length from phase I (baseline), throughout phase II (similar perfusion time 
as phase II in (B)) to phase III (similar perfusion time as phase III in (B)), in control cells. Relative 
sarcomere length changes compared with phase I of each corresponding group. E, % increase change 
of sarcomere shortening. F, % increase of diastolic Ca2+-level. G, % delay of the Ca2+ -relaxation time 
constant, tau, indicative of Ca2+-reuptake. Figures 5E, 5F and 5G are all % changes relative to phase 
I in IA-treated cells. Corresponding data are presented in Table 2. *p<0.05 versus Phase I. Data was 
compared using 1-way ANOVA followed by Bonferroni post hoc test. 7 heart samples from adult 
wild-type male Wistar rats were used; 17 to 18 (Ctrl-group) and 17 to 20 (IA-group) cardiomyocytes 
were analysed.
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ventricular compliance was measured in isolated Langendorff-perfused rat hearts, 
in which CK was inactivated, in the absence and presence of the intracellular Ca2+-
chelator BAPTA-AM. Diastolic pressure-volume (PV) relationships were performed 
in hearts arrested in Ca2+-free buffer following inhibition of CK with 2,4-dinitro-1-
fluorobenzene (DNFB) and with BAPTA-AM (Fig. 6A). DNFB (20 μM) inhibited CK 
activity reaction by 42±8%, i.e. about equal to iodoacetamide effect. Diastolic PV 
slope increased in hearts perfused with DNFB in Ca2+-free solution (Fig. 6B), indicative 
of reduced LV compliance. In other hearts, addition of BAPTA-AM (20μM) to Ca2+-free 
solution (-Ca2++BATPA) did not change diastolic PV slope compared to -Ca2+ solution 
(Fig. 6B), but prevented the increase in diastolic PV slope following DNFB (Fig. 6B). 
To understand whether Ca2+ alone could account for the increased PV slope, 200 μM 
of caffeine was added to induce Ca2+-release (Fig. 6B). The PV slope only showed 
a modest increase compared to CK-inhibition (Fig. 6B). Together, these results indicate 
that the combined presence of CK-inactivation and diastolic [Ca2+] are needed for 
the observed decline in ventricular compliance in whole heart preparations. 
figure 6. Left ventricle (LV) compliance declines following creatine kinase (CK)-inactivation in isolated 
rat hearts. A, Mean diastolic pressure-volume (PV) relationship in Langendorff-perfused hearts arrested 
in Ca2+-free buffer without and with inhibition of CK. Hearts (N=6) were perfused with nominally 
Ca2+-free solution for 60 min then the diastolic PV relationship was measured (-Ca2+). 2,4-dinitro-1-
fluorobenzene (DNFB; 20 μM) was then perfused for a further 30 min and measurements repeated 
(-Ca2++DNFB). In a separate group of hearts (N=5), the intracellular Ca2+-chelator BAPTA-AM (20μM) 
was added to -Ca2+ solution and perfused for 60 min (-Ca2++BAPTA), followed by perfusion for 30 
min with DNFB (-Ca2++DNFB+BAPTA). B, Slope of the diastolic PV relationship. DNFB reduced left 
ventricle compliance in -Ca2+ solution, shown by a steeper diastolic PV relationship. BAPTA did not 
change diastolic PV slope compared to -Ca2+. However, BAPTA prevented the increase in diastolic PV 
slope following DNFB perfusion. In a separate group of hearts (N=2), addition of low concentration of 
caffeine (200 μM) in Ca2+-free solution appears to be sufficient to cause diastolic Ca2+-leak, indicative 
from the increase in diastolic PV slope. Although to a lesser extent than -Ca2++DNFB. Data was 
compared using 2-way repeated measures ANOVA followed by Bonferroni post hoc test. *p<0.05.
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Iodoacetamide and DNFB do not target myofilament proteins
To exclude direct effects of iodoacetamide or DNFB on myofilament proteins, 
membrane-permeabilized rat cardiomyocytes were measured before and after 
incubation with both CK-inhibitors. Maximal, submaximal Ca2+-tension and Fpas were 
not changed in the presence of both inhibitors, indicative that both CK-inhibitors 
do not directly target myofilament protein functions (Table 3). No phosphorylation 
differences after iodoacetamide treatment in the intact rat cardiomyocytes 
(Figure 5) were found for the myofilament regulators of Ca2+-sensitivity of force, 
including cardiac myosin-binding protein C, cardiac troponin I and myosin light chain, 
and the regulator of diastolic stiffness titin (data not shown). Altogether, these data 
strongly suggest that the observed CK-inhibition effects on diastolic impairment 
(Figs. 5 and 6) are due to its effects on myocardial energy reserve and independent of 
alterations of myofilament proteins.
table 3. Response of Ca2+-stimulated maximal and submaximal contraction without and with 
iodoacetamide or DNFB, in left ventricular rat membrane-permeabilized cardiomyocytes at 
sarcomere length 2.2 μm.
sample before incubation after incubation  n/n
Iodoacetamide (5 mM) N=3, n=11
32 μM Ca2+-Fact (kN/m
2) 22.3±2.7 21.0±2.3
4.0 μM Ca2+-Fact (kN/m
2) 17.1±2.0 16.2±1.8
 Fpas (kN/m
2) 1.7±0.2 1.6±0.2
DNFB (20 μM) N=3, n=9
32 μM Ca2+-Fact (kN/m
2) 20.0±1.5 19.6±1.5
4.0 μM Ca2+-Fact (kN/m
2) 14.0±1.5 13.8±1.5
 Fpas (kN/m
2) 1.2±0.2 1.1±0.2
N, number of rats; n, number of cardiomyocytes. Cardiomyocytes were measured before and after incubation with 
5 mM iodoacetamide or 20 μM DNFB, in relaxing solution, for 5 or 30 minutes, respectively. Data was compared 
using a paired-sampled Student’s t-Test. p<0.05 was considered significant.
DisCussion
Diastolic function is both dependent on the rate of myocardial relaxation and passive 
properties of the wall that allow proper filling of the ventricle. In this study we provide 
evidence that synergistic actions of ADP and Ca2+ increase actomyosin interactions 
which elevate myocardial stiffness and limit proper filling of the heart. Our findings 
show that increased cross-bridge interactions may lead to diastolic dysfunction, 
in environments with elevated ADP and increased Ca2+, evidenced by high 
cardiomyocyte stiffness and impaired diastolic re-lengthening, associated with limited 
ventricular compliance. In human and rat membrane-permeabilized cardiomyocytes, 
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physiological levels of ADP led to an increased myofilament Ca2+-sensitivity and 
stiffness, indicating a slowing or incomplete ventricular relaxation with high diastolic 
stiffness. In support, CK-inactivation limited restoration of diastolic length in intact rat 
cardiomyocytes and decreased ventricular compliance in whole rat hearts. Altogether 
these findings indicate that the increased [ADP] as observed in cardiac diseases, in 
which the metabolic function is compromised, significantly contributes to impaired 
diastolic function.
Elevated ADP and Ca2+ contribute to diastolic dysfunction
Combining studies in human and rat cardiomyocytes and hearts, we show that high 
ADP and increased Ca2+ enhance diastolic stress. In human and rat membrane-
permeabilized cardiomyocytes a combination of Ca2+ and physiological ADP levels 
increased Ca2+-sensitivity and cross-bridge stiffness (Figs. 2A and 2D, and Figs. 
3A and 3C). Similar findings in the presence of supra-physiological levels of ADP 
have been shown to elevate Ca2+-sensitivity and sarcomere stiffness in both skeletal 
rabbit myofibrils35-37 and rat trabeculae38. Additionally, in intact rat cardiomyocytes 
CK-inhibition limited diastolic relaxation (Fig. 5B). LV compliance also declined in 
isolated rat hearts (Fig. 6). Similarly, it was previously shown by Tian et al.9,16 that 
myocardial ADP accumulation increases LVEDP and impairs myocardial relaxation 
in isolated rat hearts. However, these authors argued that these changes are Ca2+-
independent.16 Our findings instead support the hypothesis that Ca2+ exacerbates the 
decline in LV compliance in the presence of ADP. This is shown by the observation that 
buffering Ca2+ prevented the decrease in compliance during CK-inactivation (Fig. 6B). 
Conversely, a low concentration of caffeine (200 μM), to induce diastolic Ca2+-release, 
showed a modest increase in PV slope compared to CK-inhibition (Fig. 6B). Thus, 
Ca2+ alone cannot completely account for the observed decline of LV compliance. 
These data suggest that in the absence of ADP resting diastolic Ca2+ has a relatively 
small contribution to diastolic stiffness and that ventricular compliance only declines 
in the presence of diastolic Ca2+ and high ADP caused by an active cross-bridge 
component. We provide evidence that high ADP and Ca2+-dependent cross-bridge 
formation imposes high myocardial diastolic stiffness associated with greater than 
normal filling pressure, which contribute to diastolic dysfunction.
Augmented contractility following elevations of ADP and Ca2+
On the basis of the observed diastolic impairment of intact rat cardiomyocytes we 
would expect a reduced fractional shortening, resulting from restricted recruitment 
of the Frank-Starling reserve. This would decrease the preload-induced force of 
contraction. In contrast, contractility was increased as evidenced by enhanced 
shortening capacity of intact rat cardiomyocytes following CK-inactivation (Fig. 5E). 
The greater than normal contractility can be explained by the increased Ca2+-sensitivity 
of force production induced by physiological levels of ADP (Figs. 2A and 3A) and 
the Ca2+-overload state promoted by CK-inactivation (Figs. 5F and 5G, and Table 2). 
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Notably, our analysis reveals that the early inotropic response following CK-inactivation 
(phase II) is not caused by disturbed Ca2+-transient (Figs. 5F and 5G, and Table 2) 
and thus explained by the ADP-induced increase of myofilament Ca2+-sensitivity 
(Figs. 2A and Fig. 3A). However, prolonged CK-inhibition (phase III) still leads to 
increased contractility, but also significantly impairs diastolic re-lengthening (Fig. 5B), 
both of which are likely caused by systolic and diastolic Ca2+-overload (Figs. 5F and 
5G, and Table 2), respectively. Our results support the theory that CK-inactivation by 
increases of cytosolic ADP stimulates a Ca2+-overload state. The Ca2+-overload can 
result from: 1) the high Ca2+-sensitivity promoted by ADP at the myofilaments; because 
the myofilaments are the main source for the buffering of Ca2+ during the cardiac 
cycle39, evidence from animal models supports that high myofilament Ca2+-sensitivity 
increases cytosolic Ca2+-binding with altered Ca2+-homeostasis in animals40,41; and/or 
2) the high [ADP/ATP] ratio caused by ADP accumulation that reduces the free energy 
released from ATP hydrolysis (∆GATP). Since the sarcoplasmic reticulum Ca
2+-ATPase, 
and other sarcolemmal pumps, including the Na+/K+-ATPase, operate close to their 
theoretical thermodynamic limits, the rise of [ADP] will favor diastolic Ca2+ rise.7 
However one cannot exclude that iodoacetamide also has an effect on Ca2+-release 
via the ryanodine receptor as was shown in skeletal muscle from rabbits.42 Hence, in 
our experiments ‘artificial’ elevation of Ca2+ that is not coupled to CK-inhibition may 
also be present.
Enhanced actomyosin interactions lead to high diastolic stress
It has been proposed that expression of the stiffer titin isoform or its altered 
phosphorylation represents a major contributor to high diastolic stiffness observed 
in HF patients with diastolic dysfunction.3,5 Within these studies, there is no evidence 
to support a role for altered cross-bridge interaction to high diastolic stiffness.3,5 In 
the majority of the studies membrane-permeabilized cardiomyocytes and muscle 
strips, with thick- and thin-filament extraction by KCl and KI, have been employed 
to study passive properties of HF myocardium.3,5 There are however limitations to 
the latter approaches that need to be addressed: 1) KCl and KI treatment is designed 
to assess the contribution of collagen to sarcomere stiffness as it removes thick- and 
thin-filament anchors in the sarcomere, and thereby abolishes any contribution of 
the actomyosin interaction43; 2) chemical digestion of the sarcolemma in membrane-
permeabilized cardiomyocytes causes myofilament lattice expansion (and less 
approximation of myosin towards actin) that decreases force generation44,45; 3) 
the relatively low temperature (15ºC) used in the experiments reduces cross-bridge 
active force, shortening velocity and power46; 4) rapid shortening and re-lengthening 
procedures mechanically detach myosin from actin47,48; and importantly 5) membrane-
permeabilized cardiomyocytes lack important contributors in the intracellular milieu 
of normal and failing intact cardiomyocytes. These include the in vivo diastolic Ca2+ 
and cytosolic ADP. King et al.28 has recently reported that cross-bridges account for up 
to ~30% of diastolic stress at a sarcomere length of 2.1 μm using mouse membrane-
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permeabilized cardiomyocytes measured at 37ºC in the presence of dextran to 
normalize lattice spacing. In the present study we adapted this protocol to evaluate 
the cross-bridge contribution to diastolic stress in rat membrane-permeabilized 
cardiomyocytes under disease conditions, including those where metabolic function 
is affected that elevates ADP in the presence of diastolic Ca2+, and showed that cross-
bridges greatly contribute to diastolic stress (Fig. 4). Our data support the idea that 
cross-bridges may slow myocardial relaxation and impose high diastolic stiffness in 
disease, and in concert with titin and other diastolic mediators, contribute to diastolic 
dysfunction in HF patients. Importantly our results support the notion that the diastolic 
phase is not purely a passive process, but is accompanied by active stress.
Limitations
At present, we are unable to directly control intracellular ADP concentration in 
the intact cardiomyocytes and whole heart preparations. To increase cytosolic ADP, 
we opted for the use of two well-known drugs that inhibit the CK reaction, i.e. 
iodoactemide and DNFB. Iodoacetamide allows us to estimate ADP elevations due 
to its well-characterized effects on the ATP-regeneration system.16 Based on previous 
findings using similar amounts of iodoactemide16, ADP is estimated not to exceed 
73 μM in our experiments, while ATP, PCr, inorganic phosphate and pH levels are 
unaltered. A limitation of iodoactemide which makes it unsuitable for whole heart 
experiments, is that it unspecifically targets enzymes of the glycolytic reaction.16 This 
is not problematic in single cells because of the short duration of the experiment 
(3 min). In contrast, this might be detrimental in the whole heart experiments, which 
required longer periods of CK-inhibition (30 min). Therefore, DNFB was used in those 
experiments, as it does not target enzymes of the glycolytic pathway.32 However, 
using DNFB we are unable, to our knowledge, to carefully estimate the expected 
intracellular ADP concentration. We believe that overall the effects of both drugs are 
interchangeable between experiments, which is partly supported by similar inhibition 
of the CK reaction (~40%).
Conclusion
Based on our experimental data, we propose that conditions which elevate myocardial 
ADP and Ca2+ contribute to diastolic dysfunction by increasing residual actomyosin 
interactions. This leads to high cardiomyocyte stiffness and impaired relaxation, 
associated with limited ventricular compliance. Our study provides a mechanistic 
basis for how the elevated ADP and diastolic Ca2+-overload can contribute to diastolic 
dysfunction in HF patients.
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Translational Perspective
Here we show that actomyosin-related force development may be an important 
contributor to high diastolic stiffness and may explain the development of diastolic 
dysfunction in environments where high ADP and increased diastolic [Ca2+] are present, 
such as in the failing myocardium. These findings establish a clear link between deficits 
of myocardial energy reserve and disturbed Ca2+-handling, which together leads to 
inappropriate cross-bridge formation and high diastolic stiffness. These findings may 
provide insight in how energy-sparing therapies (that reduce cellular ATP usage), such 
as beta-blockers, angiotensin-receptor blockers and angiotensin converting enzyme 
inhibitors, improve symptoms and reduce mortality in congestive HF patients 1. Our 
data highlight the need for more targeted therapies aimed at lowering myocardial 
ADP levels to improve the prognosis of human HF.
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aDP-stimulateD ContraCtion: a PreDiCtor of 
tHin-filament aCtivation in CarDiaC Disease
Sequeira V, Najafi A, Paul J.M. Wijnker, Remedios Cd, Michelle Michels,  
Kuster DWD, van der Velden J
ADP-stimulated contraction:  
a predictor of thin-filament activation in cardiac disease 
Proc Natl Acad Sci. 2015
“Nature, and Nature’s Laws lay hid in Night. God said, Let Newton be!  
and All was Light.”
Alexander Pope
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abstraCt
Diastolic dysfunction is general to all idiopathic dilated (IDCM) and hypertrophic 
cardiomyopathy (HCM) patients. Relaxation deficits may result from increased 
actin-myosin formation during diastole due to altered tropomyosin position, 
which block myosin-binding to actin in the absence of Ca2+. We investigated if 
ADP-stimulated force development (without Ca2+) can be used to reveal changes in 
actin-myosin blockade in human cardiomyopathy cardiomyocytes. Cardiac samples 
from HCM patients, harboring thick- (MYH7mut, MYBPC3mut) and thin-filament 
(TNNT2mut, TNNI3mut) mutations, and IDCM, were compared with sarcomere 
mutation-negative HCM (HCMsmn) and non-failing donors. Myofilament ADP-
sensitivity was higher in IDCM and HCM compared with donors, while it was lower 
for MYBPC3. Increased ADP-sensitivity in IDCM, HCMsmn and MYH7mut was caused 
by low phosphorylation of myofilament proteins, as it was normalized to donors by 
protein kinase A (PKA) treatment. Troponin exchange experiments in a TNNT2mut 
sample corrected the abnormal actin-myosin blockade. In MYBPC3trunc samples, 
ADP-sensitivity highly correlated with cardiac myosin-binding protein-C (cMyBP-C) 
protein level. Incubation of cardiomyocytes with cMyBP-C antibody against the actin-
binding N-terminal region reduced ADP-sensitivity, indicative of cMyBP-C’s role in 
actin-myosin regulation. In the presence of Ca2+, ADP increased myofilament force 
development and sarcomere stiffness. Enhanced sarcomere stiffness in sarcomere 
mutation-positive HCM samples was irrespective of the phosphorylation background. 
In conclusion, ADP-stimulated contraction can be used as a tool to study how protein 
phosphorylation and mutant proteins alter accessibility of myosin-binding on actin. 
In the presence of Ca2+, pathologic [ADP] and low PKA-phosphorylation, high actin-
myosin formation could contribute to the impaired myocardial relaxation observed in 
human cardiomyopathy.
signifiCant statement
Diastolic dysfunction is characteristic of patients with cardiomyopathy. Evidence 
indicates that diseased hearts show basal sarcomeric activation capable of impairing 
diastolic performance. By activating human cardiomyopathy muscle in ADP-containing 
solutions without Ca2+ we showed that actin-myosin blockade is disrupted. This may 
be caused by the presence of mutations and/or the reduced phosphorylation of 
myofilament proteins. Our mechanistic study supports the novel idea that protein 
kinase A-target phosphorylation and myosin-binding protein-C regulate the OFF-ON 
transition of the thin-filaments. ADP increased myofilament force and stiffness in 
the presence of Ca2+ in cardiomyopathy samples, suggesting this condition limits 
muscle relaxation through increased actin-myosin interactions. We conclude that 
ADP-stimulated contraction can be used to reveal conformational changes in 
the 3-state model of thin-filament activation.
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introDuCtion
Heart failure (HF) is a syndrome clinically defined as the inability of the heart to 
sufficiently supply blood to organs and tissues.1 Systolic dysfunction is present in 
approximately half of the HF population, while diastolic dysfunction is a common 
feature in almost all HF patients.2 Moreover, in hypertrophic cardiomyopathy (HCM), 
which is caused by mutations in genes encoding thin- and thick filament proteins, 
impaired diastolic function is frequently observed.3 Impaired relaxation of the heart 
may be caused by high myofilament Ca2+-sensitivity. This increased sensitivity for 
Ca2+ would result in residual myofilament activation at diastolic [Ca2+], which may 
delay the onset of ventricular relaxation and limit proper filling of the heart. High 
myofilament Ca2+-sensitivity has been observed in both acquired and genetic forms 
of cardiomyopathy.3,4 In human idiopathic dilated cardiomyopathy (IDCM), high 
myofilament Ca2+-sensitivity has been associated with reduced β-adrenergic receptor-
mediated phosphorylation by protein kinase A (PKA).4 Reduced PKA-phosphorylation 
of cardiac troponin I (cTnI) and cardiac myosin-binding protein-C (cMyBP-C) increases 
myofilament Ca2+-sensitivity.5-8 Likewise, high myofilament Ca2+-sensitivity is a common 
characteristic of HCM and may be caused by the mutant protein or by reduced 
PKA-mediated protein phosphorylation secondary to HCM disease progression.3,9
Contractile performance of the heart muscle may thus be perturbed by 
mutation-induced and phosphorylation-mediated protein changes that affect thin-
filament transitions. Ca2+-induced cardiac muscle contraction is tightly modulated by 
the troponin-tropomyosin complex that regulates the interactions between the actin 
thin-filament and myosin thick-filament (i.e. cross-bridge formation). Accordingly, 
the myofilaments oscillate between three transitions termed the blocked (B-state), 
closed (C-state) and open (M-state) states of thin-filament regulation that represent 
the distinct position of tropomyosin on actin(Fig. 1).10-12 In the absence of Ca2+ 
(B-state), tropomyosin sterically blocks the myosin-binding sites on actin 
(Fig. 1A). Upon electrical activation of cardiomyocytes the rise of cytosolic [Ca2+] alters 
the conformation of the troponin-tropomyosin complex, which moves tropomyosin 
on actin and exposes myosin-binding sites (C-state). Weakly-bound cross-bridges 
(myosin-ADP-Pi) populate the C-state (Fig. 1B).10,12 Transition to the M-state involves 
release of inorganic phosphate (Pi) from the cross-bridge and strong-binding cross-
bridge formation (myosin-ADP) that induces additional movement of tropomyosin, 
resulting in myofilament contraction and sliding (Fig. 1C).
The 3-state model of cross-bridge interaction implies that the main task of Ca2+ is 
to uncover myosin-binding sites on actin and that formation of myosin-ADP represents 
the main regulator of force development and contraction. Notably, solution10 
and cryo-electron microscopy13 studies have shown that in the absence of Ca2+ 
the myofilaments are not entirely blocked, as ~5% of the thin-filaments have 
tropomyosin localized in the C-state position. This observation suggests that conditions 
that promote myosin-ADP formation can trigger myofilament contraction in Ca2+-free 
conditions and thereby impair relaxation. Indeed, in membrane-permeabilized rabbit 
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skeletal muscle fibers14, bovine myocardium15,16 and human cardiac muscle17 mM 
levels of ADP stimulate force development in the absence of Ca2+.
figure 1. Three-state model of thin-filament activation. Seven actin monomers (circles), spanned 
by one tropomyosin dimer (red strand) together with the troponin complex (not shown) comprise 
one functional unit (A7TmTn). Two functional units are depicted, and individual myosins are 
shown as triangles (weak, weak-binding cross-bridges; strong, strong-binding cross-bridges). (A) 
B-state (blocked); when ATP is present and cytoplasmic [Ca2+] is low and is not bound to cardiac 
troponin C (cTnC), tropomyosin is sterically blocking the myosin-binding sites on actin. (B) C-state 
(Ca2+-induced); upon rise in cytoplasmic [Ca2+], Ca2+ binds to cTnC, inducing conformational changes 
of the troponin complex, resulting in a ~25º movement of tropomyosin on the thin-filament, thereby 
exposing myosin-binding sites on actin. In the C-state the myofilament is not yet activated as non-
tension-generating cross-bridges bind weakly to actin. (C) M-state (Myosin-induced); the strong-
binding of tension-generating cross-bridges induces a ~10º movement of tropomyosin on actin, 
resulting in myofilament activation and contraction.
Since ADP-stimulated contraction is due to myosin-ADP binding to the non-blocked 
sites of the thin-filament in the absence of Ca2+, it provides an experimental tool to 
assess changes in tropomyosin’s position in acquired and genetic cardiomyopathies 
in which altered protein phosphorylation and mutant proteins may alter myofilament 
activation. In addition, it could represent a pathomechanism underlying the diastolic 
dysfunction seen in both disease states. Solution studies with mutant troponin 
proteins, which are known to cause HCM, showed a reduction in the B-state at low 
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Ca2+ conditions compared to wild-type troponin proteins.18,19 Mutation-induced 
irregularities in troponin-tropomyosin interactions disrupt the B-state and shift 
the thin-filament to the C-state, increasing the available myosin-binding sites on actin.
In addition to Ca2+-induced changes of the thin-filament, tropomyosin location 
may also be altered by the thick-filament protein cMyBP-C. Recent evidence supports 
that the N-terminal extension of cMyBP-C binds the low Ca2+-state (B-state) position 
of tropomyosin on actin and interferes with tropomyosin-actin interactions, dislocating 
tropomyosin into the C-state position (i.e. the presence of cMyBP-C sensitizes 
the thin-filament to Ca2+).20,21 Since it was previously shown that in Ca2+-free conditions 
(B-state) approximately 5% of the thin-filaments (lacking cMyBP-C) have tropomyosin 
localized in the C-state position10, more myofilaments may be in the C-state in 
the presence of cMyBP-C. We22 and others23 have shown that cMyBP-C mutations, 
that are a major cause of HCM, have a reduced level of healthy cMyBP-C protein 
compared to non-failing hearts (i.e. haploinsufficiency), which may alter tropomyosin 
position on the thin-filament.
To verify if ADP-stimulated contraction provides an experimental tool to assess 
mutation-induced and phosphorylation-mediated changes in thin-filament transitions, 
that precede Ca2+-activation of myofilaments, we tested the following hypotheses: 
1) that IDCM and HCM samples with thin-filament mutations are more sensitive to 
ADP, as a result of a higher accessibility of myosin-binding sites on actin, while 2) 
cMyBP-C haploinsufficient HCM myocardium has a reduced ADP-sensitivity (i.e. less 
cMyBP-C causes reduced displacement of tropomyosin from the B-state) compared 
with cells from non-failing hearts. To answer our hypotheses we activated membrane-
permeabilized human cardiomyocytes in ADP containing Ca2+-free solutions. Cells 
were isolated from HCM patients with mutations in genes encoding thick- (MYH7, 
MYBPC3) and thin-filament (TNNT2, TNNI3) proteins and patients with IDCM and 
compared with cells from sarcomere mutation-negative HCM (HCMsmn) and non-failing 
donors. Finally, we investigated if the ADP level as observed in diseased hearts, in 
the presence of Ca2+, increases myofilament force development in cardiomyocytes 
from human cardiomyopathy hearts.
We conclude that in HCM with thin-filament mutations tropomyosin’s ability to 
block myosin-binding sites on actin is reduced. This effect is exacerbated in HCM 
samples by the low PKA-phosphorylation of myofilament proteins, which is also 
observed in human IDCM. In contrast, cMyBP-C HCM-causing mutations reduce 
accessibility of myosin for actin. The findings in this study provide evidence that ADP-
mediated activation can be used as an experimental tool to reveal mutation- and 
phosphorylation-mediated changes in tropomyosin location on the thin-filament.
186
metHoDs
Myocardial human samples
Human left ventricular (LV) tissue was obtained during open heart surgery from 
end-stage failing (n=4; IDCM) and HCM patients. HCM heart samples harboring 
thick- and thin-filament gene mutations were obtained during myectomy surgery to 
relieve LV outflow obstruction. Our study included patients carrying heterozygous 
mutations in MYBPC3 (n=13), MYH7 (n=3; MYH7mut) and TNNI3 (n=1; TNNI3mut) and 5 
HCM patients in whom no mutation was found after screening of 8 genes (sarcomere 
mutation-negative HCM; HCMsmn). The MYBPC3 group consisted of patients with 
truncating (n=10; MYBPC3trunc) and missense (n=3; MYBPC3mut) mutations. Data for 
these two MYBPC3 groups are presented separately. Tissue was also obtained from 1 
end-stage failing HCM patient carrying a homozygous TNNT2 mutation (TNNT2mut). 
Specific gene mutation information of HCM patients is listed in Table 1. Heart tissue 
from 4 non-failing donors served as controls. IDCM and non-failing donor samples 
were collected in cardioplegic solution. Tissue was immediately frozen and stored in 
liquid nitrogen. Samples were obtained after written informed consent and the study 
protocol was approved by the local ethical committees. The investigation conforms 
with the principles outlined in the Declaration of Helsinki (1997).
Experimental solutions for isometric force measurements in membrane-
permeabilized cardiomyocytes
The composition of all solutions was calculated based on a computer program similar 
to that described previously.24 The pH of all solutions was adjusted to 7.1 at 15ºC 
by KOH and ionic strength was adjusted to 180 mM with KCl. The relaxing solution 
contained 2 mM free Mg2+, 1 mM MgATP, 20 mM EGTA, 10 mM BES and 14.5 mM 
phosphocreatine (PCr). ADP-activating solutions contained 2 mM free Mg2+, 1 mM 
MgATP, 20 mM EGTA, 10 mM BES and MgADP in increasing concentrations from 1 to 
10 mM. Nominal free Ca2+ was present. Ca2+- activating solutions in the presence of 
100 µM ADP consisted of 2 mM free Mg2+, 1 mM MgATP, 20 mM EGTA, 10 mM BES, 
and free Ca2+ varied from 1 to 32 μM. PCr was omitted from the activating solutions 
to preserve the MgADP/MgATP ratio. All force measurements were performed at 
15ºC. We maintained [ATP] constant at 1 mM to avoid rigor cross-bridge formation 
(reported to occur when [ATP] falls below 0.1 mM25).
Isometric force measurements
Small human cardiac tissue samples were thawed in relaxing solution and 
cardiomyocytes were mechanically isolated by tissue disruption as described 
previously.26 Cardiomyocytes were membrane-permeabilized by incubation for 5 
minutes in relaxing solution containing 0.5% (v/v) Triton-X100 and glued between 
a force transducer and a piezoelectric motor. The sarcomere length of the preparation 
was measured in relaxing solution and adjusted to 2.2 μm. Average sarcomere lengths 
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were determined by means of a spatial Fourier transformation as described previously.26 
The force measurements started with a maximal activation at ADP concentration of 10 
mM (ADP-Ftotal). After a series of seven activations at submaximal ADP concentrations, 
another measurement was carried out at maximal ADP activation of 10 mM. 
Total ADP-force was measured from the zero force value obtained from slacking 
the cardiomyocyte to 70% of its original length within 1 ms, after the plateau of force 
was reached. Force was corrected for myocyte deterioration by linear interpolation 
between maximal force values. The intermediate results, obtained at higher ADP 
values, were normalized to the interpolated maximal force values. The measurements 
were continued until a full ADP-force curve was obtained. Cells were excluded from 
the study when the final force measurement at maximal ADP was less than 80% 
compared to the first maximal control measurement. To obtain passive force (Fpass) 
the cardiomyocyte was slackened to 70% of its original length for 10 seconds in relaxing 
solution by means of the piezoelectric motor from the initial sarcomere length of 2.2 
μm. The decrease in force during this procedure equals the passive force at 2.2 μm 
sarcomere length. Active tension (ADP-Fact) was calculated as Fact=Ftotal-Fpass. Absolute 
tensions were normalized to cardiomyocyte cross-sectional area and expressed as 
developed tension (in kN/m2). Similarly, Ca2+-force measurements in the presence of 
100 µM ADP were determined as described previously.17 Residual force measurements, 
an indication of sarcomere stiffness, were measured after a slack-restretch procedure 
at high Ca2+ (32 μM) with 100 µM ADP as follows: after steady state force was reached, 
cardiomyocytes were shortened to 70% of their original length within 1 ms and then 
re-stretched to the original length after 30 ms. Residual force was calculated from 
the initial force recovery reached after the length change and normalized to each total 
steady-state force reached before length change. Measurements are normalized to 
each corresponding total force as described previously.17 Finally, force measurements 
were performed following exogenous protein kinase A (PKA) treatment of cells 
for 40 minutes at 20ºC in relaxing solution containing the catalytic subunit of PKA 
(100 U/incubation, Sigma). To control for protocol artefacts (e.g. incubation time, 
buffer solution) cardiomyocytes harvested from failing hearts were incubated with 
PKA-buffer solution but without PKA. No statistical changes were observed between 
the absence (3.59±0.17 mM ADP) and presence of PKA-buffer (3.65±0.20 mM ADP).
Data analysis isometric force measurements
Ca2+- and/or ADP-force relations were determined by a non-linear fit procedure 
using a modified Hill equation using KaleidaGraph version 3.6 (Synergy Software, 
Reading, PA) as follows:
P (ADP) / P0 = [ADP]
nH / (K nH + [ADP]nH)
P (Ca2+-ADP) / P0 = [Ca
2+-ADP]nH / (K nH + [Ca2+-ADP]nH)
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where P is steady-state force. P0 denotes the steady isometric force at either high 
[ADP] and saturating [Ca2+] with ADP, nH describes the steepness of the relationship, 
and K represents the [Ca2+] and/or [ADP] at which force is half-maximal (0.5 x P0). 
Myofilament Ca2+ and/or ADP-sensitivity is denoted as EC50.
Exchange of recombinant human wild-type troponin complex in single 
cardiomyocytes
Troponin exchange protocol
Troponin exchange was performed as described previously.8,9 In brief, single 
cardiomyocytes from the TNNT2mut heart were mechanically isolated by tissue 
disruption in ice-cold rigor solution (132 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM Tris, 
table 1.  Hypertrophic cardiomyopathy samples information.
samples mutation type 
MYBPC3trunc
Cardiac myosin-binding protein-C
(cMyBP-C)
Truncating mutations
1 p.Y340X termination codon
2 p.R493X termination codon
3 c.927-2A>G splice site
4 c.927-2A>G splice site
5 c.1458-1G>C splice site
6 c.2373duplicationG insertion
7 c.2373duplicationG insertion
8 c.2373duplicationG insertion
9 c.2864.2865delCT deletion
10 c.3407.3409del deletion
MYBPC3mut
Cardiac myosin-binding protein-C
(cMyBP-C)
Missense mutations
11 p.E258K missense
12 p.G531R missense
13 p.R597Q missense
MYH7mut Myosin-heavy chain (MyHC)
14 p.R403Q missense
15 p.R403Q missense
16 p.V606M missense
TNNT2mut Cardiac troponin T (cTnT)
17 p.K280N missense
TNNI3mut Cardiac troponin I (cTnI)
18 p.R145W missense
trunc, truncating mutation; mut, missense mutation; p, protein amino residue; c, codon region; X, stop codon.
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5 mM EGTA, 1 mM NaAzide, pH 7.1). Cardiomyocytes were membrane-permeabilized 
by incubation for 5 minutes in rigor solution containing 0.5% (v/v) Triton-X100. After 
permeabilization, cardiomyocytes were washed twice with rigor solution followed by 
washing in exchange solution (10 mM imidazole, 200 mM KCl, 5 mM MgCl2, 2.5 mM 
EGTA, 1 mM DTT, pH 6.9). Next, single cardiomyocytes were incubated overnight at 
4°C in exchange solution containing the appropriate concentration of recombinant 
human wild-type troponin complex (1.0 mg/mL) with the addition of 4 mM CaCl2, 
4 mM DTT, 5 µl/mL protease inhibitor cocktail (PIC, Sigma, P8340) and 10 µl/mL 
phosphatase inhibitor cocktail 2 and 3 (PhIC, Sigma, P2850, P5726) (pH 6.9). The next 
day, cells were washed twice in rigor solution followed by washing in relaxing solution.
Determination of troponin exchange percentage
Half of the cardiomyocyte suspension was used for isometric force measurements, 
while the other half was used to analyze troponin exchange percentage. This half 
was treated with 2D-clean-up kit (GE Healthcare), homogenized in sample buffer 
(15% glycerol, 62.5 mM Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v) DTT) and protein 
concentration was measured with RCDC Protein Assay kit II (Biorad).
To determine the degree of exchange of endogenous mutant troponin by 
recombinant wild-type cardiac troponin Western blotting was performed. Recombinant 
wild-type cTnT contains a myc-tag, which allowed differentiation between 
endogenous and recombinant cardiac troponin complex. Proteins were separated on 
a 1D SDS-PAGE and blotted onto a nitrocellulose membrane. A specific monoclonal 
antibody was used against cTnT (Clone JLT-12, Sigma) to detect endogenous and 
recombinant cTnT by chemiluminescence (ECL, Amersham Biosciences) as described 
previously.
Myofilament protein phosphorylation and levels 
Phosphorylation of cTnI
ProQ-Diamond stained 1D-gels were used to assess phosphorylation of 
the myofilament protein cTnI as previously described.27
Western blot analysis of cMyBP-C total protein
Total protein of cMyBP-C was assessed using specific antibodies in Western blots 
(E-7; sc-137180, Santa Cruz Biotechnology).
Incubation of failing cardiomyocytes with specific cMyBP-C antibodies
Single cardiomyocytes from 4 IDCM samples were incubated for 90 minutes with 
a 1:100 dilution of either specific N’ cMyBP-C antibody (mouse monoclonal E-7; 
sc-137180, Santa Cruz Biotechnology), C’ cMyBP-C antibody (generously provided by 
Sakthivel Sadayappan, Loyola University Chicago, Maywood, IL, USA) or an antibody 
against nucleolar protein nucleophosmin (mouse monoclonal, sc-32256, Santa Cruz 
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Biotechnology). The C’ cMyBP-C antibody or nucleolar phosphoprotein antibody 
(control ab) served as the incubation negative controls.
Statistical analysis
Data analysis and statistics were performed using Prism version 6.0 (Graphpad Software, 
Inc., La Jolla, CA) and SPSS version 15.0 (IBM, Armonk, NY). Data are presented as 
mean ± SEM of all single cardiomyocytes per patient group (8 groups, i.e. 1 IDCM 
group, the 5 HCM sarcomere mutation positive groups (HCMmut), HCMsmn and non-
failing donor). To take into account the repeated sample assessments within patient/
donor groups multilevel analysis was performed as shown previously.9 Comparison 
between all groups was performed for ADP-sensitivity and Ca2+-ADP-sensitivity at 
2.2 μm sarcomere length before and after PKA treatment. All data was tested for 
normality using the Shapiro-Wilk Test. Normality was assumed when p>0.05 and 
the variances were equal. Paired samples t-Test was conducted when one variable was 
tested between 2 groups of data. When more than one variable was tested in more 
than 2 groups a 2-way ANOVA was conducted followed by a Bonferroni post-hoc test 
if significant differences were found. Each test is clearly specified in Tables or Figure 
legends. The level of significance was set at p<0.05.
results
ADP-sensitivity in idiopathic dilated and hypertrophic cardiomyopathy
To evaluate the accessibility of myosin-binding sites on actin, force production of 
single membrane-permeabilized cardiomyocytes was measured at varying ADP 
concentrations, in the absence of Ca2+. Tissue from human IDCM and HCM hearts 
were selected and compared with non-failing donors. Typical tension tracings of 
single cardiomyocytes from IDCM, MYH7mut, MYBPC3trunc, and TNNT2mut samples 
at 2.2 μm sarcomere length during ADP-maximal (10 mM) and submaximal (4 mM) 
activation are shown in Figure 2. 
We have previously shown that all IDCM and HCM samples, except for the HCM 
TNNT2mut sample, have lower phosphorylation of PKA-target proteins in the myofilament 
compared to donor myocardium.4,9 Figure 3A shows that the phosphorylation level 
of the PKA target protein cTnI is lower in the IDCM and HCM samples relative to 
non-failing donor, which was set to 1. One exception is the homozygous TNNT2mut 
sample, which showed similar cTnI phosphorylation as in donor myocardium. To 
determine the effect of low myofilament phosphorylation, force-ADP relations were 
constructed for all samples before and after PKA treatment (Fig. 2 right panels). As 
shown in Figure 3B, ADP-sensitivity (denoted as EC50) was higher in IDCM and several 
HCM patient groups, including MYH7mut, TNNT2mut, TNNI3mut and HCMsmn, while it 
was lower in MYBPC3mut (missense mutations) and MYBPC3trunc (truncating mutations) 
compared with donors (Table 2). PKA normalized ADP-sensitivity to donor levels in 
IDCM, MYH7mut and HCMsmn, while TNNT2mut and TNNI3mut remained more sensitive 
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figure 2. Myofilament ADP-activation and ADP-sensitivity in idiopathic dilated (IDCM) and 
hypertrophic (HCM) cardiomyopathy membrane-permeabilized cardiomyocytes. Left panels show 
typical tension recordings of a single membrane-permeabilized cardiomyocytes at 2.2 μm sarcomere 
length during ADP maximal (10 mM) and submaximal activation (4 mM) at 15ºC and 1 mM ATP for 
IDCM (A), MYH7mut (B), MYBPC3trunc (C) and TNNT2mut (D). Right panels show normalized force-ADP 
relationship for IDCM (A), MYH7mut (B), MYBPC3trunc (C) and TNNT2mut (D) cardiomyocytes before and 
after protein kinase A (PKA)-treatment. MYH7mut, myosin heavy chain mutations; MYBPC3trunc, myosin-
binding protein-C (truncating) mutations; TNNT2mut, cardiac troponin T mutation.
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to ADP (Fig. 3C and Table 2). Interestingly, after PKA MYBPC3mut and MYBPC3trunc 
were still less sensitive to ADP than donor cells (Fig. 3C and Table 2).
These results indicate that PKA-target phosphorylation of the myofilaments reduces 
accessibility of myosin-binding sites on actin in the absence of Ca2+. At baseline 
(before PKA administration) the myofilaments from cardiomyopathy samples are more 
sensitive to ADP-activation, except for the low sensitivity to ADP of MYBPC3mut and 
MYBPC3trunc. PKA-phosphorylation normalized sensitivity to ADP in IDCM, MYH7mut 
and HCMsmn, suggesting that any putative disruption of tropomyosin’s B-state position 
(and the greater accessibility of myosin-binding sites on actin) in these samples may 
be due to the low baseline phosphorylation of PKA target proteins.
table 2. ADP-sensitivity (EC50) of non-treated (A) and protein kinase A (PKA)-treated (B) cardiomyocytes.
samples
a vs. donor p value 95% Ci (mmol/l) ns
IDCM *p=0.041 -0.83 to -0.018 N=4, n=14
MYH7mut 
*p=0.003 -1.08 to -0.23 N=3, n=11
MYBPC3mut (missense) 
*p=0.010 0.14 to 0.98 N=3, n=12
MYBPC3trunc (truncating) 
*p=0.004 0.16 to 0.85 N=10, n=28
TNNT2mut 
*p=0.002 -1.57 to -0.36 N=1, n=4
TNNI3mut 
*p=0.003 -1.54 to -0.32 N=1, n=4
HCM smn 
*p=0.038 -0.77 to 0.02 N=5, n=18
b. vs. donor p value 95% Ci (mmol/l) ns
IDCM p=0.895 -0.44 to 0.39 N=4, n=14
MYH7mut p=0.106 -0.80 to -0.08 N=3, n=11
MYBPC3mut (missense) 
*p=0.032 -0.04 to 0.92 N=3, n=12
MYBPC3trunc (truncating) 
*p=0.001 0.26 to 0.96 N=10, n=28
TNNT2mut 
*p=0.001 -1.67 to -0.41 N=1, n=4
TNNI3mut 
*p=0.017 -1.40 to -0.14 N=1, n=4
HCM smn p=0.870 -0.35 to 0.42 N=5, n=18
Multilevel analysis. *p<0.05 was considered significant. N= number of samples; n= number of cardiomyocytes. 16 
cardiomyocytes from 4 non-failing hearts (donor) served as controls; IDCM, idiopathic dilated cardiomyopathy; 
MYH7mut, myosin-heavy chain mutations; MYBPC3, myosin-binding protein C mutations; TNNT2mut, cardiac 
troponin T mutation; TNNI3mut, cardiac troponin I mutation; HCMsmn, sarcomere mutation-negative.
cMyBP-C regulates ADP-sensitivity
We22 and others23 have shown that cMyBP-C truncating mutations lack the presence 
of the smaller truncated protein, but have a lower total level of healthy full length 
cMyBP-C (i.e. haploinsufficiency). To assess if the expression level of cMyBP-C in 
MYBPC3trunc correlates with ADP-sensitivity (as cMyBP-C modulates thin-filament 
transitions20,21), cMyBP-C expression was determined. Total cMyBP-C protein level 
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figure 3. (A) Idiopathic dilated (IDCM) and hypertrophic (HCM) cardiomyopathy samples showed 
reduced phosphorylation of the protein kinase A (PKA) target protein cardiac troponin I (cTnI) 
relative to non-failing donor, which was set to 1. Only the homozygous TNNT2mut sample showed 
relatively high cTnI phosphorylation similar as observed in donor tissue. Myofilament ADP-sensitivity 
in IDCM and HCM cardiomyopathy membrane-permeabilized cardiomyocytes. ADP-sensitivity (EC50) 
before (B) and after (C) PKA treatment in IDCM, HCM and donor samples. Data was compared 
using multilevel analysis. Detailed statistics, sample numbers and number of cardiomyocytes used 
are shown in Table 2. MYH7mut, myosin heavy chain mutations; MYBPC3mut, myosin-binding protein-C 
(missense) mutations; MYBPC3trunc, myosin-binding protein-C (truncating) mutations; TNNT2mut, 
cardiac troponin T mutation; TNNI3mut, cardiac troponin I mutation; HCMsmn, sarcomere mutation-
negative HCM samples.
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(relative to tropomyosin) was 45±9% reduced in MYBPC3trunc compared to controls 
(Fig. 4A). To correlate cMyBP-C level to thin-filament activation, the level of cMyBP-C 
per sample was plotted against its ADP-sensitivity value obtained after PKA treatment 
(to normalize for differences in phosphorylation). Indeed, we observed a strong 
correlation between cMyBP-C protein level and ADP-sensitivity (Fig. 4B), indicating 
that a reduction in cMyBP-C diminishes the number of available myosin-binding sites 
on actin (i.e. favors the B-state formation).
To confirm and provide the proof-of-concept that cMyBP-C indeed regulates thin-
filament transitions via its N-terminal region, IDCM samples were incubated for 90 
minutes with an antibody that binds the C0 domain of cMyBP-C (the domain involved 
in thin-filament binding). We expected that antibody binding to cMyBP-C, decreased 
cMyBP-C affinity for the thin-filament. ADP-sensitivity was reduced after incubation 
with specific N-terminal cMyBP-C antibody, suggesting that antibody competition 
for cMyBP-C resulted in less cMyBP-C affinity for  the thin-filament and hence, 
a reduced accessibility of myosin-binding sites (Fig. 4C). Maximal ADP-Fact significantly 
reduced upon cMyBP-C N-terminal antibody incubation, while it did not affect passive 
tension (ADP-Fpass) (Table 3). To control for protocol artefacts (e.g. unspecific antibody 
binding), another set of cardiomyocytes was incubated for 90 minutes with an antibody 
against the C10 domain of cMyBP-C (domain involved in cMyBP-C anchoring to 
the thick-filament) or a control antibody (against nucleophosmin, a nucleolar protein). 
Increased responsiveness to ADP was found for the C10 antibody associated with 
a small drop in ADP-Fpass, while no alterations in ADP-sensitivity, maximal force and 
ADP-Fpass was found using nucleolar protein antibody (Fig. 4C and Table 3). These 
data support that the effects seen for the C0 antibody were specific to the N-terminal 
region of cMyBP-C.
Finally, haploinsufficiency was also reported in HCM with MYBPC3 missense 
mutations23, including the mutation investigated in our study (E258K). Indeed, 
samples with MYBPC3mut missense mutations in our study showed a 22±9% reduction 
in cMyBP-C protein level compared with donors.
Correction of ADP-sensitivity in HCM with mutant cTnT by human recombinant 
wild-type troponin
To evaluate whether mutant thin-filament protein directly causes destabilization of 
the B-state and changes sensitivity to ADP, troponin exchange experiments were 
performed in cardiomyocytes from the TNNT2mut sample. Because the homozygous 
TNNT2mut results in 100% mutant cTnT protein, it provides the unique opportunity to 
control the amount of wild-type human troponin complex incorporated. 
Exchange was performed with 1 mg/mL of wild-type human troponin complex 
and resulted in 85±2% troponin exchange based on Western blot analyses of 
endogenous and myc-tag labeled wild-type cTnT (Fig. 5A). We have previously 
shown that this protocol does not affect other sarcomeric (phospho)proteins.8,9  In 
exchanged cells without PKA treatment, replacement of mutant troponin with 
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figure 4. Cardiac myosin-binding protein-C (cMyBP-C) regulates ADP-sensitivity. A) cMyBP-C 
protein levels were assessed in MYBPC3trunc (n=9) and Donor (n=3) samples. Western blots were 
stained with specific antibodies for total cMyBP-C and tropomyosin (loading control). No traces of 
truncated cMyBP-C proteins were found in MYBPC3trunc samples. (B) Expression level of cMyBP-C was 
significantly lower in MYBPC3trunc than in donors. cMyBP-C protein levels from MYBPC3trunc samples 
were plotted against their corresponding sample average for ADP-sensitivity (after protein kinase 
A (PKA) treatment). (C) Single membrane-permeabilized cardiomyocytes isolated from idiopathic 
dilated cardiomyopathy heart samples were incubated with a specific cMyBP-C N’-terminal (mouse 
monoclonal) antibody, cMyBP-C C’-terminal (rabbit polyclonal) or a control (mouse monoclonal) 
antibody against nucleophosmin (antibodies used at 1:100 dilutions). Myofilament ADP-sensitivity 
(EC50) before (-) and after (+) treatment with cMyBP-C antibody (N’ or C’ cMyBP-C ab) or nucleophosmin 
antibody (control ab). Myofilament ADP-sensitivity was significantly reduced after N’ cMyBP-C ab 
treatment, but not after C’ cMyBP-C ab or control ab. Data were compared using Paired samples 
t-Test for each specific group of antibodies. 8-11 cardiomyocytes from 3 to 4 failing heart samples 
were used per group.
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recombinant unphosphorylated wild-type troponin did not restore the ADP-sensitivity 
(Fig. 5B, 3.16±0.16 mM ADP) to donor levels (Fig. 3B, 3.96±0.15 mM ADP). Notably, 
PKA treatment in exchanged cells containing 85% wild-type troponin complex 
restored ADP-sensitivity (Fig. 5B, 4.16±0.24 mM ADP) to donor levels that were 
PKA-treated (Fig. 3C, 4.38±0.16 mM ADP). Control TNNT2mut cardiomyocytes, in 
the presence of exchange buffer without wild-type troponin complex showed similar 
ADP-sensitivity (Fig. 5B, 2.86±0.07 mM ADP before PKA and 2.98±0.05 mM ADP after 
PKA) as TNNT2mut cardiomyocytes without the exchange procedure (Fig. 3B and 3C, 
3.00±0.17 mM ADP before PKA and 3.34±0.13 mM ADP after PKA). Together, these 
results support that this specific cTnT mutant protein disrupts tropomyosin’s B-state 
position on actin and hence, is highly susceptible for ADP-activated myosin-binding.
Physiological ADP levels increase Ca2+-sensitivity in idiopathic dilated and 
hypertrophic cardiomyopathy
We recently provided evidence that elevation of myocardial ADP levels, even in 
the μmolar range, in the presence of diastolic Ca2+, contribute to diastolic dysfunction 
by increasing residual actin-myosin interactions and elevating myofilament Ca2+-
sensitivity.17 This leads to high cardiomyocyte stiffness and abnormal relaxation, 
associated with limited ventricular compliance.17 In HCM animal models an increased 
table 3. Response of ADP-stimulated contraction with cardiac myosin-binding protein C (cMyBPC) 
and control antibodies.
sample before after ns
N’ cMyBPC ab (2.2 μm) N’ cMyBPC ab (2.2 μm)
IDCM N=4, n=11
ADP-Fact (kN/m
2) 8.4±1.0 6.6 ±0.9*
ADP-Fpass (kN/m
2) 0.36±0.1 0.33±0.1
nucleolar ab  (2.2 μm) nucleolar ab  (2.2 μm) N=3, n=8
IDCM 
ADP-Fact (kN/m
2) 9.3±1.1 9.0±1.0
ADP-Fpass (kN/m
2) 0.57±0.1 0.50±0.1
C’ cMyBPC ab  (2.2 μm) C’ cMyBPC ab  (2.2 μm) N=3, n=11
IDCM 
ADP-Fact (kN/m
2) 11.7±1.9 10.8±2.0
ADP-Fpass (kN/m
2) 1.5±0.3 1.2±0.2*
Paired samples t-Test. p<0.05 was considered significant; *vs before antibodies; ab, antibody; C’ cMyBPC or 
nucleolar antibody served as controls for unspecific binding; N= number of samples; n= number of cardiomyocytes; 
2.2 μm sarcomere length; IDCM, idiopathic dilated cardiomyopathy; ADP-Fact, ADP total tension (10 mM ADP); 
ADP-Fpass, ADP passive tension
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[ADP] was observed from ~60 μM in controls to ~100 μM in diseased hearts.28-30 
We therefore investigated if an ADP level as reported in diseased hearts (100 μM) 
in concert with Ca2+ increases force generation in human membrane-permeabilized 
cardiomyocytes from IDCM and HCM hearts compared to non-failing donor 
myocardium. Figures 6A and 6B show normalized force-Ca2+ relations in the presence 
of 100 μM ADP, before and after PKA treatment, for MYH7mut and MYBPC3mut samples. 
figure 5. Cardiac troponin T (cTnT) regulates ADP-sensitivity. Endogenous mutant cTnT in TNNT2mut 
cardiomyocytes was exchanged by exogenous recombinant human wild-type troponin complex. 
TNNT2mut cells were incubated with 1 mg/mL wild-type human troponin complex or without troponin 
complex (Control). (A) Quantification of troponin exchange in cardiomyocytes from a TNNT2mut heart. 
Immunoblots stained with a specific antibody against cTnT that recognizes both endogenous mutant 
cTnT (lower band) and recombinant myc-tag wild-type cTnT (cTnT-myc; upper band). TNNT2mut 
without recombinant troponin complex (lanes 1 and 2; Control cells) and with 1 mg/mL recombinant 
wild-type troponin complex (lanes 3 and 4). Exchange resulted in 85±2% troponin exchange based 
on Western blot analyses of endogenous and myc-tag labeled wild-type cTnT. (B) Myofilament 
ADP-sensitivity (EC50) before (-) and after (+) protein kinase A (PKA)-treatment. ADP-sensitivity was 
significantly reduced after PKA treatment in troponin-exchanged cardiomyocytes. No change in 
myofilament ADP-sensitivity was observed in control cardiomyocytes from the TNNT2mut heart. Data 
were compared using 2-way ANOVA followed by Bonferroni post-hoc test. 4 cardiomyocytes from 1 
TNNT2mut heart were used per group.
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In the presence of 100 μM ADP, myofilament Ca2+-sensitivity was significantly higher 
in IDCM and HCM samples compared to donors (Fig. 6C). Because we have previously 
demonstrated that the high myofilament Ca2+-sensitivity in human cardiomyopathy 
samples correlates well with the low phosphorylation of PKA myofilament targets4,9, 
we repeated the measurements after treatment with exogenous PKA. PKA treatment 
figure 6. Myofilament Ca2+-sensitivity and sarcomere stiffness, in the presence of 100 µM ADP, 
in idiopathic dilated (IDCM) and hypertrophic (HCM) cardiomyopathy membrane-permeabilized 
cardiomyocytes. Normalized force-Ca2+ relationships before and after protein kinase A (PKA) in 
the presence of ADP for MYH7mut (A) and MYBPC3mut (B) heart samples. Myofilament Ca
2+-sensitivity in 
the presence of ADP (EC50) before (C) and after (D) PKA treatment in IDCM, HCM and donor samples. 
Residual force, a measure of sarcomere stiffness, at high Ca2+ with 100 µM ADP (EC50) before (E) 
and after (F) PKA treatment in IDCM, HCM and donor samples. Data was compared using multilevel 
analysis. N= number of samples; n= number of cardiomyocytes. IDCM (N=4, n=18) MYH7mut, myosin 
heavy chain mutations (N=3, n=10); MYBPC3mut, myosin-binding protein-C (missense) mutations 
(N=3, n=10); MYBPC3trunc, myosin-binding protein-C (truncating) mutations (N=4, n=12); TNNT2mut, 
cardiac troponin T mutation (N=1, n=4); TNNI3mut, cardiac troponin I mutation (N=1, n=4); HCMsmn, 
sarcomere mutation-negative HCM samples (N=3, n=8). 14 cardiomyocytes from 5 non-failing hearts 
(donor) served as controls.
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normalized the high Ca2+-sensitivity in HCM with MYBPC3 and TNNI3mut mutations 
and HCMsmn, while Ca
2+-sensitivity remained higher in IDCM, MYH7mut and TNNT2mut 
samples (Fig. 6D). In addition, we observed augmented sarcomere stiffness for all 
sarcomere-mutation positive HCM samples evidenced by high residual force compared 
to non-failing donors (Fig. 6E). Residual force values in IDCM and HCMsmn were 
similar to those observed in non-failing donor cells before and after PKA treatment 
(Figs. 6E and 6F). The increase in sarcomere stiffness suggests an increased strain for 
each individual cross-bridge and/or an enhanced number of actin-myosin interactions 
for HCM samples with sarcomeric mutant proteins. 
DisCussion
In this study we show that ADP-stimulated contraction can be used as experimental 
tool to assess changes in thin-filament transitions induced by sarcomeric mutations and 
phosphorylation-mediated protein alterations. These mutation- and phosphorylation-
related changes in ADP-sensitivity are explained by changes in tropomyosin’s 
position and the number of accessible myosin-binding sites on actin. In accordance 
with our first hypothesis, we show that HCM cardiomyocytes containing troponin 
mutations have high ADP-sensitivity, irrespective of the phosphorylation background. 
High ADP-sensitivity was corrected to control values upon incorporation of healthy 
troponin in HCM cardiomyocytes harboring a homozygous TNNT2mut mutation. These 
data indicate that the troponin mutations investigated in the present study disrupt 
the steric blockade imposed by tropomyosin, which favors accessibility of myosin-
binding sites on actin. The high responsiveness to ADP observed in IDCM, MYH7mut 
and HCMsmn is, in this context, solely explained by reduced PKA-phosphorylation 
of myofilament proteins. This is consistent with the idea that PKA phosphorylation 
of the myofilaments stabilizes the B-state thin-filament formation, which reduces 
myosin-binding sites on actin. Moreover, in agreement with our second hypothesis 
HCM samples with MYBPC3 mutations were shown to have less sensitivity to ADP 
compared with cells from non-failing hearts, in support for the enhanced stabilization 
of the steric blockade of tropomyosin. 
Finally, a pathophysiologic level of ADP elevated myofilament Ca2+-sensitivity in 
all disease samples. Furthermore, under these conditions, high myofilament stiffness 
was observed in samples from HCM patients with sarcomeric mutations. The high 
myofilament Ca2+-sensitivity in the presence of ADP was corrected to control values 
by PKA in all HCM samples, except for the samples with MYH7 and TNNT2 mutations, 
while myofilament stiffness was unaffected by PKA in all mutation-positive HCM 
samples. These data illustrate the complex interaction between changes in protein 
phosphorylation, calcium and ADP. Overall, our data support the notion that increased 
actin-myosin interactions during the diastolic phase may occur in environments 
where the myofilaments are highly sensitized by the complex interactions of low 
phosphorylation of PKA-targets, elevated in vivo levels of ADP and of diastolic Ca2+, 
which may limit muscle relaxation.
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Modulation of ADP-sensitivity by PKA-mediated phosphorylation
We showed that PKA-mediated phosphorylation of the myofilaments reduced 
the responsiveness to ADP, supporting the stabilization of the B-state formation 
(Figs. 2 and 3C). In the intact heart, regulation of [Ca2+]i transients is accomplished 
via sympathetic stimulation of β-adrenergic receptors, which results in positive 
inotropic (contraction), lusitropic (relaxation) and chronotropic (frequency) effects.31 
At the myofilament level, PKA main targets are cTnI, cMyBP-C and titin. Multiple 
roles have been assigned to increased PKA-phosphorylation of myofilament proteins, 
such as reduced myofilament Ca2+-sensitivity, increased length-dependent activation 
(cellular basis of the Frank-Starling relation) and enhanced cross-bridge cycling 
kinetics via phosphorylation of cTnI and cMyBP-C.5-8
The reduced ADP-sensitivity following PKA incubation implies strengthening of 
the B-state localization of tropomyosin. There are likely mechanisms, which may act 
synergistically, that could explain this effect:
Firstly, the reduction in ADP-sensitivity may be explained by cTnI phosphorylation. 
Two sites on cTnI are known to be target of PKA-induced phosphorylation in human, 
Serines 23 and 24.32,33 Phosphorylation of these sites is associated with reduced Ca2+-
affinity of troponin C (cTnC)34 due to structural changes of cTnC that diminish its Ca2+-
affinity35-37. Although cTnC changes are likely sufficient to account for the reduction 
of myofilament Ca2+-sensitivity upon PKA activation, they do not necessarily apply to 
the present conditions where Ca2+ is absent. It has been shown that the C-terminal 
half of cTnI docks the troponin-tropomyosin complex onto the outer domain of 
actin at low cytoplasmic [Ca2+]38, thereby stabilizing the formation of the B-state. 
The reduced ADP-sensitivity after PKA treatment likely reflects potentiation of 
the inhibitory function of cTnI-tropomyosin on actin as PKA decreases the affinity 
of cTnI for cTnC. The PKA-mediated conformational changes would increase 
tropomyosin-mediated blockade of myosin-binding sites on actin.
Secondly, PKA-mediated phosphorylation of cMyBP-C may underlie the observed 
reduction in ADP-sensitivity. PKA-phosphorylation of cMyBP-C occurs at the M-domain 
where it interacts with actin.39 It was shown that M-domain phosphorylation reduces 
the N-terminal affinity of cMyBP-C for actin40, consistent with less activation of the thin-
filament41. One can speculate that cMyBP-C phosphorylation reduces competition 
between cMyBP-C and tropomyosin on actin, and subsequently decreases the number 
of myosin-binding sites on actin.
Modulation of ADP-sensitivity by the N’ and C’ terminus of cMyBP-C
In the heart, up to 9 transverse stripes (half-sarcomere) of cMyBP-C are observed in 
the C-zone, where it is recently been proposed to modulate myofilament activation.42 
The C-terminus of cMyBP-C is important for proper localization and anchoring onto 
the thick-filament and the rod region of myosin.43,44 The N-terminal region has been 
shown to directly interact with actin in in vitro studies45,46 and in situ 3D reconstructions, 
where it was shown to regulate thin-filament transitions via direct competition for 
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the low Ca2+-state (B-state) position with tropomyosin20,21. Here we provide further 
evidence for N-terminal cMyBP-C’s interaction with tropomyosin by showing that 
cMyBP-C regulates thin-filament transitions via its N-terminal region (Fig. 4C). 
Pre-incubation of IDCM myofilaments with a N-terminal cMyBP-C antibody is expected 
to decrease cMyBP-C’s affinity to bind and compete with tropomyosin and shift it 
towards the C-state. Indeed, N-terminal cMyBP-C antibody pre-incubation decreased 
ADP-sensitivity in membrane-permeabilized cardiomyocytes, consistent with less 
myosin-ADP binding to actin. In addition to its effect on the thin-filament, there is 
general agreement that cMyBP-C acts as brake on myosin cross-bridge cycling.47-
49 This effect is mediated by the interaction of cMyBP-C’s N’ terminus (C1-C2) with 
subfragment 2 (S2) of myosin50, whereby cMyBP-C is able to slow cross-bridge cycling 
kinetics. Interestingly, incubation of membrane-permeabilized cardiomyocytes with 
specific antibody binding to the C’ terminus of cMyBP-C increased the responsiveness 
to ADP (Fig. 4C). This might be due to allosteric protein changes that translate their 
effects from the C-terminal domain of cMyBP-C to its N-terminal region, which release 
part of the brake on myosin.
Haploinsufficiency of cMyBP-C reduces ADP-sensitivity of myofilaments
Our data indicate that loss of cMyBP-C full length protein (i.e. haploinsufficiency) 
in HCM with truncating cMyBP-C mutations weakens cMyBP-C-tropomyosin 
interactions and result in a reduced accessibility of myosin-binding sites on actin, 
evident from a reduced ADP-sensitivity (Figs. 3B and 3C). This is consistent with 
the recent observation that the N-terminal region of cMyBP-C binds to the low Ca2+-
state position of tropomyosin (B-state), which is sufficient to interfere and compete 
with tropomyosin-actin interactions, moving tropomyosin into the C-state position.20,21 
A schematic picture is presented in Figure 7A to illustrate that the loss of cMyBP-C 
full length protein weakens the overall cMyBP-C-tropomyosin interaction resulting 
in reduced accessibility of myosin-binding sites on the actin filament in the absence 
of Ca2+. In contrast, the presence of cMyBP-C competes with tropomyosin for 
the B-state position on actin and increases the accessibility of myosin-binding 
sites on the actin filament (Fig. 7B). Reduced ADP-sensitivity was also observed in 
cMyBP-C HCM samples with missense mutations, where loss of full length protein 
may similarly decrease the availability of myosin-binding sites on actin. However, 
in these samples cMyBP-C poison peptide effects on muscle function cannot be 
excluded. The mutant protein could directly interfere with cMyBP-C-tropomyosin 
interactions. One can speculate that in particular the E258K mutation (localized on 
the actin-binding site51) has the potential to reduce its actin-affinity and thereby alter 
cMyBP-C-tropomyosin competition.
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Increased diastolic actin-myosin interactions in cMyBP-C haploinsufficient tissue
While ADP responsiveness of myofilaments from HCM with MYBPC3 mutations is 
reduced (Fig. 2B), myofilament sensitivity to Ca2+ is increased in the presence of 
pathophysiological levels of ADP (Fig. 5C). In the absence of Ca2+ and with low levels 
of cMyBP-C, an increased pool of myosins is less restrained by cMyBP-C at the thick-
filament C-zone area. However, the myosin-binding sites on actin are less accessible 
due to the higher steric blockade as a result of reduced cMyBP-C-tropomyosin 
interactions (Fig. 6A). Hence, fewer actin-myosin interactions are formed. In 
the presence of Ca2+, Ca2+ binding to troponin causes the movement of tropomyosin 
on actin and leads to the uncovering of myosin-binding sites. The reduced restraining 
effect on myosin caused by the low levels of cMyBP-C in combination with increased 
accessibility of myosin-binding sites on actin cause an increased myofilament Ca2+-
sensitization. Based on our findings this suggests that even low levels of Ca2+, as those 
that exist in vivo during the diastolic phase, are sufficient to increase actin-myosin 
interactions in HCM heart with MYBPC3 mutations and may be capable of limiting 
relaxation during diastole. This is indeed observed in cMyBP-C KO mice with a HCM 
phenotype, where cross-bridge cycling is accelerated in membrane-permeabilized 
cardiomyocytes47,48, consistent with impaired relaxation of intact cardiomyocytes52. 
Pohlmann et al.52 observed that cardiomyocytes with total cMyBP-C ablation 
contracted at very low Ca2+ levels and had lower diastolic sarcomere length, that 
was associated with high actin-myosin interactions (i.e. diastolic length was partially 
normalized to controls following addition of the cross-bridge inhibitor BDM). This 
is also consistent with the augmented sarcomere stiffness observed in MYBPC3 
mutations (Fig. 5E) that could not be rescued after PKA treatment (Fig. 5F). Although 
counter-intuitive with the findings in the absence of Ca2+ (Fig. 2), where cross-
bridge formation is reduced, it likely reflects the complex interaction of the factors 
discussed above, including thin-filament accessibility and Ca2+-responsiveness. 
Overall, the results supports the concept that cMyBP-C restrains actin-myosin 
interactions at low Ca2+ to allow complete relaxation and filling during diastole.
Troponin mutants increase ADP-sensitivity of myofilaments
Here we provide evidence that mutations in troponin subunits may increase the 
availability of myosin-binding sites on actin, illustrated by higher myofilament ADP-
sensitivity (Fig. 3B). A schematic picture is presented in Figure 7C to illustrate that 
more myosin-binding sites are accessible due to the greater disruption of the B-state 
caused by troponin mutations. Notably, troponin exchange experiments provide 
the direct proof that the endogenous mutant cTnT, used in this study, impairs 
tropomyosin’s B-state position (Fig. 5B). This is in good agreement with solution 
studies with reconstituted HCM mutant troponin-tropomyosin proteins (in cTnI19 and 
cTnT18) that support for a disrupted B-state. The C-terminal half of cTnI (residues 
137-210) docks the troponin-tropomyosin complex onto the outer domain of actin at 
low [Ca2+] and thereby maintains formation of the B-state.38 It is likely that the present 
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figure 7. Schematic diagram of a half-sarcomere illustrating thin-filament transitions, in the absence 
of Ca2+. The average length of the thin-filament (half-sarcomere) is 1.05 μm53,54, which consists of 
a 38.5 nm periodicity of the actin-tropomyosin-troponin (A7TmTn, functional unit) complex
55,56, i.e. 
each half thin-filament consists of 27 A7TmTn units (red and green rectangular boxes depict functional 
units). The length of the thick-filament is ~1.63 μm. After subtracting the thick-filament bare zone 
(M-band region that is deprived of myosin heads; 0.16 μm), the thick-filament length per half-
sarcomre is ~0.74 μm57. Since the distance between myosin helical repeats is 42.9 nm (on the ame 
axis layer)58, ~18 myosins occupy each half-thick filament. (A) Solution studies indicate that ~95% of 
the myofilaments in the free Ca2+ state are blocked (B-state) in the absence of cardiac myosin-binding 
protein-C (cMyBP-C)10. This indicates that ~26 A7TmTn units are blocked (depicted in red) and only 
a single unit of A7TmTn is in the C-state position (depicted in green) per half-thin filament. The single 
“C”-state functional unit is randomly drawn in the scheme. This situation parallels cMyBP-C truncating 
mutations, where reduced total cMyBP-C protein levels have been found.22,23 Please note that for 
clarity no cMyBP-C is shown (i.e. mimicking full lack of cMyBP-C). (B) In the presence of cMyBP-C more 
myosin-binding sites are available on actin, since the N-terminal extension of cMyBP-C dislocates 
tropomyosin into the C-state position20,21 (depicted as 7 green functional units). Assuming that cardiac 
muscle contains a minimum of 7 cMyBP-C at regular intervals of 43 nm starting from “stripe” 5 to 
11 in the C-zone (215 nm from the M-band)59, cMyBP-C would coincide with the 2nd to 3rd myosin 
counting from the M-band in the scheme. This situation mimics healthy donor samples. (C) Mutations 
in troponin subunits disrupt troponin-tropomyosin interactions, which causes the thin-filament to be 
less blocked. As shown in the picture more functional units are in the C-state.
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cTnI mutation (R145W) disrupts cTnI-tropomyosin interactions, which increases 
the availability of myosin-binding sites on actin. Likewise, cTnT via its interaction with 
tropomyosin stabilizes the thin-filament in the B-state60,61, supporting that, at least 
the current cTnT mutation may confer a greater availability of myosin-binding sites 
on actin. Altogether these findings indicate that mutations in troponin proteins may 
disrupt the blockade of tropomyosin on actin, which precede the rise of cytosolic 
Ca2+, and are able to augment actin-myosin interactions during the diastolic phase 
in HCM patients.
Clinical implications
Our study shows that the high basal sarcomeric activation previously observed in 
animals and humans with HCM9,62-64 with thin-filament mutations may be partly due 
to the diminished steric blockade of myosin-binding sites on actin by tropomyosin 
that precede the rise in cytosolic Ca2+ (Fig. 3B). Our data illustrate that this effect 
is exacerbated by the diminished PKA protein phosphorylation in HCM and IDCM 
hearts (Fig. 3C). The high myofilament Ca2+-sensitivity in patient samples with low PKA 
phosphorylation in the presence of pathologic ADP levels (Fig. 6) may be sufficient to 
slow ventricular relaxation. Additionally, sarcomere mutation-positive HCM samples 
show augmented sarcomere stiffness, which is not caused by low PKA phosphorylation 
(Figs. 6E and 6F). The increased myofilament Ca2+-sensitivity and high sarcomere 
stiffness in the presence of ADP is in line with our previous study, where we showed 
that the complex interactions of Ca2+ and ADP increased myofilament Ca2+-sensitivity 
and stiffness in membrane-permeabilized rat cardiomyocytes, limited restoration of 
diastolic length in intact rat cardiomyocytes and diminished ventricular compliance 
in whole rat hearts.17 Altogether these myofilament changes have the potential to 
delay the onset of ventricular relaxation and limit proper filling, which are seen in 
patients65,66 and animal models62,63 of HCM, and human IDCM4. 
ConClusion
We conclude that a rather straightforward activation assay with ADP, in a membrane-
permeabilized muscle preparation, can be used to reveal conformational changes 
in the 3-state model of thin-filament activation induced by mutations and post-
translational modifications such as phosphorylation. The ADP-stimulated contraction 
assay indicates that increased force at diastolic Ca2+ levels, as observed in 
cardiomyopathies, involves increased cross-bridge formation, and is not restricted 
to changes in Ca2+-binding affinity of cTnC. In addition, we show that pathologic 
ADP levels increase myofilament Ca2+-sensitivity and stiffness, which may together 
contribute to the diastolic dysfunction seen in acquired and genetics forms of 
cardiomyopathy in humans.
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summary, ConClusions & future PersPeCtives
“All truths are easy to understand once they are discovered; the point is to discover them.”
Galileo Galilei
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summary
The purpose of this thesis was to dissect the cellular and mechanical alterations 
related to myocardial inactivation that limit diastolic performance in patients with 
familial hypertrophic cardiomyopathy (HCM) and patients with non-familial causes of 
heart failure. From experiments at the cellular and whole organ level, in humans and 
rats, we are able to translate our findings into the in vivo human setting to obtain 
a better understanding of human cardiac performance.
High myofilament Ca2+-sensitivity is a common characteristic in human HCM
Significant efforts have been made to identify a common pathomechanism triggered 
by mutations that could explain the multitude of intracellular events observed in 
HCM. Impaired relaxation is a general finding in humans and animals carrying HCM 
gene mutations. Impaired diastolic function is observed before the development 
of hypertrophy and fibrosis. Impaired relaxation may be explained by the elevated 
myofilament Ca2+-sensitivity (the “high Ca2+-state”), which is observed in the majority 
of in vitro and transgenic mice studies. The high myofilament Ca2+-sensitivity would 
be sufficient to cause ‘systolic’ activation at low [Ca2+] capable of delaying the onset of 
relaxation. In Chapter 3 we performed a comprehensive study on a large set of human 
HCM samples to identify if high myofilament Ca2+-sensitivity is characteristic of human 
HCM with mutations in thick- and thin-filament proteins. Since high myofilament 
Ca2+ sensitization depends on muscle length and the phosphorylation state of 
myofilaments, cardiomyocyte force measurements were performed at two different 
sarcomere lengths (i.e. length-dependent activation), without and with treatment with 
exogenous protein kinase A (PKA). Measurements were performed in HCM samples 
and compared with sarcomere mutation-negative and non-failing donors. We 
observed that high myofilament Ca2+-sensitivity is a common characteristic of human 
HCM, though partly reflects the hypophosphorylated state of PKA targets and cannot 
solely be related to the mutant protein itself. In addition, reduced length-dependent 
myofilament Ca2+-activation was shown to represent a common pathomechanism 
in HCM with missense mutations, which is independent of the phosphorylation 
background. Moreover, a blunted increase in maximal force development upon 
an increase in sarcomere length was found in HCM carrying missense mutations. 
The diminished length-dependent myofilament Ca2+-activation was not rescued upon 
PKA administration in HCM with sarcomeric mutations. Finally, we provided direct 
proof that mutant troponin T (at least for the K280N) impairs length-dependent 
activation, supporting that mutations affect thin-filament geometry.
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High myofilament Ca2+-sensitivity and length-dependent activation are 
regulated by PKA and PKC phosphorylation of cardiac troponin I
In Chapter 4 the effects of troponin I (cTnI) phosphorylation at threonine 143 (Thr143) 
site by protein kinase C (PKC) on myofilament Ca2+-sensitivity and length-dependent 
activation were studied. Because Thr143 is a well characterized PKC-phosphorylation 
site that is highly phosphorylated in human failing hearts, we investigated if 
phosphorylation of Thr143 modifies myofilament Ca2+-sensitivity and length-dependent 
activation in human cardiomyocytes. PKC-mediated phosphorylation at Thr143 may 
be detrimental for the diastolic phase. The effects of Thr143 phosphorylation were 
compared with the well-known protein kinase A (PKA) phosphosites serines 23 and 
24 (Ser23/24) of cTnI. Troponin exchange experiments were performed in membrane-
permeabilized human cardiomyocytes. Isometric force was measured at various [Ca2+] 
in exchanged cardiomyocytes with recombinant wild-type (Wt) troponin or troponin 
mutated at the PKC site Thr143, or Ser23/24 into aspartic acid (D) or alanine (A) to 
mimic phosphorylation and dephosphorylation, respectively. In troponin-exchanged 
donor cardiomyocytes experiments were repeated after incubation with exogenous 
PKA. Pseudo-phosphorylation of Thr143 site increased Ca2+-sensitivity compared to 
controls (Wt) without affecting length-dependent activation of control cardiomyocytes. 
Subsequent PKA treatment enhanced the length-dependent shift in Ca2+-sensitivity 
after Wt and 143D exchange. Exchange with Ser23/24 phosphosites demonstrated 
that pseudo-phosphorylation of both Ser23 and Ser24 sites is required for the length-
dependent increase in Ca2+-sensitivity. cTnI pseudo-phosphorylation did not alter 
length-dependent changes in maximal force. In conclusion, phosphorylation at Thr143 
enhances myofilament Ca2+-sensitivity without affecting length-dependent activation, 
while Ser23/24 bisphosphorylation is needed to enhance the length-dependent 
increase in myofilament Ca2+-sensitivity. This study provides evidence that low PKA-
mediated phosphorylation as observed in HCM cardiomyopathy may cause the high 
Ca2+-sensitivity (the “high Ca2+-state”) and impair length-dependent activation    
Energy depletion and diastolic dysfunction - detrimental effects of high ADP 
On the basis of the previous findings that human HCM tissue confers a high degree 
of thin-filament activation, even at low Ca2+, we sought to characterize the impact of 
sustained basal systolic stress in relation to myocardial energy deficiency. Increased 
myofilament ATP consumption has been observed in HCM animal models and our 
group recently confirmed this in human HCM patients, evident from the increased cost 
(ATP utilization) for myofilament contraction, i.e. reduced tension cost. The impaired 
tension cost may result from an increased Ca2+-induced myosin-ATPase activity, which 
would decrease myocardial energy supply for other ATP-dependent processes in 
the cardiac muscle cells. There is a general consensus that the myocardial energy 
reservoir in HCM patients is reduced, as a result of reductions in ATP content, also 
termed the “myocardial energy depletion hypothesis”. Although attractive, this 
hypothesis fails to address the paradigm that in vivo ATP levels at rest in animal models 
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of heart failure are mostly unchanged and that even during increased workloads, 
the [ATP] is never rate-limiting to power actomyosin interactions. To this end, in 
Chapter 5 we performed a basal study ranging from experiments at the cellular level to 
the whole organ, in humans and rats, as to provide the proof-of-concept that myocardial 
accumulation of ADP (instead of reduced ATP), even in the micromolar amount, can 
contribute to diastolic dysfunction. We provide evidence that synergistic actions of 
physiological levels of ADP and diastolic Ca2+ increase actomyosin interactions, which 
elevate myocardial stiffness and limit proper filling of the heart. Our findings show that 
increased cross-bridge interactions may lead to diastolic dysfunction in environments 
with elevated ADP and diastolic Ca2+, evidenced by high cardiomyocyte stiffness and 
impaired diastolic re-lengthening, associated with limited ventricular compliance. In 
addition, we also showed that the contribution of cross-bridge interaction to total 
diastolic stress in rat membrane-permeabilized cardiomyocytes is much higher than 
previously considered. Perhaps most importantly, we showed that physiological 
levels of ADP (which increase strong-binding cross-bridge formation) are sufficient 
to increase myofilament Ca2+-sensitivity and result in diastolic Ca2+-overload. We 
speculate that the latter rise of diastolic Ca2+ can either result from the high Ca2+-
sensitivity that buffers more Ca2+ at the myofilaments and/or alterations in the 
ADP/ATP ratio that reduce the free energy released from ATP hydrolysis (∆GATP) of 
the sarcoplasmic reticulum Ca2+-ATPase (SERCA). Our study supports the idea that 
elevations of intracellular ADP, in specific types of cardiac disease where myocardial 
energy reserve is limited, contribute to diastolic dysfunction by recruiting cross-
bridges even at low Ca2+ (“high Ca2+-state”).
High cross-bridge component in HCM
The fact that impaired relaxation is an almost universal finding in heart failure patients, 
and that this may result from inappropriate formation of force-producing cross-bridges 
during diastole (“high Ca2+-state”) lead us to study the mechanical changes associated 
with the blockade of actomyosin interactions, i.e. alterations in tropomyosin’s position 
in Chapter 6. To this end, we investigated if the accessibility of myosin-binding sites 
on actin is altered in human idiopathic dilated cardiomyopathy (IDCM) and HCM 
samples. By measuring cardiomyocyte force-production in ADP-containing solutions 
(without Ca2+) without and with exogenous PKA, the ability of myosin-ADP to bind 
non-blocked sites on actin was assessed. It is important to stress that any alteration in 
actomyosin interaction at this stage (no Ca2+, but with ADP), precedes changes that 
occur in the presence of Ca2+ as occurs during muscle activation. In other words, an 
increased contribution of force-producing cross-bridges at the blocked state (B-state) 
will enhance the number of cross-bridges that are recruited in the presence of Ca2+. 
Our study supports that diseased muscle has disrupted steric blockade of the thin-
filament. This is either caused by the presence of mutant proteins, lack of protein 
in the case of cMyBP-C haploinsufficiency and/or reduced PKA-phosphorylation of 
myofilament proteins. Our mechanistic study supports the novel idea that the OFF 
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to ON transition of the thin-filaments is regulated by PKA-target phosphorylation 
and cMyBP-C. In addition, we show that, in the absence of Ca2+, troponin mutations 
increase the actomyosin interactions; in contrast cMyBP-C and PKA both reduce 
accessibility of myosin-binding sites on actin. 
Finally, cardiomyocyte from IDCM and HCM were shown to be more sensitive to 
Ca2+ in the presence of a pathologic level (100 μM) of ADP compared to controls. 
Exogenous treatment with PKA revealed that, except for troponin T mutations and 
myosin heavy chain mutations, all HCM samples were normalized to controls. Although 
PKA reduced myofilament Ca2+-sensitivity in all samples, EC50 values in HCM in 
the presence of ADP (mimicking energy depletion) do not increase to the value 
observed in non-failing donor myocardium in the absence of ADP (i.e. healthy 
condition; Figure 1). In other words, our data suggest that even in environments 
where PKA-phosphorylation is preserved or normalized to controls, Ca2+-sensitivity 
remains high due to an elevation of ADP. The detrimental effect of ADP in myofilament 
function is exacerbated when PKA-phosphorylation background is reduced compared 
to controls. In summary, our data support that enhanced actomyosin interaction 
contributes to diastolic dysfunction as myofilaments are highly sensitized by 
the synergistic actions of low phosphorylation of PKA-targets, elevated in vivo levels 
of ADP and of Ca2+.
figure 1. Myofilament Ca2+-sensitivity at a sarcomere length of 2.2 μm. Myofilament Ca2+-sensitivity 
in the absence (gray bars) and presence of 100 µM ADP (black bars) in hypertrophic cardiomyopathy 
(HCM) cardiomyocytes. Myofilament Ca2+-sensitivity before (A) and after (B) protein kinase A (PKA). 
Data was compared using multilevel analysis. MYBPC3mut, myosin-binding protein-C mutations; 
MYH7mut, myosin heavy chain mutations; TNNT2mut, cardiac troponin T mutation; TNNI3mut, cardiac 
troponin I mutation; HCMsmn, sarcomere mutation-negative HCM samples. Non-failing hearts (donor) 
served as controls. Data from Chapter 3 and chapter 6 were combined to assess the effects of calcium 
in the absence (Chapter 3) and presence (Chapter 6) of a pathologic ADP level. Moreover, these 
graphs illustrate the effect of hypophosphorylation, which is frequently observed in cardiomyopathy. 
If  we assume that ADP in HCM is high and phosphorylation of myofilament proteins is low, EC50 in 
HCM myocardium would be ~1 μM, compared to ~3 μM in non-failing donor myocardium with high 
PKA-phosphorylation and no ADP.
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ConClusions
The main message of my studies is that a high level of cross-bridge interaction, which 
increases myofilament Ca2+-sensitivity, contributes to force development during 
the diastolic phase. This may impair ventricular relaxation and limit ventricular filling. 
An optimal therapeutic strategy would be to reduce the ‘high Ca2+-state’ and in parallel 
correct low PKA-phosphorylation and the elevated myocardial ADP. As highlighted, 
the ‘high Ca2+-sensitive’ state has the potential to slow myocardial relaxation, limit 
diastolic re-lengthening and heart cavity size. These would reduce the Frank-Starling 
reserve and may ultimately lead to sudden cardiac arrest. Overall our data suggests 
that a combination of adrenergic and metabolic treatment might be beneficial for 
diastolic heart failure patients. 
future PersPeCtives
Based on our recent findings published in Chapters 3, 5 and 6, we propose that high 
myofilament Ca2+-sensitivity (‘the high Ca2+-state’) is a common characteristic in human 
HCM, which may associate with high ADP levels. It is currently unclear why HCM 
patients would suffer from high myocardial ADP, but this may result from depleted 
myocardial energy reserve. Currently scarce data is available to explain why and how 
the energetic reserve is reduced in HCM individuals. There are several candidates that 
deserve focused attention, including creatine kinase (CK) and mitochondrial activity. 
Unpublished data from our group shows that CK expression is reduced in sarcomere-
mutation positive HCM patients (Figure 2A). 
This coincides with a substantial reduction in CK-activity compared with non-failing 
controls (Figure 2B). The change in protein expression was independent of changes 
that precede CK protein transcription, since mRNA of CK levels were not significantly 
altered in the majority of HCM samples. The only exception was a reduction in 
mitochondrial CK (CK-mt) mRNA in thin-filament mutations (Figure 3B). 
figure 2. Creatine Kinase (CK) protein-expression (A) and activity (B) in human hypertrophic 
cardiomyopathy (HCM) samples. Data was compared using multilevel analysis. MYBPC3mut, myosin-
binding protein-C mutations; MYH7mut, myosin heavy chain mutations; Thinmut, Thin-filament mutations 
consist of cardiac troponin T and cardiac troponin I mutations; HCMsmn, sarcomere mutation-negative 
HCM samples. Non-failing hearts (donor) served as controls. Unpublished data.
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In summary, the present data will strengthen the overall idea about the essential 
role of myocardial energetic reserve in HCM and will possibly provide alternative 
areas to carefully study in HCM pathophysiology. Measurements of mitochondrial 
activity require fresh human HCM samples. We will analyse mitochondrial oxygen 
consumption in our future studies. In addition, it is imperative to quantitatively 
measure the precise levels of ADP in the cell, which can already be accomplished 
nowadays with high-sensitive fluorescent biosensors, such as “PercevalHR”. It is our 
belief that a complex of myofilament and Ca2+-handling changes is triggered by 
deficient (mitochondrial) energetics in HCM. Future approaches should use animal 
models and test novel drugs to improve myocardial energetic reserve, including 
the promising SS-31 (Szeto-Schiller), a mitochondrial-targeted antioxidant peptide 
that promotes mitochondrial respiration and ADP regeneration to ATP. These have 
the future potential to partially rescue HCM progression in humans.
figure 3. Creatine Kinase (CK) mRNA-expression of muscle (A) and mitochondrial forms (B) in human 
hypertrophic cardiomyopathy (HCM) samples. Data was compared using 1-way ANOVA analysis. 
MYBPC3mut, myosin-binding protein-C mutations; MYH7mut, myosin heavy chain mutations; Thinmut, 
Thin-filament mutations consist of cardiac troponin T and cardiac troponin I mutations; HCMsmn, 
sarcomere mutation-negative HCM samples. Non-failing hearts (donor) served as controls. Values 
were set to 1, relative to donor. Unpublished data.
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“Finally we shall place the Sun himself at the center of the Universe.”
Nicolaus Copernicus
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The heart and a balloon have more in common than meets 
the eye. Like the heart, a balloon is a exible bag that can 
be inated and emptied. Using this example one can 
readily understand basic heart function and several reasons 
for failure. Consider a balloon that is lled with air for 10 
seconds and then empties its volume for 10 seconds. The 
total time of balloon function or “balloon cycle” (lling and 
ejecting) is 20 seconds. Now let us imagine that the balloon 
cycle time of lling (“balloon lling”) is reduced to 5 
seconds; we have less time available to ll the balloon with 
air and hence the balloon will only be partially inated. 
Thus a “balloon failure” condition appears. The ability to ll 
a balloon with air is also dependent on the properties of 
the material that it is made of. The thicker and more 
inexible the material (“stiffer”1), the harder it will be to 
inate (“balloon stiffness”), and a greater force or “stress”2 
must be applied to achieve the same results. This is 
analogous to a condition where the walls of the heart 
become thicker and/or increase in stiffness (“heart 
stiffness”) and it gets harder for the heart to ll. Again the 
“failure” condition ensues. Importantly these processes 
can occur without changing the balloon lling time. Since 
both types of balloon failure described (balloon lling time 
and balloon stiffness) occur during the lling of the balloon 
we term it “balloon lling dysfunction”. 
The heart is not that different from a balloon, and a 
chronic perturbation of the heart cycle – “cardiac cycle” – is 
clinically classied as a cardiac disease or heart failure (HF) 
condition. Just in Europe over 15 million people are 
diagnosed with HF and this number continues to rapidly 
increase, representing a major cause of hospitalization and 
death. About half of the HF patient population have a heart 
which is unable to proper relax and distend (ll). Classically, 
heart function has been separated into several distinct 
phases. Even though the events of the cardiac cycle are 
mutually related, their modus operandi is distinct. Similar to 
the emptying and lling of the  balloon, the heart needs to 
rst stop “squeezing” (ejecting blood) so that it can start to 
relax – “myocardial relaxation” (inactivation). Only after the 
heart relaxes will it be able to ll and distend. During the 
lling phase alterations to the macro- (e.g. wall thickness, 
chamber geometry) or micro-properties (e.g. sarcomere 
stiffness and collagen deposition) of the tissue will change 
the heart’s diastolic stiffness, stress and “elasticity”3. It 
takes a healthy heart ~0.1 seconds to completely relax 
(isovolumetric relaxation); and another ~0.4 seconds to ll 
and distend to a total of 120 ml of blood (lling phase) 
before “isometric contraction” takes place. Together these 
processes of relaxation and lling are known as the 
diastolic phase of heart function. Hence, perturbations or 
disruption to these processes lead to “DIASTOLIC 
DYSFUNCTION”.
In this thesis, I have studied the mechanisms that affect 
myocardial relaxation and contribute to 
DIASTOLIC DYSFUNCTION of the heart. 
These include changes of “SARCOMERE LENGTH”, 
“Ca2+“ and “MYOCARDIAL ENERGETICS”.
A heart completely lled with blood is able to generate 
more pressure during contraction than a half full heart. This 
is because more of the heart muscle is engaged to contract 
and eject blood. This provides the basic frame work for 
what is known as the “FRANK-STARLING LAW”. This Law 
relates the extent of heart lling (known as 
“length-dependency”) with the amount of pressure 
generated during contraction. From these ndings comes 
the universal principle that the amount of blood ejected 
from the heart must equal the amount of blood acquired 
during lling. The force for heart contraction is generated 
by the unitary building blocks of the heart muscle, which 
are known as “sarcomeres”. Sarcomeres increase in length 
during lling which increases contractility of the heart cells. 
The term “SARCOMERE LENGTH-DEPENDENT 
ACTIVATION” describes the FRANK-STARLING LAW at the 
single cell level. Disruption of sarcomere lengthening 
function can result in improper lling of the heart 
(DIASTOLIC DYSFUNCTION) which affects the hearts 
ability to generate force and limits the amount of blood 
pumped to the body. If it takes the healthy heart ~0.5 
second to entirely ll to a total of 120 ml blood during the 
diastolic phase, it will take another ~0.3 seconds to 
contract and eject – “systolic phase” – 70 ml of that blood 
to maintain a steady ow to the body. The heart never 
completely empties as residual volume is present at all 
times. In HF patients the FRANK-STARLING RESERVE is 
limited, which is detrimental to maintaining a steady blood 
perfusion to the body (cardiac output). Exploring deeper 
into the sarcomeres reveals the myolament proteins. 
These come in two types: thin- (actin-containing) and thick- 
(myosin-containing). Molecular interactions between the 
actin and myosin proteins (“cross-bridges”) generate the 
contraction of the sarcomere. Cross-bridges activation is 
regulated by Ca2+ and the MYOCARDIAL ENERGY 
RESERVE that regenerates ATP from ADP.
As it will be seen, it is the interplay of SARCOMERE 
LENGTH, Ca2+ and MYOCARDIAL ENERGETICS that 
regulate the diastolic function of the heart. 
When any, or several, of these mechanisms fail 
DIASTOLIC DYSFUNCTION follows.
1Stiffness - The rigidity of an object to which it resists deformation in 
response to an applied force. The SI unit is N/m.
2Stress or Pressure - The force exerted on a material normalized to 
the area over which the force is acting. The SI unit of stress is the 
pascal (Pa). 1 Pa = 1 N/m2. Force applied perpendicular to the 
material surface – compressional or extension stress. Force exerted 
parallel to the surface - shear stress.
3Elasticity - The property of a material to deform in response to an 
applied force and returns to its original state when the force is 
removed.
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